

C. t. t.

Company Director

Board

Executive Director

- M. GUAN W (Chairman)
- M. WANG L

Non-Executive Director

- M. QIN H
- M. LI C

Independent Non-Executive Director

- M. ZHONG W
- M. LIU N

Audit Committee

- M. ZHONG W (Chairman)
- M. LIU N
- M. LI C

Nominating Committee

- M. LIU N (Chairman)
- M. GUAN W

Remuneration Committee

- M. ZHONG W
- M. LIU N

Management Director

- M. GUAN W (Chairman)
- M. ZHONG W
- M. QIN H

Supervisor Committee

- M. XU N (Chairman)
- M. XU Y
- M. XIE T
- M. QIAN C

Executive Director

- M. WANG J
- M. WONG W C

Executive Director

- M. GUAN W
- M. WONG W C

Director

BDO CAS LLP P A LLP

L A H K L

C C

R O H O

PRC

S R
H R D
W , Z
PRC

CONTACT INFORMATION

Parent Company

40/F, Daxi Square
248 Qianjiang Road
Wenzhou
H K

HSR

China H K IVS L
S 1712-1716, 17 F
H C
183 Qianjiang Road
Wenzhou
H K

SC

2120

Company Website

www.kangninghospital.com

IVR

Tel: (86) 577 8877 1689
Fax: (86) 577 8878 9117
E-mail: info@kangninghospital.com

Wen Zhou Kang Ning Hospital

Financial Data

	Financial Data, December 31,				
	2022 MB'000	2021 RMB'000 (RMB)	2020 RMB'000 (RMB)	2019 RMB'000	2018 RMB'000
Revenue	1,484,903	1,297,430	989,012	860,692	745,972
Operating Profit	15,605	95,691	83,509	55,523	106,910
Interest Income	26,574	54,831	30,662	-17,295	-31,941
Net Income	-10,969	40,860	52,847	38,228	74,969
Non-Operating Income	-24,221	44,036	64,961	57,289	80,596
Net Income	13,252	-3,176	-12,114	-19,061	-5,627
		Assets, December 31,			
	2022 MB'000	2021 RMB'000 (RMB)	2020 RMB'000 (RMB)	2019 RMB'000	2018 RMB'000
Total Assets	2,637,787	2,377,955	2,161,262	2,117,352	1,840,724
Total Liabilities	1,311,885	1,097,676	946,349	855,843	635,451
Total Equity	1,325,903	1,280,279	1,214,913	1,261,509	1,205,273
Equity	1,201,585	1,208,264	1,122,248	1,164,484	1,120,995
Net Income	124,318	72,015	92,665	97,025	84,278

Notes: 1. The financial data for the period from January 1, 2021 to December 31, 2021 are audited by the accounting firm of the Company, and the audit opinion is "Standard Unqualified".

Calendar

December

February, Guangdong Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital) was established on December 31, 2022 (February 2022).

In 2022, the company has completed the annual work plan, and the COVID-19 epidemic prevention and control work has achieved significant results. The company has completed the annual work plan, and the COVID-19 epidemic prevention and control work has achieved significant results. The company has completed the annual work plan, and the COVID-19 epidemic prevention and control work has achieved significant results.

Since the outbreak of the COVID-19 epidemic in 2020, the company has always adhered to the "people-oriented" concept, and has taken a series of measures to ensure the safety of patients and staff. In 2022, the company has completed the annual work plan, and the COVID-19 epidemic prevention and control work has achieved significant results. The company has completed the annual work plan, and the COVID-19 epidemic prevention and control work has achieved significant results.

During the year, the company has completed the annual work plan, and the COVID-19 epidemic prevention and control work has achieved significant results. The company has completed the annual work plan, and the COVID-19 epidemic prevention and control work has achieved significant results. The company has completed the annual work plan, and the COVID-19 epidemic prevention and control work has achieved significant results.

I 2022, G RMB1,484.9 , 14.4% 2021,
 RMB1,366.8 , 13.6%
 2021. I G , G
 Z P . T G 27
 2021 29 2022 (). T
 8,728 2021 9,688 2022. W
 , G
 G

I 2022, G -
 G . T
 , -
 ,
 !

T ,
 L , G
 ,
 K !
 F B D , I
 ,

GUAN W
 C

Z , PRC
 A 28, 2023

M
D
A

B
R
O

P
M
I
C

T
A
H

W
P
A
T
;
;

O
C
C
P
S
H
C
O
P
O
;

Management Discussion and Analysis

On December 18, 2019, 12 shareholders of Ningbo Kangning Hospital (NKH) held a 2019 Annual Meeting of Shareholders (A-Share) (2019-2022), which was attended by 12 shareholders, representing 100% of the total shares of the company. The meeting discussed and approved the 2019 Annual Report, the 2020 Business Plan, and the 2020-2022 Share Incentive Plan (the "Plan").

On September 9, 2021, the Shareholders of Ningbo Kangning Hospital (NKH) held a 2021 Annual Meeting of Shareholders (A-Share) (2021-2025), which was attended by 100 shareholders, representing 100% of the total shares of the company. The meeting discussed and approved the 2021 Annual Report, the 2022 Business Plan, and the 2022-2025 Share Incentive Plan (the "Plan").

On January 10, 2022, 21 shareholders of Ningbo Kangning Hospital (NKH) held a 2022 Annual Meeting of Shareholders (A-Share) (NDRC) (NKH), which was attended by 14 shareholders, representing 100% of the total shares of the company. The meeting discussed and approved the 2022 Annual Report, the 2023 Business Plan, and the 2023-2025 Share Incentive Plan (the "Plan").

On April 27, 2022, the Shareholders of Ningbo Kangning Hospital (NKH) held a 2022 Annual Meeting of Shareholders (A-Share) (NKH), which was attended by 14 shareholders, representing 100% of the total shares of the company. The meeting discussed and approved the 2022 Annual Report, the 2023 Business Plan, and the 2023-2025 Share Incentive Plan (the "Plan").

On December 14, 2022, the Shareholders of Ningbo Kangning Hospital (NKH) held a 2022 Annual Meeting of Shareholders (A-Share) (2022-2035), which was attended by 14 shareholders, representing 100% of the total shares of the company. The meeting discussed and approved the 2022 Annual Report, the 2023 Business Plan, and the 2023-2035 Share Incentive Plan (the "Plan").

Management Discussion and Analysis

Business Review

In 2022, the company continued to adhere to the business strategy of "Quality First, Innovation Driven, and Market-Oriented", focusing on the core business of medical services, and actively expanding the business scale. The company has achieved significant progress in the field of medical services, with the total number of inpatient beds increasing by 10% compared to the same period last year. The company has also strengthened its cooperation with various medical institutions, and the quality of medical services has been further improved. In addition, the company has also actively participated in social charity activities, and made significant contributions to society.

The company's main business is medical services, which includes inpatient services, outpatient services, and medical research. In 2022, the company's medical services business continued to grow, with the total number of inpatient beds increasing by 10% compared to the same period last year. The company has also strengthened its cooperation with various medical institutions, and the quality of medical services has been further improved. In addition, the company has also actively participated in social charity activities, and made significant contributions to society.

Management Discussion and Analysis

On January 1, 2022, the company's total assets were 1,107 million yuan, and total liabilities were 3,266 million yuan. In 2022, the company's total assets increased by 12,172 million yuan, and total liabilities increased by 12,172 million yuan. The company's net assets increased by 12,172 million yuan. The company's net assets increased by 12,172 million yuan. The company's net assets increased by 12,172 million yuan.

COVID-19 cases in 2022 were significantly higher than in 2021. The company's COVID-19 cases in 2022 were significantly higher than in 2021. The company's COVID-19 cases in 2022 were significantly higher than in 2021.

In 2022, the company's operating income was significantly higher than in 2021. The company's operating income was significantly higher than in 2021. The company's operating income was significantly higher than in 2021.

The company's operating income was significantly higher than in 2021. The company's operating income was significantly higher than in 2021. The company's operating income was significantly higher than in 2021.

B. H. In 2022, the company's R&D investment was significantly higher than in 2021. The company's R&D investment was significantly higher than in 2021. The company's R&D investment was significantly higher than in 2021.

The company's R&D investment was significantly higher than in 2021. The company's R&D investment was significantly higher than in 2021. The company's R&D investment was significantly higher than in 2021.

In 2022, the company's R&D investment was significantly higher than in 2021. The company's R&D investment was significantly higher than in 2021. The company's R&D investment was significantly higher than in 2021.

The company's R&D investment was significantly higher than in 2021. The company's R&D investment was significantly higher than in 2021. The company's R&D investment was significantly higher than in 2021.

Management Discussion and Analysis

Business Overview

The Group's main business is the provision of medical services, including hospital inpatient services, medical diagnosis, and medical research.

(1) Revenue. In 2022, the Group's revenue was RMB 1,014.5 million, an increase of 69.3% compared to RMB 600.0 million in 2020. The increase was primarily due to the expansion of the Group's business scale and the improvement of the operating efficiency of the Group's hospitals. The Group's revenue is mainly derived from the provision of medical services, including hospital inpatient services, medical diagnosis, and medical research.

(2) Operating Costs. In 2022, the Group's operating costs were RMB 614.5 million, an increase of 68.6% compared to RMB 364.0 million in 2020. The increase was primarily due to the expansion of the Group's business scale and the improvement of the operating efficiency of the Group's hospitals. The Group's operating costs are mainly derived from the provision of medical services, including hospital inpatient services, medical diagnosis, and medical research.

Management Discussion and Analysis

Financial Results

Total operating income decreased by RMB1,484.9 million, or 14.4%, from RMB13,666.8 million in 2021 to RMB12,181.9 million in 2022. Total operating expenses decreased by RMB352.9 million, or 7.3%, from RMB10,100.0 million in 2021 to RMB9,747.1 million in 2022. Total operating profit decreased by RMB24.2 million, or 0.2%, from RMB3,566.8 million in 2021 to RMB3,542.6 million in 2022. Total operating profit margin decreased by 0.2 percentage points, from 25.4% in 2021 to 25.2% in 2022. Total operating profit margin decreased by 0.2 percentage points, from 25.4% in 2021 to 25.2% in 2022. Total operating profit margin decreased by 0.2 percentage points, from 25.4% in 2021 to 25.2% in 2022.

Revenue and Cost

Total operating income decreased by 14.4% from RMB13,666.8 million in 2021 to RMB12,181.9 million in 2022. Total operating expenses decreased by 7.3% from RMB10,100.0 million in 2021 to RMB9,747.1 million in 2022. Total operating profit decreased by 0.2% from RMB3,566.8 million in 2021 to RMB3,542.6 million in 2022. Total operating profit margin decreased by 0.2 percentage points, from 25.4% in 2021 to 25.2% in 2022.

Financial Results December 31,
2022 2021
(MB'000) (RMB'000)

Medical Services, Diagnostic Services, and Administration

Item	Unit	December 31,	
		2022	2021
		(MB'000)	(RMB'000)
Balance	RMB	1,425,005	1,229,996
Loss of income from special medical services	RMB	43,545	-18
	RMB	14,643	27,240
Balance	RMB	1,366,817	1,202,774

Note:

- (1) Loss of income from special medical services refers to the estimated unrecoverable charges for offering medical services by the Group to extremely deprived community members, low-end patients who are impoverished due to illness and other persons with special difficulties stipulated by the people's government at or above the county level (the "Special Medical Services") pursuant to relevant policies.

For the period, the Group's balance of special medical services receivables at the end of 2021, RMB1,425.0 million, increased by 15.9% compared with RMB1,229.996 million at the end of 2020. The increase was mainly due to the increase in the number of patients with special difficulties. The Group's balance of special medical services receivables at the end of 2022, RMB1,366.817 million, decreased by 4.1% compared with RMB1,425.0 million at the end of 2021. The decrease was mainly due to the decrease in the number of patients with special difficulties. The Group's balance of special medical services receivables at the end of 2023, RMB1,202.774 million, decreased by 11.7% compared with RMB1,366.817 million at the end of 2022. The decrease was mainly due to the decrease in the number of patients with special difficulties.

Medical Expenses, Depreciation and Amortization

The following table shows the changes in the carrying amount of the above items:

	December 31, 2022 (MB'000)	December 31, 2021 (RMB'000)
Medical Expenses		
B R	1,119,887	962,408
C	770,287	658,194
G	349,600	304,214
Prepaid Expenses		
B R	305,118	267,588
C	269,828	238,918
G	35,290	28,670
Buildings and Equipment		
C	1,040,115	897,112
G	384,890	332,884

December 31, 2022, the carrying amount of the above items is RMB1,425.0 million.

M^a / D^a / A^a

T 40 B RV 4G ' 4

F 4^a

Medical Materials, Drugs, and Accessories

Drugs, B RMB1,218.3 million, 15.6% in 2021, () G' - 13.0%, Q K H, Y K H, T K H, W N H, W C H, P C Y H, Y Y H J S H () G' 2.4%. T B R B R 85.5% (2021: 85.7%).

Drugs, B RMB206.7 million, 17.2% in 2021, 30.9% 10.5%. T B R B R 14.5% (2021: 14.3%).

Drugs, B RMB1,218.3 million, 15.6% in 2021, 78.6% (2021: 78.2%) B R ; B R 14.0% 2021, 21.4% (2021: 21.8%) B R 12.8% (2021: 13.8%), B R 71.9% (2021: 69.3%).

C G' T G' :

Financial Data 31,

	2022 (MB'000)	2021 (RMB'000)
P	339,777	310,090
E	390,107	321,207
D	33,584	42,283
D	99,553	75,386
C	63,747	53,470
T	27,588	25,595
O	85,759	69,081
C	1,040,115	897,112

Medical Materials, Drugs, and Accessories

During the reporting period, the company's medical materials, drugs, and accessories were purchased for RMB1,040.1 million, an increase of 15.9% compared to 2021. The company's medical materials, drugs, and accessories were sold for RMB96.6 million, an increase of 9.6% compared to 2021. The company's medical materials, drugs, and accessories were sold for RMB21.5 million, an increase of 21.5% compared to 2021. The company's medical materials, drugs, and accessories were sold for RMB32.1 million, an increase of 32.1% compared to 2021.

The company's medical materials, drugs, and accessories were sold for RMB32.7 million (2021: RMB34.6 million). The company's medical materials, drugs, and accessories were sold for RMB37.5 million (2021: RMB35.8 million). The company's medical materials, drugs, and accessories were sold for RMB12.8 million (2021: RMB13.1 million).

The company's medical materials, drugs, and accessories were sold for RMB110.0 million, an increase of 110.0% compared to 2021. The company's medical materials, drugs, and accessories were sold for RMB85.5 million (2021: RMB51.6 million).

The company's medical materials, drugs, and accessories were sold for RMB8.1 million (2021: RMB23.6 million), an increase of 8.1% compared to 2021. The company's medical materials, drugs, and accessories were sold for RMB8.1 million (2021: RMB23.6 million).

The company's medical materials, drugs, and accessories were sold for RMB352.9 million, an increase of 7.3% compared to 2021. The company's medical materials, drugs, and accessories were sold for RMB326.7 million, an increase of 6.9% compared to 2021. The company's medical materials, drugs, and accessories were sold for RMB326.7 million, an increase of 6.9% compared to 2021.

Financial Results of the Reporting Period

	2022	2021
Total	27.4%	29.6%
Profit	11.6%	10.7%
Operating Profit	23.9%	25.4%
Profit	22.2%	24.7%
Cost of Sales	23.8%	25.4%

Management Discussion and Analysis

During the reporting period, the company's operating income increased by 23.8% (2021: 25.4%), and the net profit attributable to shareholders increased by 2.2% (2021: 1.1%). The company's operating income in 2021 was RMB43.6 million.

Key Statistics

During the reporting period, the company's operating income was RMB5.0 million (2021: RMB5.8 million).

Shareholders

During the reporting period, the company's net profit attributable to shareholders was RMB15.0 million (2021: RMB10.3 million). The company's net profit margin was 1.1% (2021: 0.9%).

Assets and Liabilities

During the reporting period, the company's total assets increased by 1.1% (2021: 0.9%), and the total liabilities increased by 1.1% (2021: 0.9%). The company's total assets and total liabilities were RMB205,887 thousand and RMB176,372 thousand, respectively, as of December 31, 2022.

Financial Position as of December 31, 2022 and 2021
(in MB'000) (RMB'000)

	2022	2021
	(MB'000)	(RMB'000)
Equity	111,252	100,510
Debt	24,761	22,117
Current assets	29,187	13,014
Total assets	4,359	2,835
Other	36,328	37,896
Total	205,887	176,372

During the reporting period, the company's operating income was RMB205.9 million, an increase of 16.7% (2021: 15.1%). The company's net profit attributable to shareholders was RMB13.5 million, an increase of 15.1% (2021: 14.7%).

Medical Expenses

Medical expenses include the cost of medical services provided to patients, including the cost of medical materials, medical equipment, and medical personnel. The cost of medical services is the primary component of medical expenses, which is directly related to the volume of medical services provided. The cost of medical materials and medical equipment is also an important component of medical expenses, which is related to the quality of medical services. The cost of medical personnel is also an important component of medical expenses, which is related to the quality of medical services.

	December 31,	2022	2021
		(RMB'000)	(RMB'000)
Cost of medical services		18,899	16,487
Cost of medical materials		9,803	8,059
Cost of medical equipment		4,053	3,114
Cost of medical personnel		273	302
Total		33,028	27,962

Medical expenses were RMB33.0 million in 2022, an increase of 18.2% compared with RMB27.962 million in 2021.

Management Discussion and Analysis

During the reporting period, the company's operating income was RMB6.7 billion, an increase of 51.1% compared with the same period in 2021, and the net profit was RMB2.4 billion, an increase of 51.1% compared with the same period in 2021.

Operating Income

Operating income is the total amount of revenue from the company's main business activities, including revenue from the sale of goods, services, and other operating activities. It is the primary source of the company's operating income.

Financial Position at the End of the Reporting Period
2022 2021
(RMB'000) (RMB'000)
(RMB million)

Operating Income	-15,927	-6,566
Cost of Sales	18,063	7,075
Depreciation and Amortization	714	6,429
	2,850	6,938

During the reporting period, the company's operating income was RMB2.9 billion, an increase of 51.1% compared with the same period in 2021, and the net profit was RMB15.9 billion, an increase of 51.1% compared with the same period in 2021.

Cost of Sales

During the reporting period, the company's cost of sales was RMB25.2 billion (2021: RMB2.1 billion), an increase of 51.1% compared with the same period in 2021.

Assets

During the reporting period, the company's assets were RMB10.3 billion, an increase of 51.1% compared with the same period in 2021.

Management Discussion and Analysis

Non-Operating Income and Non-Operating Expenses

Operating income is the primary source of revenue for the Company. The Company's operating income is derived from the provision of medical services, including hospitalization, outpatient, and emergency services. The Company's operating income is significantly affected by the number of inpatients, the number of outpatients, and the number of emergency cases. The Company's operating income is also affected by the price of medical services and the cost of medical services. The Company's operating income is expected to increase in 2023 due to the recovery of the medical market and the expansion of the Company's business.

	Financial Position at December 31,	
	2022 (RMB'000)	2021 (RMB'000)
Goodwill	55	266
Derivatives	7,436	9,470
Debt	-	1,800
Other	1,063	300
Non-current assets	8,554	11,836
Lease	1,588	166
Debt	3,928	3,333
Expense	1,754	1,399
Expense	-	2,000
Other	2,071	1,739
Non-current liabilities	9,341	8,637

During the reporting period, the Company's operating income was RMB3.3 billion, an increase of 21% compared with RMB2.7 billion in 2021. The Company's operating income is primarily derived from the provision of medical services, including hospitalization, outpatient, and emergency services. The Company's operating income is significantly affected by the number of inpatients, the number of outpatients, and the number of emergency cases. The Company's operating income is also affected by the price of medical services and the cost of medical services. The Company's operating income is expected to increase in 2023 due to the recovery of the medical market and the expansion of the Company's business.

Income Tax Expense

During the reporting period, the Company's income tax expense was RMB26.6 million (2021: RMB54.8 million), a decrease of 51.5% compared with 2021. The Company's income tax expense is primarily derived from the provision of medical services, including hospitalization, outpatient, and emergency services. The Company's income tax expense is significantly affected by the number of inpatients, the number of outpatients, and the number of emergency cases. The Company's income tax expense is also affected by the price of medical services and the cost of medical services. The Company's income tax expense is expected to increase in 2023 due to the recovery of the medical market and the expansion of the Company's business.

Medical Materials

Financial Position

Inventory

As of December 31, 2022, the company's inventory was RMB58.3 million (December 31, 2021: RMB56.5 million), an increase of 4.4% compared to the end of 2021.

Accounts Receivable

As of December 31, 2022, the company's accounts receivable was RMB382.8 million (December 31, 2021: RMB311.8 million), an increase of 22.8% compared to the end of 2021. This was primarily due to the growth of the company's business.

During the reporting period, the company's accounts receivable turnover was 42 times (2021: 37 times).

Other Receivables

As of December 31, 2022, the company's other receivables were RMB69.4 million (December 31, 2021: RMB41.8 million).

Other Non-current Assets

As of December 31, 2022, the company's other non-current assets were RMB63.1 million (December 31, 2021: RMB65.8 million). During the reporting period, the company's other non-current assets decreased by RMB2.7 million, primarily due to the disposal of certain non-current assets.

Contract Assets

As of December 31, 2022, the company's contract assets were RMB152.5 million (December 31, 2021: RMB43.8 million), an increase of 246.8%. This was primarily due to the company's business expansion and the recognition of contract assets.

Prepaid Expenses

As of December 31, 2022, the company's prepaid expenses were RMB190.4 million (December 31, 2021: RMB257.4 million), a decrease of 26.0%. This was primarily due to the company's business expansion and the recognition of prepaid expenses.

Prepaid Expenses

As of December 31, 2022, the company's prepaid expenses were RMB85.8 million (December 31, 2021: RMB69.2 million).

Medical Debt

Receivable Accounts

As of December 31, 2022, the amount of receivable accounts was RMB 29.9 million (December 31, 2021: RMB16.3 million).

Other Payables

As of December 31, 2022, the amount of other payables was RMB72.2 million (December 31, 2021 ()): RMB57.3 million), of which the amount of long-term payables was RMB17.0 million.

Long-term Debt

The amount of long-term debt was RMB 227,221 million (December 31, 2021: RMB 193,896 million).

	December 31, 2022 (MB'000)	December 31, 2021 (RMB'000)
--	----------------------------------	-----------------------------------

Long-term debt	227,221	193,896
Other long-term debt		

12.1 应收账款

截至2022年12月31日，应收账款账面余额为人民币116.2万元，坏账准备为人民币0.0万元，应收账款净额为人民币116.2万元。截至2021年12月31日，应收账款账面余额为人民币116.5万元，坏账准备为人民币0.0万元，应收账款净额为人民币116.5万元。2022年应收账款余额较2021年增加0.3万元，主要系公司2022年业务开展所致。

12.2 预付款项

截至2022年12月31日，预付款项账面余额为人民币616.5万元，坏账准备为人民币0.0万元，预付款项净额为人民币616.5万元。截至2021年12月31日，预付款项账面余额为人民币553.2万元，坏账准备为人民币402.7万元，预付款项净额为人民币150.5万元。2022年预付款项余额较2021年增加63.3万元，主要系公司2022年业务开展所致。

Major Events and Awards

Exchange of Shares

On December 29, 2022, the Company completed the exchange of shares between the Company and the shareholders. The total amount of shares exchanged was 10,000,000 shares, with a total value of HKD 100,000,000. The exchange was completed on December 29, 2022.

As of December 31, 2022, the Company's total assets were RMB 1,234,567,890, and the total liabilities were RMB 567,890,123. The Company's net assets were RMB 666,677,767. The Company's revenue for the year ended December 31, 2022, was RMB 123,456,789, and the net profit was RMB 12,345,678.

Government Grants

As of December 31, 2022, the Company has received government grants of RMB 123,456,789 (2021: RMB 98,765,432), which accounted for 49.7% (2021: 46.2%) of the Company's net profit for the year.

Employee Compensation

As of December 31, 2022, the Company's total employee compensation was RMB 4,196,543,210 (2021: RMB 3,661,234,567). The Company's employee compensation for the year ended December 31, 2022, was RMB 529,432,109 (2021: RMB 443,321,098). The Company's employee compensation for the year ended December 31, 2022, was RMB 124,321,098 (2021: RMB 123,456,789). The Company's employee compensation for the year ended December 31, 2022, was RMB 123,456,789 (2021: RMB 123,456,789).

Shareholders

The Company's shareholders are listed in the following table. The Company's shareholders are listed in the following table. The Company's shareholders are listed in the following table. The Company's shareholders are listed in the following table. The Company's shareholders are listed in the following table.

The Company's shareholders are listed in the following table. The Company's shareholders are listed in the following table. The Company's shareholders are listed in the following table. The Company's shareholders are listed in the following table. The Company's shareholders are listed in the following table.

三、主要会计政策和会计估计变更及前期会计差错更正

1. 重要会计政策变更

本报告期内, 公司未发生重要会计政策变更。

2. 重要会计估计变更

本报告期内, 公司未发生重要会计估计变更。

3. 前期会计差错更正

本报告期内, 公司未发生前期会计差错更正。

(一) 重要会计政策变更

1. 执行《企业会计准则解释第15号》

财政部于2022年11月30日发布《企业会计准则解释第15号》, 自2023年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

2. 执行《企业会计准则解释第14号》

财政部于2021年11月30日发布《企业会计准则解释第14号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

3. 执行《企业会计准则解释第13号》

财政部于2021年10月26日发布《企业会计准则解释第13号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

4. 执行《企业会计准则解释第12号》

财政部于2021年9月17日发布《企业会计准则解释第12号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

5. 执行《企业会计准则解释第11号》

财政部于2021年7月26日发布《企业会计准则解释第11号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

6. 执行《企业会计准则解释第10号》

财政部于2021年6月17日发布《企业会计准则解释第10号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

7. 执行《企业会计准则解释第9号》

财政部于2021年5月28日发布《企业会计准则解释第9号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

8. 执行《企业会计准则解释第8号》

财政部于2021年4月30日发布《企业会计准则解释第8号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

9. 执行《企业会计准则解释第7号》

财政部于2021年3月31日发布《企业会计准则解释第7号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

10. 执行《企业会计准则解释第6号》

财政部于2021年3月31日发布《企业会计准则解释第6号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

11. 执行《企业会计准则解释第5号》

财政部于2021年3月31日发布《企业会计准则解释第5号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

12. 执行《企业会计准则解释第4号》

财政部于2021年3月31日发布《企业会计准则解释第4号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

13. 执行《企业会计准则解释第3号》

财政部于2021年3月31日发布《企业会计准则解释第3号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

14. 执行《企业会计准则解释第2号》

财政部于2021年3月31日发布《企业会计准则解释第2号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

15. 执行《企业会计准则解释第1号》

财政部于2021年3月31日发布《企业会计准则解释第1号》, 自2022年1月1日起施行。本报告期内, 公司未发生重要会计政策变更。

(二) 重要会计估计变更

1. 坏账准备的计提

本报告期内, 公司未发生重要会计估计变更。

2. 存货跌价准备的计提

本报告期内, 公司未发生重要会计估计变更。

3. 固定资产折旧年限的估计

本报告期内, 公司未发生重要会计估计变更。

4. 无形资产摊销年限的估计

本报告期内, 公司未发生重要会计估计变更。

5. 长期待摊费用摊销年限的估计

本报告期内, 公司未发生重要会计估计变更。

6. 预计负债的估计

本报告期内, 公司未发生重要会计估计变更。

7. 或有负债的估计

本报告期内, 公司未发生重要会计估计变更。

8. 或有资产的估计

本报告期内, 公司未发生重要会计估计变更。

9. 收入确认的估计

本报告期内, 公司未发生重要会计估计变更。

10. 成本费用的估计

本报告期内, 公司未发生重要会计估计变更。

11. 公允价值估计

本报告期内, 公司未发生重要会计估计变更。

12. 金融工具的估计

本报告期内, 公司未发生重要会计估计变更。

13. 所得税估计

本报告期内, 公司未发生重要会计估计变更。

14. 其他估计

本报告期内, 公司未发生重要会计估计变更。

(三) 前期会计差错更正

本报告期内, 公司未发生前期会计差错更正。

Ma / , , D , , a / A /

- (3) D E I S
- (a) F E I S
T C , , I S
Pa . W I S Pa , Pa
S C T Pa ,
I S - . I S
Pa . T
. U - , Pa
I S
Pa .
- () S S E I S - - D
T I S E I S
S , C
- () A E I S
C
Pa 2,460,000 S E I S ,
3.30% C ,
4.45% - D S .

Major Disasters and Accidents

- (4) **Vehicle Accidents** - **Employee Injuries**
 - (a) Vehicle accident involving an employee on duty. The employee was injured and hospitalized for 10 days. The accident occurred on July 26, 2018 (Internal Affairs No. 26, 2018). The employee was injured and hospitalized for 10 days.
 - (b) Vehicle accident involving an employee on duty. The employee was injured and hospitalized for 48 days. The accident occurred on July 29, 2018 (Internal Affairs No. 29, 2018); Internal Affairs No. 48 (July 28, 2022).
 - (c) Vehicle accident involving an employee on duty. The employee was injured and hospitalized for 48 days. The accident occurred on July 29, 2018 (Internal Affairs No. 29, 2018); Internal Affairs No. 48 (July 28, 2022).
- (5) **General** - **Employee Injuries**
 - (a) Traffic accident involving an employee on duty. The employee was injured and hospitalized for 48 days. The accident occurred on July 29, 2018 (Internal Affairs No. 29, 2018); Internal Affairs No. 48 (July 28, 2022).
 - (b) Traffic accident involving an employee on duty. The employee was injured and hospitalized for 48 days. The accident occurred on July 29, 2018 (Internal Affairs No. 29, 2018); Internal Affairs No. 48 (July 28, 2022).
 - (c) Traffic accident involving an employee on duty. The employee was injured and hospitalized for 48 days. The accident occurred on July 29, 2018 (Internal Affairs No. 29, 2018); Internal Affairs No. 48 (July 28, 2022).
 - (d) Traffic accident involving an employee on duty. The employee was injured and hospitalized for 48 days. The accident occurred on July 29, 2018 (Internal Affairs No. 29, 2018); Internal Affairs No. 48 (July 28, 2022).
 - (e) Traffic accident involving an employee on duty. The employee was injured and hospitalized for 48 days. The accident occurred on July 29, 2018 (Internal Affairs No. 29, 2018); Internal Affairs No. 48 (July 28, 2022).

Ma... D... A...

- (6) G P E I S T G P I S RMB10.47 S ;T G P I S RMB10.47 S .
- () B G P E I S C S , G P RMB10.47 E I S I S

Major Shareholders' Information

For the period ended December 31, 2022, the following table provides information on the major shareholders of the Company.

Shareholder Name	Shareholder Type	Shareholding Period	Shareholding Percentage (%)	Number of Shares (10,000)	Number of Shares (10,000)	Number of Shares (10,000)		Number of Shares (10,000)	Number of Shares (10,000)	Number of Shares (10,000)
						At the End of the Reporting Period	At the Beginning of the Reporting Period			
D										
M. WANG L ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	248,328	-	248,328	-	-	-
M. WANG H ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	95,511	-	95,511	-	-	-
S										
M. SUN F ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	14,327	-	14,327	-	-	-
M. XIET ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	4,776	-	4,776	-	-	-
O										
M. XU Y ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	28,653	-	28,653	-	-	-
M. WANG B ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	4,776	-	4,776	-	-	-
M. WANG L ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	4,776	-	4,776	-	-	-
M. WANG H ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	4,776	-	4,776	-	-	-
M. XU Q ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	4,776	-	4,776	-	-	-
M. GUAN W ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	19,102	-	19,102	-	-	-
M. SUN H ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	30,563	-	30,563	-	-	-
M. WANG H ()	Individual	J 18, 2021 - J 28, 2022	35.95	10,47	4,776	-	4,776	-	-	-

Report of the Board

T B 31, 2022. G

P A

T G C, D

C R L R

T C , PRC C L , H K L R , SFO, H K C O , S , C T C B D .

L G M H L PRC 《中華人民共和國精神衛生法》, L P ' R C P B M H G 《中華人民共和國基本醫療衛生與健康促進法》(J 1, 2020), M R M I 《醫療機構管理條例》 R I M R M I 《醫療機構管理條例實施細則》.

T G . I

T C . T D G 2022 L P D .

P I P

F D 31, 2022, G .

U P I P O

Report of the Board

Director's Report

The Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (the "Company") has completed its work for the year ended December 31, 2022.

Business Performance

In accordance with the Enterprise Income Tax Law of the People's Republic of China (《中華人民共和國企業所得稅法》) (the "Income Tax Law") promulgated by the State Council on January 1, 2008, the Company is a resident enterprise in the People's Republic of China. The Company is a company registered in the State Administration of Taxation (SAT) system, and is a resident enterprise in the People's Republic of China. The Company is a company registered in the State Administration of Taxation (SAT) system, and is a resident enterprise in the People's Republic of China. The Company is a company registered in the State Administration of Taxation (SAT) system, and is a resident enterprise in the People's Republic of China.

In accordance with the Enterprise Income Tax Law of the People's Republic of China (the "Income Tax Law"), the Company is a resident enterprise in the People's Republic of China. The Company is a company registered in the State Administration of Taxation (SAT) system, and is a resident enterprise in the People's Republic of China. The Company is a company registered in the State Administration of Taxation (SAT) system, and is a resident enterprise in the People's Republic of China. The Company is a company registered in the State Administration of Taxation (SAT) system, and is a resident enterprise in the People's Republic of China.

SG

December 31, 2022, the Company's net assets attributable to shareholders of RMB233.5 million.

R

December 31, 2022, the Company's net assets attributable to shareholders of RMB233.5 million.

DR

As of December 31, 2022, the Company's net assets attributable to shareholders of RMB233.5 million.

PPPE

SD I F .M ()0.0() .5 ()0.0()0.6 ()0 5 ()0 6 ()0.5 ()0 5 ()0.5 ()0 .5 ()0 .5 ()0

Report of the Board

DIRECTORS

For the period from January 1, 2022, to December 31, 2022, the Board of Directors has completed its work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations of the Board of Directors of the Company.

EXECUTIVE DIRECTORS

For the period from January 1, 2022, to December 31, 2022, the Executive Directors have completed their work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations of the Board of Directors of the Company.

SECRETARY

For the period from January 1, 2022, to December 31, 2022, the Secretary has completed his work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations of the Board of Directors of the Company.

SUPERVISORS

For the period from January 1, 2022, to December 31, 2022, the Supervisors have completed their work in accordance with the provisions of the Company Law of the People's Republic of China, the Articles of Association, and the Regulations of the Board of Directors of the Company.

DEPARTMENT

The Department of the Board of Directors is the Board of Directors.

MEMBERS OF THE BOARD OF DIRECTORS

- M. GUAN W (Chairman)
- M. WANG L
- M. WANG H (Independent Director, since January 1, 2022)

MEMBERS OF THE SUPERVISOR BOARD

- M. QIN H
- M. LI C

MEMBERS OF THE INDEPENDENT NON-EXECUTIVE DIRECTOR BOARD

- M. ZHONG W
- M. LIU N
- M. ZHAO X (since March 10, 2023)

S

T S R P :

M . XUN (C) (F ,19, 2022)

M . XU Y

M . XIE T

M . QIAN C

M . SUN F (C) (F ,15, 2022)

M . CHEN J (J ,17, 2022)

B R A K I F P

F , 31, 2022, F H M D A

D ' S ' I T , A C

S R B - C T N F S - R
C ,
D S , D S ,
D 31, 2022 R P .

C S ' I C S

S R B - C T N F S - R
C S
G C

M C

D R P , C
C

Report of the Board

NON-EXECUTIVE

At the 2022 Annual General Meeting of Shareholders, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (the "Company") has reviewed the Company's financial statements for the year ended 31 December 2022, and has approved the financial statements for the year ended 31 December 2022. The financial statements are set out in the Annual Report of the Company for 2022.

The Board of Directors has also reviewed the Company's performance for the year ended 31 December 2022, and has approved the Company's performance report for the year ended 31 December 2022.

DIRECTORS' CONFERENCE AND FINANCIAL STATEMENTS

The Board of Directors has reviewed the Company's financial statements for the year ended 31 December 2022, and has approved the financial statements for the year ended 31 December 2022. The financial statements are set out in the Annual Report of the Company for 2022.

The Board of Directors has also reviewed the Company's performance for the year ended 31 December 2022, and has approved the Company's performance report for the year ended 31 December 2022.

DIRECTORS' INTERESTS

The Board of Directors has reviewed the Company's financial statements for the year ended 31 December 2022, and has approved the financial statements for the year ended 31 December 2022. The financial statements are set out in the Annual Report of the Company for 2022.

项目	金额	占净资产比例	项目	金额	占净资产比例
应付账款	1,234,567.89	12.34%	应付账款	1,234,567.89	12.34%
预收款项	2,345,678.90	23.45%	预收款项	2,345,678.90	23.45%
其他应付款	3,456,789.01	34.56%	其他应付款	3,456,789.01	34.56%
合计	7,037,035.80	70.37%	合计	7,037,035.80	70.37%

Report of the Board

I S S S

As of December 31, 2022, the Company has 336 shareholders, of which 336 are natural persons. The Company is a public company listed on the Shanghai Stock Exchange (SSE) under the code 600203. The Company's registered office is located at No. 23, Pan XV SFO, H K S. The Company's fiscal year is from January 1 to December 31. The Company's legal representative is [Name]. The Company's board of directors consists of [Number] members, including [Number] independent non-executive directors. The Company's board of supervisors consists of [Number] members, including [Number] independent non-executive supervisors. The Company's internal control system is sound and effective. The Company's financial statements are true and fair. The Company's business operations are stable and sustainable. The Company's future development prospects are bright.

Shareholder Name	Shareholding Percentage (%)	Shareholding Percentage (%)
------------------	-----------------------------	-----------------------------

CHEN RUI D 陳睿 (中央企業鄉村產業投資基金股份有限公司) (Central Enterprise Rural Industry Investment Fund Co., Ltd.)	7,466,666(L)	13.51%	10.00%
SUN JIE M D 孫捷 (上海金浙企業管理中心(有限合夥)) ⁽²⁾	4,540,000(L)	8.22%	6.09%
FAN Y ⁽²⁾	4,540,000(L)	8.22%	6.09%
SUN J ⁽²⁾	4,540,000(L)	8.22%	6.09%
SUN J J E D 孫健 (上海金浦健服股權投資管理有限公司) ⁽²⁾	4,540,000(L)	8.22%	6.09%
W J E I D 溫金寧 (溫州金寧股權投資合夥企業(有限合夥))(J I)	4,540,000(L)	8.22%	6.09%
XU Y ⁽⁶⁾	5,785,350(L)	10.47%	7.76%
SUN T I L.P. (上海檀英投資合夥企業(有限合夥))	4,519,003(L)	8.18%	6.06%

名稱	類別	股權性質	數量	佔總股本比例	佔總資產比例
上海樂進投資合夥企業(有限合夥) ⁽³⁾	D	其他	4,519,003(L)	8.18%	6.06%
LIN L	D	其他	6,506,309(L)	11.77%	8.72%
上海正心谷投資管理有限 公司(上海正心谷投資管理 有限公司) ⁽⁴⁾	D	其他	6,506,309(L)	11.77%	8.72%
萬得信息技術股份有限公司	D	其他	3,333,000(L)	6.03%	4.47%
上海荷花緣企業 管理中心(有限合夥)	D	其他	3,333,000(L)	6.03%	4.47%
萬得影響力股權 投資(嘉興)合夥企業(有限合夥) (萬得影響力股權 投資(嘉興)合夥企業(有限合夥))	D	B	3,333,000(L)	6.03%	4.47%
青島金石灝洩投資有 限公司	D	B	2,780,000(L)	5.03%	3.73%
金石灝洩投資有限公司 ⁽⁵⁾	D	其他	2,780,000(L)	5.03%	3.73%
OM A LLC	HS	其他	1,454,000(L)	7.52%	1.95%
OM C LLC	HS	其他	2,150,900(L)	11.12%	2.88%
OM P M F L	HS	B	1,279,900(L)	6.62%	1.72%
OM P II, L.P.	HS	B	1,052,000(L)	5.44%	1.41%
UBS G AG	HS	I	1,029,400(L)	5.32%	1.38%
ZOU H (鄒海麗)	HS	B	1,680,000(L)	8.69%	2.25%
14933,000(L)984,30((11.12%)-4094 0.465%☒					

Report of the Board

N :

(L): L

- (1) T 55,260,000 D S 19,340,300 H S (74,600,300 S) C D 31, 2022.
- (2) FAN Y 50% S J E M C (L) (上海金浙企業管理中心(有限合夥)) S J E M C (L) (上海金浙企業管理中心(有限合夥)) W J E I (L) (溫州金寧股權投資合夥企業(有限合夥)). SUN J 33.94% W J E I (L) (溫州金寧股權投資合夥企業(有限合夥)). S J J E I M C , L . (上海金浦健服股權投資管理有限公司) W J E I (L) . T , XV SFO, FAN Y , S J E M C (L) (上海金浙企業管理中心(有限合夥)), SUN J S J J E I M C , L . (上海金浦健服股權投資管理有限公司) D S W J E I (L) (溫州金寧股權投資合夥企業(有限合夥)) C
- (3) S L I L.P. (上海樂進投資合夥企業(有限合夥)) 99.99% S T I L.P. (上海檀英投資合夥企業(有限合夥)). T , XV SFO, S L I L.P. (上海樂進投資合夥企業(有限合夥)) D S S T I L.P. (上海檀英投資合夥企業(有限合夥)) C
- (4) S L V I M C , L (上海正心谷投資管理有限公司) (S S I I M C , L (上海盛歌投資管理有限公司)) S Q I M (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) S T I L.P. (上海檀英投資合夥企業(有限合夥)). T , XV SFO, S L V I M C , L D S S I M (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) (1,987,356 D S C S T I L.P. (上海檀英投資合夥企業(有限合夥)) C
- (5) Q J H I C , L . (青島金石灑汭投資有限公司) J I C , L . (金石投資有限公司). T , J I C , L . (金石投資有限公司) D S Q J H I I C , L . (青島金石灑汭投資有限公司) C , XV SFO.
- (6) M . WANG H N X K I M L.P. N E K I M (L) 50.62% 37.10%, , XV SFO, M . WANG H D S M . XU Y M . WANG H . M . XU Y D S M . WANG H XV SFO.

S , D 31, 2022, D , (D , S C , D 2 3 S S C D 2 3 P XV SFO, C S 336 SFO.



Report of the Board

C

Shanghai Kangning Hospital, R P , C

March 10, 2023, M. ZHAO X (M.) B , F
M. Z , H K L R : () B
R 3.10 H K L R ; ()
R 3.25 H K L R ; ()
R 3.27A H
March 10, 2023, B M. JIN L (M.)
D , B
M. J B C T C V D

S P F

B C D L
P D , C S H
K L R

I B R P

T R P N XIII F S - B

A C

T A C B D C C G ' 2022
2022 C A
S B E

A

T BDO C S L P C P A LLP
(BDO).

R 浙 大 附 属 第 一 医 学 院 附 属 第 一 医 院 控 股 有 限 公 司 于 2022 年 10 月 16 日 召 开 第 一 次 临 时 股 东 大 会 ， 审 议 通 过 了 公 司 更 名 为 浙 大 附 属 第 一 医 学 院 附 属 第 一 医 院 有 限 公 司 的 决 议 ， 自 2022 年 11 月 18 日 起 实 施 。

A P 浙 大 附 属 第 一 医 学 院 附 属 第 一 医 院 有 限 公 司 控 股 有 限 公 司 于 2022 年 10 月 16 日 召 开 第 一 次 临 时 股 东 大 会 ， 审 议 通 过 了 公 司 更 名 为 浙 大 附 属 第 一 医 学 院 附 属 第 一 医 院 有 限 公 司 的 决 议 ， 自 2022 年 11 月 18 日 起 实 施 。

W 浙 大 附 属 第 一 医 学 院 附 属 第 一 医 院 有 限 公 司 控 股 有 限 公 司 于 2022 年 10 月 16 日 召 开 第 一 次 临 时 股 东 大 会 ， 审 议 通 过 了 公 司 更 名 为 浙 大 附 属 第 一 医 学 院 附 属 第 一 医 院 有 限 公 司 的 决 议 ， 自 2022 年 11 月 18 日 起 实 施 。

A 浙 大 附 属 第 一 医 学 院 附 属 第 一 医 院 有 限 公 司 控 股 有 限 公 司 于 2022 年 10 月 16 日 召 开 第 一 次 临 时 股 东 大 会 ， 审 议 通 过 了 公 司 更 名 为 浙 大 附 属 第 一 医 学 院 附 属 第 一 医 院 有 限 公 司 的 决 议 ， 自 2022 年 11 月 18 日 起 实 施 。

F 2 3 4 5 6 7 8 9

Report of the Board

(2) C 2020

(Unit: RMB,)

Item	Amount	Change	Balance
Operating Profit	63,465,824	-12,878	63,478,702
Operating Expenses	542,683,617	-12,878	542,696,495
Operating Income	2,161,261,775	-12,878	2,161,274,653
Operating Costs	76,603,400	-9,203,741	85,807,141
Operating Expenses	606,077,103	-9,203,741	615,280,844
Operating Income	946,349,216	-9,203,741	955,552,957
Operating Expenses	214,856,099	9,190,863	205,665,236
Operating Income	1,122,247,550	9,190,863	1,113,056,686
Operating Expenses	1,214,912,559	9,190,863	1,205,721,695
Operating Income	2,161,261,775	-12,878	2,161,274,653

(3) C 2021

(Unit: RMB,)

Item	Amount	Change	Balance
Operating Profit	29,925,488	-12,878	29,938,366
Operating Expenses	609,602,623	-12,878	609,615,501
Operating Income	2,377,954,989	-12,878	2,377,967,867
Operating Costs	57,319,524	-9,203,741	66,523,265
Operating Expenses	535,774,635	-9,203,741	544,978,376
Operating Income	1,097,675,868	-9,203,741	1,106,879,609
Operating Expenses	6,937,845	-12,878	6,950,723
Operating Income	257,098,624	9,190,863	247,907,761
Operating Expenses	1,208,263,897	9,190,863	1,199,073,034
Operating Income	1,280,279,120	9,190,863	1,271,088,257
Operating Expenses	2,377,954,989	-12,878	2,377,967,867

Opinions of the Independent Non-executive Directors

The Independent Non-executive Directors have reviewed the financial statements of Wenzhou Kangning Hospital Co., Ltd. for the year 2022. They believe that the financial statements are prepared in accordance with the applicable accounting standards and are true and fair. The Independent Non-executive Directors have no objections to the financial statements.

Opinions of the Board

The Board of Directors has reviewed the financial statements of Wenzhou Kangning Hospital Co., Ltd. for the year 2022. The Board believes that the financial statements are prepared in accordance with the applicable accounting standards and are true and fair. The Board has no objections to the financial statements.

Opinions of the Supervisory Committee

The Supervisory Committee has reviewed the financial statements of Wenzhou Kangning Hospital Co., Ltd. for the year 2022. The Supervisory Committee believes that the financial statements are prepared in accordance with the applicable accounting standards and are true and fair. The Supervisory Committee has no objections to the financial statements.

Opinions of the Audit Committee

The Audit Committee has reviewed the financial statements of Wenzhou Kangning Hospital Co., Ltd. for the year 2022. The Audit Committee believes that the financial statements are prepared in accordance with the applicable accounting standards and are true and fair. The Audit Committee has no objections to the financial statements.

Wenzhou Kangning Hospital Co., Ltd. (N. XV F. S. - O.)

T S :

I 2022, S C , PRC C L , A ,
S C , T B , S
C
D C S .

D R P , S C B C
C C

T S C - C R
P , D B ,

I 2023, S C - C
. T S C , S C
S C

F S C
XUN
C

Z , PRC
A 14, 2023

Corporate Governance Report

T C .T C CGC .
 T D , C , CGC R P .T C CGC .

T B

B^a, C , .
 A I P D , B D , D , - D
 D - D .T D
 D , S S M .T B
 C
 T B

T C H K L R .T C - D
 D R 3.13 H K L
 R .

A D , - D ,
 , B , B ,
 I - D A C , N C ,
 R C S R M C .

T CGC D C
 C .T D
 C

T C B .T C
 , D C
 C C
 B .T C
 B .

Corporate Governance Report

R F D B

T B - C D B . T C I

T B C () D . F A

I , B A C , N C , R C S R M C C . F

A D C S

T C D

C C E

Corporate Governance Report

C 董 事 会 成 员 简 介

O D 31, 2021, M . WANG H C M . JIN H C J 10, 2022.

O J 17, 2022, S C M . CHEN J

O F 15, 2022, M . SUN F S C

O F 19, 2022, S C M . XUN

O J 12, 2022, M . NG W S A R 4T) C H KH 4T T 0 16 C DO 622 C L D KH

Corporate Governance Report

I. C P D D

D R P , C . A B D ,
H K L R . T
B - . T D

D R P , D C M . GUAN W , M . WANG L , M . WANG H (S 1, 2022), M . QIN H , M . LI C , M . ZHAO X (M 10, 2023), M . ZHONG W M . LIU N , D

C M C

A.3 M C , 30
() ,
(B1, - , P.). P B.8 M
C

T C J 30, 2022 (I)
J 10, 2023. I D 28, 2022, C D ,
S C , ()
I R ; () D C S
C B - P (. D 11, 2022 J 10, 2023).

O J 5, 2023, C M . WANG L (M .) , D ,
M . W 100,000 S C M .
W J , C RMB13.28 S D 19, 2022 (D,) . P D , M . W / B D
C A M . W S C B - P
C D C M . W
A.3 B.8 M C .

Corporate Governance Report

T C , S , M C :

- (1) M . W D (M . W) C B ;
- (2) D , S M C C C
- (3) D , S C

T B C B - P C T C M C D , S

T C , S B - P . T C C S , C , C . I

S , C M C C D , S D S M C R P .

Corporate Governance Report

C

O Ma 10, 2023, M . ZHAO X , M . ZHAO X
 - 2 D C R C B
 N C B . F M . ZHAO X ,
 - 2 D C H K
 L R : () B - 2 R 3.10
 H K L R ; () - 2
 R 3.25 H K L R ; ()
 - 2 R 3.27A H K L R . O Ma 10, 2023, B
 M . JIN L - 2 D
 C R C B , N C
 B . A C M . JIN L
 - 2 D . F , C Ma 10, 2023.

S , B C
 CGC R P .

S C D S

E D (- 2 D) S
 C .

T S A , . N
 D S C , C .

A S

T C C A S B E 2017,
 C O (C 622 H K) (C O) .

A P

A P

T A S B E - B
 S , M F
 F 15, 2006 (A B
 E) .

T . T H K C O
 Ma 3, 2014. C
 H K C O .

Corporate Governance Report

Chapter 10: Corporate Governance

Section 10.1: General Principles of Corporate Governance

10.1.1: Basic Principles

10.1.1.1: The Company adheres to the principle of equal treatment of all shareholders, ensuring that all shareholders enjoy equal rights and bear equal responsibilities. The Company's operations are conducted in accordance with the law, and the interests of all shareholders are protected.

10.1.1.2: The Company's management is transparent and accountable, and the Company's financial statements are audited by an independent audit firm.

10.1.1.3: The Company's management is committed to the long-term development of the Company and the interests of all shareholders.

10.1.2: Board of Directors

Executive Director	M. GUAN W (Chairman)	11/11
	M. WANG L	11/11
	M. WANG H (Independent Director)	5/5

10.1.3: Non-Executive Director

	M. QIN H	11/11
	M. LI C	11/11

10.1.4: Independent Non-Executive Director

	M. ZHAO X (Independent Director)	11/11
	M. ZHONG W	11/11
	M. LIU N	11/11

10.1.4.1: The Company's independent non-executive directors are independent and objective, and they play a significant role in the Company's decision-making process.

10.1.4.2: The Company's independent non-executive directors are committed to the long-term development of the Company and the interests of all shareholders.

Corporate Governance Report

Directorates, including the Board of Directors, the Board of Supervisors, the Management, and the Independent Directors:

Directorates	Name	Term of Office
Executive Directorates	M. GUAN W (Chairman)	1/1
	M. WANG L	1/1
	M. WANG H (Secretary since August 1, 2022)	0/0
Non-executive Directorates	M. QIN H	1/1
	M. LI C	1/1
Independent Directorates	M. ZHAO X (since March 10, 2023)	1/1
	M. ZHONG W	1/1
	M. LIU N	1/1

Corporate Governance Report

B 董事會

本公司董事會由 5 名成員組成，包括 3 名獨立非執行董事及 2 名執行董事。本公司董事會成員均具備豐富之管理經驗，並持有適當之專業資格。本公司董事會成員之履歷詳情載於本報告之「董事及高級管理人員」一節。

A 薪酬

本公司董事及高級管理人員之薪酬政策及架構，以及其如何與本公司表現掛鈎，載於本報告之「董事及高級管理人員薪酬」一節。本公司董事及高級管理人員之薪酬詳情載於本報告之「董事及高級管理人員薪酬」一節。

本公司董事及高級管理人員之薪酬詳情載於本報告之「董事及高級管理人員薪酬」一節。本公司董事及高級管理人員之薪酬詳情載於本報告之「董事及高級管理人員薪酬」一節。

本公司董事及高級管理人員之薪酬詳情載於本報告之「董事及高級管理人員薪酬」一節。

本公司董事及高級管理人員之薪酬詳情載於本報告之「董事及高級管理人員薪酬」一節。

姓名	職銜	薪酬
M. ZHONG W (鍾文)	獨立非執行董事	5/5
M. LIU N (劉南)	獨立非執行董事	5/5
M. LI C (李成)	獨立非執行董事	5/5

Corporate Governance Report

NEEDS

The Company's Board of Directors, Supervisory Board, and Management have fully understood the importance of corporate governance. They have established a sound corporate governance system, including the Company Law, Articles of Association, and various internal control systems. The Company has also established a sound risk management system and an internal control system to ensure the company's long-term and stable development.

The Company's Board of Directors, Supervisory Board, and Management have fully understood the importance of corporate governance. They have established a sound corporate governance system, including the Company Law, Articles of Association, and various internal control systems. The Company has also established a sound risk management system and an internal control system to ensure the company's long-term and stable development.

The Company's Board of Directors, Supervisory Board, and Management have fully understood the importance of corporate governance. They have established a sound corporate governance system, including the Company Law, Articles of Association, and various internal control systems. The Company has also established a sound risk management system and an internal control system to ensure the company's long-term and stable development.

The Company's Board of Directors, Supervisory Board, and Management have fully understood the importance of corporate governance. They have established a sound corporate governance system, including the Company Law, Articles of Association, and various internal control systems. The Company has also established a sound risk management system and an internal control system to ensure the company's long-term and stable development.

The Company's Board of Directors, Supervisory Board, and Management have fully understood the importance of corporate governance. They have established a sound corporate governance system, including the Company Law, Articles of Association, and various internal control systems. The Company has also established a sound risk management system and an internal control system to ensure the company's long-term and stable development.

M. LIU N (Chairman)	2/2
M. GUAN W (Vice Chairman)	2/2
M. ZHAO X (Secretary)	2/2

The Company's Board of Directors, Supervisory Board, and Management have fully understood the importance of corporate governance. They have established a sound corporate governance system, including the Company Law, Articles of Association, and various internal control systems. The Company has also established a sound risk management system and an internal control system to ensure the company's long-term and stable development.

Corporate Governance Report

R C

T C R C CGC
R C B . T D
D
D
;
/ D C 17 H K L R ;
D C
B .

A , R C - D , M .
ZHONG W M . LIU N . T R C
E.1.2() CGC (. . B
D (. .) . O R C R P ,
C 2021.

T D R C R P
:

D		
M . ZHAO X (C) (M 10, 2023)		1/1
M . ZHONG W		1/1
M . LIU N		1/1

T G , D C
D / . T -
D D ,
B .

T D D 31, 2022 N F S -
R

Corporate Governance Report

S R C
T C S R M C

Corporate Governance Report

一、董事、监事及高级管理人员

Age Group	Gender	Education	Professional Title
30-49 (3)	Male (33.3%)	1-5 (4)	
50-59 (3)	Male (66.7%)	6-10 (2)	

截至2022年12月31日，本公司共有董事4名，其中独立董事2名，非独立董事2名；监事2名，其中职工代表监事1名，非职工代表监事1名；高级管理人员3名。所有董事、监事及高级管理人员均符合《公司法》、《上市公司治理准则》、《上市公司章程指引》、《上市公司董事、监事和高级管理人员任职资格准则》等法律法规及《公司章程》的有关规定，不存在被中国证监会采取证券市场禁入措施的情形，也不存在被证券交易所公开谴责或采取其他纪律处分的情形。

二、薪酬政策与薪酬委员会履职情况

2022年，公司薪酬委员会根据《上市公司薪酬管理制度》及《薪酬管理办法》的规定，结合公司实际情况，对高级管理人员薪酬进行了审议。2022年，公司高级管理人员薪酬总额为4,196万元（含税），其中现金薪酬3,337万元，占薪酬总额的79.5%。薪酬委员会认为，公司高级管理人员薪酬政策符合相关法律法规及《公司章程》的规定，薪酬水平与公司的经营业绩、行业薪酬水平及公司实际情况相匹配。

三、内部控制评价

报告期内，公司按照《企业内部控制基本规范》及《上市公司内部控制指引》的要求，结合公司实际情况，建立健全了内部控制体系。截至2022年12月31日，公司内部控制体系运行有效，未发现重大缺陷。公司内部控制评价结论如下：

- (一) 内部控制设计合理，能够有效防范和控制经营风险；
- (二) 内部控制执行有效，能够确保公司各项业务活动的规范运行；
- (三) 内部控制监督有效，能够及时发现和纠正内部控制缺陷；
- (四) 内部控制评价结果客观、公正，能够真实反映公司的内部控制状况。

报告期内，公司未发现重大缺陷。公司内部控制评价结论如下：

- (1) 内部控制设计合理，能够有效防范和控制经营风险；
- (2) 内部控制执行有效，能够确保公司各项业务活动的规范运行；
- (3) 内部控制监督有效，能够及时发现和纠正内部控制缺陷；
- (4) 内部控制评价结果客观、公正，能够真实反映公司的内部控制状况。

Corporate Governance Report

Director's Report

On December 31, 2022, the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (the "Company") has completed its duties for the year. The Board has reviewed the Company's financial statements and business performance for the year, and has approved the following resolutions:

The Board has approved the Company's financial statements for the year, including the profit distribution plan. The Board has also reviewed the Company's internal control system and risk management measures, and has found them to be effective.

Management Report

The Management Team has implemented the Board's resolutions and has made significant progress in the Company's business operations. The Company's revenue has increased, and its operating profit has improved. The Management Team has also strengthened the Company's internal control system and risk management measures.

The Management Team has also focused on improving the Company's financial performance. It has implemented various cost-saving measures and has optimized the Company's capital structure. The Management Team has also strengthened the Company's relationships with its customers and suppliers, and has improved the Company's service quality.



WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT

Corporate Governance Report

Shareholder Structure

Total number of shares held by the top 10 shareholders as of December 31, 2022:

Name of Shareholder (MB)	Number of Shares
0-700,000	1
700,001-1,400,000	6

Annual Report

For the period ending December 31, 2022, the Group's financial performance, BDO, PricewaterhouseCoopers (PwC) audit firm for the period ending December 31, 2022, and the audit opinion issued by the audit firm are as follows:

The audit firm issued an unqualified audit opinion on the financial statements of the Group for the period ending December 31, 2022, with a total audit fee of RMB5,300,000.

Non-audit services provided by the audit firm for the period ending December 31, 2022, include the audit of the Group's financial statements for the period ending December 31, 2022, and the audit of the Group's financial statements for the period ending December 31, 2022, with a total fee of RMB1,066,300.

Joint Shareholders

The Director Mr. M. WONG Wai C is also a shareholder of the Company. Mr. M. WANG J is also a shareholder of the Company. The relationship between Mr. M. WONG Wai C and Mr. M. WANG J is as follows:

Director Mr. M. WONG Wai C holds 15% of the shares of the Company. Mr. M. WANG Wai C holds 3.29% of the shares of the Company. Mr. M. WANG J holds 15% of the shares of the Company. The relationship between Mr. M. WONG Wai C and Mr. M. WANG Wai C is as follows:

On July 12, 2022, Mr. M. WONG Wai C and Mr. M. WANG Wai C entered into a Shareholders' Agreement (SWCSA) with Mr. M. WANG Wai C. The SWCSA is a written agreement between Mr. M. WONG Wai C and Mr. M. WANG Wai C, and it is a written agreement between Mr. M. WONG Wai C and Mr. M. WANG Wai C.

Corporate Governance Report

C O R P O R A T E S T A T U S I N F O R M A T I O N

Wen Zhou Kang Ning Hospital Co., Ltd. (Wen Zhou Kang Ning Hospital) is a public company listed on the Shanghai Stock Exchange (603003). The company is a leading provider of medical services in the region, with a focus on high-quality patient care and medical innovation.

The company's registered capital is RMB 1,000 million. The company is a public company with a total of 100 million shares, all of which are listed on the Shanghai Stock Exchange. The company's main business is the provision of medical services, including general practice, specialty care, and medical research.

The company's headquarters are located in Wenzhou, Zhejiang. The company has a total of 10,000 employees and a total revenue of RMB 1,000 million in 2022. The company is a leading provider of medical services in the region, with a focus on high-quality patient care and medical innovation.

The company's main products include general practice, specialty care, and medical research. The company is a leading provider of medical services in the region, with a focus on high-quality patient care and medical innovation.

The company's main products include general practice, specialty care, and medical research. The company is a leading provider of medical services in the region, with a focus on high-quality patient care and medical innovation.

S H A R E H O L D I N G S

Public Shareholders (EPS) and Corporate Shareholders (EGM)

Shareholders: EGM

Shareholders: EGM 10% Shareholders: A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z

Shareholders: EGM Shareholders: C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z

Shareholders: EGM Shareholders: S, C, EGM 10% Shareholders: A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z

Corporate Governance Report

I S V C . C EGM ,

I S V C EGM ,
S V C
10% S 90 S EGM
N S C S

P S () P F P G M
W C B , S C S

S 3% S 3% S
10 EGM. T
2 . T

A :
N .1 S R
H R D
W , Z
PRC
Tel: (86) 577 8878 9117
E : @

P, D, 'E, B
S B B
T :

A :
N .1 S R
H R D
W , Z
PRC
Tel: (86) 577 8878 9117
E : @

S B C

Corporate Governance Report

C C D

D R P , A .

D P

T C W C -

10% C C .T C 50%

C .S C

C C .A

C .A C S A

S S A

C N S

C C

T C ():

- (I) ;
- (II) ;
- (III) , , , , .

T C RMB S .S

C S RMB HKD. S HKD

C S

T B C

Directors, Supervisors and Senior Management

D

Executive Directors

M. G. AN 安 (管偉立), 53, B. C. H. D. H. C. F. 1996

Directors, Supervisors and Senior Management

Independent Non-executive Directors

M. ZHONG (鍾文堂), 33, Male, Bachelor's Degree, G J 2020. S (上海信公企業管理諮詢有限公司), F 2019, 2019, M. Z (上海信公企業管理諮詢有限公司), F 2016 F 2019, I C C., L., F O 2012 F 2016, P C Z T CPA L C.

M. Z F U S J 2012. S M B A F U J 2022.

M. LI (劉寧), 59, Male, Bachelor's Degree, G J 2020. H W H T G C., L. (: 300253.SZ) A 2004, S F 2018, K M T (S) C., L. (快享醫療科技(上海)有限公司), S J 2018, B W H T C., L. (北京衛寧健康科技有限公司), S O 2019, S W T C., L. (上海衛心科技有限公司), F A 1991 A 2004, U S H - (HP) C (上海金仕達衛寧醫療信息技術有限公司).

M. L F U S J 1985, H F U S J 1988, H S H - A T E S (上海市工程系列高新技術成果轉化類高級專業技術職務任職資格評審委員會) M, 2000.

S

M. X (許寧), 49, Male, Bachelor's Degree, S C. H M 2016, C H M 2016 O 2016, F N 2016 D 2017, H C J 2018 J 2022. H J 2022. H M 2023. P C W TV S (溫州電視台) (溫州新聞聯播), W N S 1998 F 2016,

Directors, Supervisors and Senior Management

M. XIAO (肖明), 45, Male, Bachelor's Degree, Graduated from Beijing Broadcasting University (北京廣播學院) (China University of Media and Communication) in 1998. He is a Senior Human Resources Management Specialist (一級人力資源管理師) and has worked for MHRSP (明華人力資源服務) since 2018.

M. XU (徐永久), 45, Male, Bachelor's Degree, Graduated from Shanghai Jiaotong University in 2021. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University. He has worked for Shanghai Jiaotong University since 2021. He is also a Senior Investment Advisor (高級投資顧問) at Wenzhou Jinning Equity Investment Partnership (有限合夥) since 2019. He is a Senior Investment Advisor (高級投資顧問) at Chengdu Yanning Hospital Co., Ltd. since 2016. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Yintong Investment Co., Ltd. since 2004. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2007. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2009. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2011. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2015. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2016. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2023.

M. XIAO (肖明), 45, Male, Bachelor's Degree, Graduated from Shanghai Jiaotong University in 2000. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2004. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2015. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2016. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2022.

M. QIAN (錢成良), 72, Male, Bachelor's Degree, Graduated from Shanghai Jiaotong University in 1977. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2017. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2007. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2012. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2015. He is a Senior Investment Advisor (高級投資顧問) at Shanghai Jiaotong University since 2022.

Directors, Supervisors and Senior Management

S M

M. ZHO CHAOYE (周朝毅), 60, ...
... C ... M. Z ... C ... F ... 2005 ...
... . H ... S ... 2014 ...
C ... P ... C ... N ... 1995
D ... 2004, M. Z ... W ... C ... H ... (温州心血管醫院)
... W , F ... 1990 O ... 1995, M. Z
...

Directors, Supervisors and Senior Management

Mr. Xu Yanyan (徐誼), 48, Male, Bachelor's Degree, Doctor, Chief Physician, Chief of Department (科長). He joined the Company in 2002 and has served as the Chairman of the Board of Directors since 2009. He has also served as the Chairman of the Board of Supervisors since 2014. He is currently the Chairman of the Board of Directors and the Chairman of the Board of Supervisors of the Company.

Directors, Supervisors and Senior Management

M. ANG (王健), 38, male, Chinese citizen, Bachelor's degree, B.A. in Business Administration, Zhejiang University, 2005. He has worked for various companies in the financial industry, including Xianfeng Securities, Xianfeng Fund Management, and Xianfeng Asset Management. He is currently the Chairman of the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. He is also a member of the China Securities Regulatory Commission (CSRC) Xiamen Branch (中國證監會廈門監管局) and the China Securities Association (中國證券協會). He is also a member of the China Association of Accountants (中國會計師協會) and the China Association of Certified Public Accountants (中國註冊會計師協會). He is also a member of the China Association of Non-professional Accountants (中國非執業會計師協會). He is also a member of the China Association of Actuaries (中國精算師協會). He is also a member of the China Association of Actuaries (中國精算師協會). He is also a member of the China Association of Actuaries (中國精算師協會).

C. J. (陳健), 42, male, Chinese citizen, Bachelor's degree, B.A. in Business Administration, Zhejiang University, 2005. He has worked for various companies in the financial industry, including Xianfeng Securities, Xianfeng Fund Management, and Xianfeng Asset Management. He is currently the Chairman of the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. He is also a member of the China Securities Regulatory Commission (CSRC) Xiamen Branch (中國證監會廈門監管局) and the China Securities Association (中國證券協會). He is also a member of the China Association of Accountants (中國會計師協會) and the China Association of Certified Public Accountants (中國註冊會計師協會). He is also a member of the China Association of Non-professional Accountants (中國非執業會計師協會). He is also a member of the China Association of Actuaries (中國精算師協會). He is also a member of the China Association of Actuaries (中國精算師協會). He is also a member of the China Association of Actuaries (中國精算師協會).

M. IN (金偉光), 55, male, Chinese citizen, Bachelor's degree, B.A. in Business Administration, Zhejiang University, 2005. He has worked for various companies in the financial industry, including Xianfeng Securities, Xianfeng Fund Management, and Xianfeng Asset Management. He is currently the Chairman of the Board of Directors of Wenzhou Kangning Hospital Co., Ltd. He is also a member of the China Securities Regulatory Commission (CSRC) Xiamen Branch (中國證監會廈門監管局) and the China Securities Association (中國證券協會). He is also a member of the China Association of Accountants (中國會計師協會) and the China Association of Certified Public Accountants (中國註冊會計師協會). He is also a member of the China Association of Non-professional Accountants (中國非執業會計師協會). He is also a member of the China Association of Actuaries (中國精算師協會). He is also a member of the China Association of Actuaries (中國精算師協會). He is also a member of the China Association of Actuaries (中國精算師協會).

M 5B12190CFB0D8

Directors, Supervisors and Senior Management

Mr. JIN Hui (金輝), 36, male, Chinese citizen, Bachelor's degree, currently serving as the Director of the Company. He has worked in the accounting field since 2002. He is a member of the Zhejiang Huaming Certified Public Accountants Firm (浙江華明會計師事務所有限公司) since 2012. He has worked in the accounting field since 2012. He is a member of the Zhejiang Huaming Certified Public Accountants Firm (浙江華明會計師事務所有限公司) since 2012. He has worked in the accounting field since 2012. He is a member of the Zhejiang Huaming Certified Public Accountants Firm (浙江華明會計師事務所有限公司) since 2012.

Mr. Wang (王), male, Chinese citizen, Bachelor's degree, currently serving as the Director of the Company. He has worked in the accounting field since 2018. He is a member of the Wenzhou Lide Certified Public Accountants Firm (溫州立德會計師事務所有限公司) since 2018. He has worked in the accounting field since 2018. He is a member of the Wenzhou Lide Certified Public Accountants Firm (溫州立德會計師事務所有限公司) since 2018.

Directors, Supervisors and Senior Management

Director/Supervisor	Position	Age	Gender	Education	Work Experience
WANG Lanyan	Director	45	Male	Master's Degree	2017
Qian Kehua	Director	52	Male	Master's Degree	2018
Bai Yuhua	Director	48	Female	Master's Degree	2019
Han Yuning	Director	42	Male	Master's Degree	2020
Zhang Fei	Director	40	Female	Master's Degree	2022
Zhang Yuhua	Director	45	Male	Master's Degree	2022
Zhang Dapeng	Director	48	Male	Master's Degree	2022
Chen Kehua	Director	45	Male	Master's Degree	2022
Chen Kehua	Supervisor	45	Male	Master's Degree	

Directors, Supervisors and Senior Management

Director/Supervisor/Executive Management	Personal Information	Education	Work Experience	Age	Gender	Start Year
XU Y	Qiang Kang, Hui Sheng, C.,L.	S	F	A	2011	
	Yi Kang, Hui Sheng, C.,L.	S	F	S	2013	
	Sun Yi, Hui Sheng, C.,L.	S	F	S	2014	
	Wang Yi, Guo Sheng, Hui Sheng, C.,L.	S	F	N	2015	
	Bai Yi, Hui Sheng, C.,L.	S	F	A	2015	
	Sun Yi, Meng Sheng, I., C.,L.	S	F	S	2015	
	Qian Yi, Hui Sheng, C.,L.	S	F	N	2015	
	Zhang Hui, Hui Sheng, C.,L.	C	F	A	2016	
	Tan Kang, Hui Sheng, C.,L.	E	F	J	2016	
	Zhang Kang, Hui Sheng, Meng (G), C.,L.	E, G	F	J	2016	
	Han Yi, Hui Sheng, C.,L.	C	F	A	2017	
	Tan Li, Cui Hui Sheng, C.,L.	E, M	F	D	2016	
	Han Kang, Hui Sheng, C.,L.	C	F	J	2018	
	Han Cui, Hui Sheng, C.,L.	E, G	F	N	2017	
	Wang Tan, TCM, C.,L.	E	F	J	2018	
	Wang Tan, TCM, C.,L.	G	F	J	2018	
	Zhang Jie, Hui Sheng, T., C.,L.	E, G	F	D	2018	
	Wang Li, Yi Hui Sheng, C.,L.	D	F	A	2020	
	Wang Jie, Jie Hui Sheng, T., C.,L.	E, G	F	D	2021	
	Wang Yi, Hui Sheng, T., C.,L.	D	F	A	2022	

Directors, Supervisors and Senior Management

Director/Supervisor: **Ma Jialiang** **Ma Jialiang** **Ma Jialiang**
Ma Jialiang Ma Jialiang Ma Jialiang

Directors, Supervisors and Senior Management

Director / Supervisor	Mr. / Ms. / Mr.	Position	Term of Office
ZHANG F	Mr. Zhang Fei	Chairman	2018
	Mr. Wang Na	Director	2019
	Mr. Liu Chao	Director	2020
YE M	Mr. Ye Ming	Director	2019 - 2022
JIN W	Mr. Jin Wei	Director	2015 - 2022
	Mr. Huo Yan	Director	2018
	Mr. Pan Y	Director	2021
	Mr. Gao Y N	Director	2021 - 2022
XUN	Mr. Xun	Director	2019
	Mr. Huo Yan	Director	2020
JIN H	Mr. Jin Hong	Director	2022
	Mr. Gao Y N	Director	2022

Abstract

Xin K. S. Bao Z [2023] N.ZA12856

Abstract of the paper titled "H... C., L..."

I. Overview

W... K... H... C., L... (... 31 D 2022, ... , ... , ... , ...)

I... 31 D 2022, ... A... S... B... E (CAS).

II. Background

W... C... S... A (CSA). O... A... R... A... F... S...

Ar t' t

III. K yA Ma

K yA Ma , . T

Arbeitsblätter

Arbeitsblätter	Hilfsblätter
1. D... 2.



Annual Report

Attachment

IV. OBJECTIVE

Members of the Commission (hereinafter referred to as "Members") are hereby notified that the Commission has received a request from the Government of Karnataka for the appointment of a member to the Commission for the year 2022. The Commission has received a request from the Government of Karnataka for the appointment of a member to the Commission for the year 2022.

The Commission has received a request from the Government of Karnataka for the appointment of a member to the Commission for the year 2022.

The Commission has received a request from the Government of Karnataka for the appointment of a member to the Commission for the year 2022.

The Commission has received a request from the Government of Karnataka for the appointment of a member to the Commission for the year 2022.

V. RECOMMENDATION

The Commission has received a request from the Government of Karnataka for the appointment of a member to the Commission for the year 2022.

The Commission has received a request from the Government of Karnataka for the appointment of a member to the Commission for the year 2022.

The Commission has received a request from the Government of Karnataka for the appointment of a member to the Commission for the year 2022.

A. 1. 1.

VI. A

Consolidated Balance Sheet

As at 31 December 2022

Assets	Liabilities	December 31, 2022	December 31, 2021	January 1, 2021
			(RMB '000)	(RMB '000)
Current Assets:				
Monetary Assets	(I)	271,094,962.97	188,734,845.77	206,499,564.42
Financial Assets	(II)	10,641,026.00	10,000,000.00	
Accounts Receivable	(III)	382,836,690.89	311,757,875.46	225,300,247.01
Prepaid Expenses	(VI)	32,201,223.97	11,858,427.06	9,909,510.16
Other Current Assets	(V)	37,195,219.68	29,925,487.99	63,465,823.77
Current Assets	(VI)	58,331,397.37	56,519,301.23	37,508,471.39
Non-current Assets:				
Property, Plant and Equipment	(VII)	752,324.77	806,685.85	
Total Assets				
		793,052,845.65	609,602,623.36	542,683,616.75
Current Liabilities:				
Accounts Payable	(VIII)	14,000,000.00		
Other Current Liabilities	(IX)	143,546,246.10	129,847,779.24	97,816,933.76
Current Liabilities	(X)	63,116,852.05	65,812,274.58	57,404,918.27
Non-current Liabilities:				
Other Non-current Liabilities				107,804,936.40
Total Liabilities				
			65,812,274.58	165,211,874.67
Equity:				
Shareholders' Equity				
Capital Reserve				
Surplus Reserve				
Retained Earnings				
Total Equity				
		793,052,845.65	609,602,623.36	542,683,616.75

Continued
As at December 31, 2022
(All amounts in RMB Yuan)

LIABILITY AND EQUITY	Notes	December 31, 2022	December 31, 2021	January 1, 2021
			(RMB Yuan)	(RMB Yuan)
Continued:				
Shareholders' equity:				
S	(XIX)	203,000,000.00	254,050,000.00	312,500,000.00
B				

China Baowu Steel Group Limited
Annual Report 2022

LIABILITY AND EQUITY	UNIT	December 31, 2022	December 31, 2021	January 1, 2021
			(RMB)	(RMB)
Liabilities:				
Short-term debt	(XXXIII)	74,600,300.00	74,600,300.00	74,600,300.00
Long-term debt	(XXXIV)	855,078,533.30	838,165,395.59	819,509,065.54
Other debt	(XXXV)	38,399,577.13	38,399,577.13	36,593,228.71
Reserves	(XXXVI)	233,506,534.43	257,098,624.31	214,856,099.61
Other liabilities				
Provisions		1,201,584,944.86	1,208,263,897.03	1,122,247,550.02
Other liabilities		124,317,673.97	72,015,223.54	92,665,008.81
Total liabilities		1,325,902,618.83	1,280,279,120.57	1,214,912,558.83
Equity:				
Capital		2,637,787,406.99	2,377,954,988.76	2,161,261,774.68

Total 1,325,902,618.83 RMB

Li: Guan W P: Jin H H: Wang M

温州康宁医院有限公司
A股 31日 2022 审计报告

A E	N XVI	D, 31, 2022	D 31, 2021	J, 31, 2021
			(R)	(R)

温州康宁医院
资产负债表
截至2022年12月31日
(人民币元)

LIABILITY AND EQUITY	December 31, 2022	December 31, 2021	January 1, 2021
	(RMB)	(RMB)	(RMB)
Current Assets:			
Cash	195,000,000.00	251,050,000.00	310,000,000.00
Financial assets			
Derivatives			
Receivables	20,689,401.73	13,161,555.37	34,954,083.13
Prepaid expenses	3,299,924.90	2,011,708.12	
Contract assets			3,480,241.45
Inventory	18,740,841.95	17,876,433.39	15,629,765.62
Other receivables	597,972.12	4,848,233.63	8,267,930.79
Other current assets	49,473,505.95	74,941,835.88	27,298,927.14
Current assets	91,487,500.00	3,000,000.00	
Non-current Assets:			
Long-term receivables	284,750,000.00	200,950,000.00	38,000,000.00
Other non-current assets			
Investment property			
Long-term equity investments	25,922,687.47		
Other non-current assets			
Prepaid expenses			
Deferred tax assets	9,037,891.00	9,341,683.00	9,645,475.00
Other non-current assets	2,291,279.89	2,853,156.89	1,607,648.32
Other non-current assets			

资产负债表
 截至2022年12月31日

LIABILITIES AND EQUITY	December 31, 2022	December 31, 2021	January 1, 2021
(RMB)	(RMB)	(RMB)	(RMB)
流动资产:			
货币资金	74,600,300.00	74,600,300.00	74,600,300.00
应收账款			
预付款项			
其他应收款			
存货	871,230,628.64	854,317,490.93	834,138,174.86
流动资产合计			23,311,143.84
长期股权投资			
其他权益工具投资	38,399,577.13	38,399,577.13	36,593,228.71
其他非流动资产	241,903,691.18	214,974,182.62	198,717,046.87
非流动资产合计	1,226,134,196.95	1,182,291,550.68	1,120,737,606.60
非流动资产合计			
所有者权益合计	1,927,425,201.96	1,762,326,156.96	1,569,621,678.05

法定代表人: 王明

财务总监: 关文

内部审计: 金洪

财务总监: 王明

合并现金流量表

2022年度
(人民币元)

项目	附注	2022年度	2021年度
		(人民币元)	(人民币元)
I. 经营活动产生的现金流量		1,484,903,042.25	1,297,430,369.83
销售商品、提供劳务收到的现金	(XXXVII)	1,484,903,042.25	1,297,430,369.83
收到的税费返还			
收到其他与经营活动有关的现金			
经营活动现金流入小计			
购买商品、接受劳务支付的现金			
支付给职工以及为职工支付的现金			
支付的各项税费			
支付其他与经营活动有关的现金			
经营活动现金流出小计			
经营活动产生的现金流量净额		1,484,903,042.25	1,297,430,369.83
II. 投资活动产生的现金流量		1,435,161,133.62	1,226,514,555.85
收回投资收到的现金	(XXXVII)	1,131,971,942.77	968,432,455.76
取得投资收益收到的现金			
处置固定资产、无形资产和其他长期资产收到的现金			
处置子公司及其他营业单位收到的现金			
收到其他与投资活动有关的现金			
投资活动现金流入小计			
购建固定资产、无形资产和其他长期资产支付的现金	(XXXVIII)	4,960,285.79	5,754,219.28
取得子公司及其他营业单位支付的现金	(XXXIX)	15,004,027.73	10,335,392.65
支付其他与投资活动有关的现金	(XL)	205,887,172.40	176,371,888.82
支付收购少数股权的现金	(XLI)	33,027,987.79	27,962,173.39
支付购买理财产品现金	(XLII)	44,309,717.14	37,658,425.95
支付其他与投资活动有关的现金		45,149,998.30	36,267,756.91
投资活动现金流出小计		2,761,765.05	1,691,366.88
投资活动产生的现金流量净额	(XLIII)	14,907,710.81	13,619,635.06
III. 筹资活动产生的现金流量		2,850,458.27	6,937,845.27
取得借款收到的现金	(XLIV)	2,850,458.27	6,937,845.27
发行债券收到的现金			
收到其他与筹资活动有关的现金			
筹资活动现金流入小计			
偿还债务支付的现金			
发行债券支付的现金			
支付其他与筹资活动有关的现金			
筹资活动现金流出小计			
筹资活动产生的现金流量净额		-15,926,847.45	-6,565,719.92
现金及现金等价物净增加额			
期初现金及现金等价物余额			
期末现金及现金等价物余额			
IV. 补充资料		16,391,935.00	92,491,794.67
处置固定资产、无形资产和其他长期资产收回的现金净额	(XLIX)	8,553,977.86	11,835,931.80
处置子公司及其他营业单位收到的现金净额	(L)	9,341,038.73	8,636,583.42
收到的其他与补充资料有关的现金			
补充资料产生的现金流量净额		15,604,874.13	95,691,143.05
现金及现金等价物净增加额	(LI)	26,573,712.49	54,830,913.00

Continued
For the year ended 2022
(All amounts in RMB Yuan)

Item: Non-Current Assets
(RMB Yuan)

资产负债表
附注
2022
(A 人民币元)

项目	附注	2022 年 12 月 31 日	2021 年 12 月 31 日
流动资产	(IV)	343,141,450.63	369,798,306.12
货币资金	(IV)	265,024,147.50	271,489,388.70
交易性金融资产		154,333.60	3,013,304.93
应收账款		1,692,773.94	3,068,742.71
预付款项		82,345,368.26	70,825,757.20
其他应收款		18,899,109.47	16,486,961.41
存货		16,480,521.45	5,650,976.01
合同资产		26,568,676.00	19,722,968.32
其他流动资产		11,229,395.04	14,521,251.32
非流动资产		6,245,933.48	5,326,738.38
长期股权投资	(V)	49,902,280.65	4,923,377.54
其他权益工具投资		-5,377,605.11	-3,485,811.81
其他非流动资产		-	-
流动资产合计		343,141,450.63	369,798,306.12
非流动资产合计		6,245,933.48	5,326,738.38
资产总计		349,387,384.11	375,125,044.50

资产负债表
F
(A 2022 RMB Y)

Item	N	XVI	Amount	A
Other receivables				
(I) O				
1. C				
2. O				
3. C				
4. C				
(II) O				
1. O				
2. C				
3. A				
4. C				
5. R				
6. E				
7. O				
I. Other receivables			26,929,508.56	18,063,484.17
Equity:				
(I) B (RMB)				
(II) D (RMB)				

T

L : P : H :
GUAN W JIN H WANG M

C **a** **t** **C** **E** **a** **t** **t** **t**
 F 2022

I	N	V	A	A
			t	t
I. C a t a t a t t t				
G v a			1,452,028,763.13	1,211,114,150.81
N a a a				
N a a a				
N a a a				

Continued
附注 2022
(A 人民币元)

Item	Notes	Amount	Amount
II. Current assets			
Monetary funds		1,650,804.41	52,119,175.58
Accounts receivable		24,100,366.61	7,777,189.35
Prepaid expenses			8,755,311.37
Other receivables		25,751,171.02	68,651,676.30
Inventory		236,910,178.88	178,536,614.68
Other current assets		53,685,701.28	48,600,000.00
Current assets	(LIV)	8,770,704.43	80,564,032.90
Non-current assets		299,366,584.59	307,700,647.58
Long-term equity investments		-273,615,413.57	-239,048,971.28
III. Current liabilities			
Accounts payable		9,153,084.38	2,900,000.00
Short-term debt		9,153,084.38	2,900,000.00
Contract liabilities		387,500,000.00	550,250,000.00
Other current liabilities	(LIV)	151,420,250.00	
Current liabilities		548,073,334.38	553,150,000.00
Long-term liabilities		324,220,000.00	428,342,970.00
Other long-term liabilities		51,554,507.56	30,297,107.09
Long-term liabilities	(LIV)	56,121,295.37	60,676,565.61
Long-term liabilities		431,895,802.93	519,316,642.70
Other long-term liabilities		116,177,531.45	33,833,357.30
IV. Total assets		78,462.87	-38,704.15
Other long-term liabilities		69,861,145.20	-11,357,819.65
Other long-term liabilities	(LV)	188,734,845.77	200,092,665.42
Other long-term liabilities	(LV)	258,595,990.97	188,734,845.77

Total

Prepared by: GUAN W Checked by: JIN H Approved by: WANG M

附注
F
(A 人民币)

项目	2022 年	2021 年
一、流动资产		
货币资金	336,363,866.37	367,674,455.38
应收账款	495,591,067.36	804,490,679.80
预付款项	831,954,933.73	1,172,165,135.18
其他应收款	153,275,777.22	176,137,498.58
存货	147,419,578.70	141,102,134.39
合同资产	2,393,183.16	9,767,527.34
其他流动资产	596,762,811.79	710,127,325.96
流动资产合计	899,851,350.87	1,037,134,486.27
二、非流动资产		
长期股权投资	-67,896,417.14	135,030,648.91
固定资产	12,396,717.38	
在建工程	2,298,348.18	7,089,189.35
无形资产	32,054.56	37,820.00
其他非流动资产		
非流动资产合计	14,727,120.12	7,127,009.35
流动资产与非流动资产合计	914,578,470.99	1,044,261,495.62
应付账款	14,643,564.50	37,662,933.95
预收款项	54,309,855.16	212,313,500.00
合同负债		
应付职工薪酬		
应交税费		
其他应付款		
其他流动负债		
非流动负债		
负债合计	68,953,419.66	249,976,433.95
所有者权益	-54,226,299.54	-242,849,424.60

浙江康宁医院股份有限公司
2022年
财务报表附注
(人民币元)

项目	注	2022年12月31日	2021年12月31日
III. 流动资产			
货币资金		334,500,000.00	518,050,000.00
应收账款		120,000,000.00	
预付款项		454,500,000.00	518,050,000.00
其他应收款		306,750,000.00	411,050,000.00
存货		26,512,297.06	19,663,754.20
其他流动资产		6,421,875.00	
流动资产合计		339,684,172.06	430,713,754.20
IV. 非流动资产			
长期股权投资		114,815,827.94	87,336,245.80
V. 流动资产与非流动资产合计			
流动资产		78,462.87	-38,704.15
非流动资产		-7,228,425.87	-20,521,234.04
流动资产与非流动资产合计		97,615,570.76	118,136,804.80
VI. 流动资产与非流动资产合计		90,387,144.89	97,615,570.76

法定代表人: 王明

王明
GUAN W

王明
JIN H

王明
WANG M

合并现金流量表
F 2022
(A RMB Y)

项目	2022		2021	
	金额	外币金额	金额	外币金额
一、经营活动产生的现金流量				
1. 销售商品、提供劳务收到的现金	1,206,263,897.03	72,015,223.54	1,280,279,120.57	72,015,223.54
2. 收到的税费返还				
3. 收到其他与经营活动有关的现金	257,098,624.31	12,214,418.85	38,999,577.13	12,214,418.85
经营活动现金流入小计	1,463,362,521.34	84,229,642.39	1,318,578,697.70	84,229,642.39
1. 购买商品、接受劳务支付的现金	(1,206,263,897.03)	(72,015,223.54)	(1,280,279,120.57)	(72,015,223.54)
2. 支付给职工以及为职工支付的现金	(23,592,089.88)	(1,221,418.85)	(24,220,782.31)	(1,221,418.85)
3. 支付的各项税费	(24,220,782.31)	(1,221,418.85)	(24,220,782.31)	(1,221,418.85)
4. 支付其他与经营活动有关的现金	(88,165,395.59)	(4,313,000.00)	(88,165,395.59)	(4,313,000.00)
经营活动现金流出小计	(1,542,242,164.91)	(18,779,061.25)	(1,617,876,080.78)	(18,779,061.25)
经营活动产生的现金流量净额	(98,879,643.57)	(4,549,418.86)	(299,297,383.08)	(4,549,418.86)
二、投资活动产生的现金流量				
1. 收回投资收到的现金				
2. 取得投资收益收到的现金				
3. 处置固定资产、无形资产和其他长期资产收回的现金净额	16,913,137.71			
4. 处置子公司及其他营业单位收到的现金净额				
5. 收到其他与投资活动有关的现金	12,214,418.85			
投资活动现金流入小计	29,127,556.56			
1. 购建固定资产、无形资产和其他长期资产支付的现金	(88,165,395.59)			
2. 投资支付的现金				
3. 取得子公司及其他营业单位支付的现金净额				
4. 支付其他与投资活动有关的现金				
投资活动现金流出小计	(88,165,395.59)			
投资活动产生的现金流量净额	(59,037,839.03)			
三、筹资活动产生的现金流量				
1. 吸收投资收到的现金				
2. 发行债券收到的现金				
3. 取得借款收到的现金				
4. 收到其他与筹资活动有关的现金				
筹资活动现金流入小计				
1. 偿还债务支付的现金				
2. 分配股利、利润或偿付利息支付的现金				
3. 支付其他与筹资活动有关的现金				
筹资活动现金流出小计				
筹资活动产生的现金流量净额				
四、汇率变动对现金及现金等价物的影响				
五、现金及现金等价物净增加额	(127,790,026.10)	(4,549,418.86)	(299,297,383.08)	(4,549,418.86)
六、现金及现金等价物期初余额	1,390,652,547.47	72,015,223.54	1,617,876,080.78	72,015,223.54
七、现金及现金等价物期末余额	1,262,862,521.37	67,465,804.68	1,318,578,697.70	67,465,804.68

Capital and Other Equity
For Year 2022
(All figures in RMB Yuan)

Item	2022		2021	
	End of the Period	Beginning of the Period	End of the Period	Beginning of the Period
(IV) Other Equity				
1. Capital Reserve				
2. Capital Reserve				
3. Surplus Reserve				
4. Other Reserves				
5. Other Equity				
6. Other				
(V) Special Reserve				
1. Special Reserve				
2. Other				
(VI) Total	4,698,718.86	5,327,411.29	628,692.43	5,327,411.29
I. Total Equity	74,600,300.00	74,600,300.00	233,506,534.43	1,201,584,944.86
II. Total Liabilities	38,999,577.13	38,999,577.13	124,317,673.97	1,325,902,618.83

Capital and Other Items
 现金流量表
 2022
 (A) (人民币千元)

	2022	2021	2020	2019	2018
	人民币千元	人民币千元	人民币千元	人民币千元	人民币千元
一、经营活动产生的现金流量					
1. 销售商品、提供劳务收到的现金	1,208,263,897.03	1,208,263,897.03	1,208,263,897.03	1,280,279,120.57	1,280,279,120.57
2. 收到的税费返还					
3. 收到其他与经营活动有关的现金	38,599,577.13	38,599,577.13	38,599,577.13	38,599,577.13	38,599,577.13
经营活动现金流入小计	1,246,863,474.16	1,246,863,474.16	1,246,863,474.16	1,318,878,697.70	1,318,878,697.70
1. 购买商品、接受劳务支付的现金	(1,208,263,897.03)	(1,208,263,897.03)	(1,208,263,897.03)	(1,280,279,120.57)	(1,280,279,120.57)
2. 支付给职工以及为职工支付的现金	(120,826,389.70)	(120,826,389.70)	(120,826,389.70)	(120,826,389.70)	(120,826,389.70)
3. 支付的各项税费	(120,826,389.70)	(120,826,389.70)	(120,826,389.70)	(120,826,389.70)	(120,826,389.70)
4. 支付其他与经营活动有关的现金	(120,826,389.70)	(120,826,389.70)	(120,826,389.70)	(120,826,389.70)	(120,826,389.70)
经营活动现金流出小计	(1,550,742,906.13)	(1,550,742,906.13)	(1,550,742,906.13)	(1,642,762,229.67)	(1,642,762,229.67)
经营活动产生的现金流量净额	(303,879,431.97)	(303,879,431.97)	(303,879,431.97)	(323,883,531.97)	(323,883,531.97)
二、投资活动产生的现金流量					
1. 收回投资收到的现金					
2. 取得投资收益收到的现金					
3. 处置固定资产、无形资产和其他长期资产收回的现金净额					
4. 处置子公司及其他营业单位收到的现金净额					
5. 收到其他与投资活动有关的现金					
投资活动现金流入小计					
1. 购建固定资产、无形资产和其他长期资产支付的现金					
2. 投资支付的现金					
3. 支付其他与投资活动有关的现金					
投资活动现金流出小计					
投资活动产生的现金流量净额					
三、筹资活动产生的现金流量					
1. 吸收投资收到的现金					
2. 取得借款收到的现金					
3. 收到其他与筹资活动有关的现金					
筹资活动现金流入小计					
1. 偿还债务支付的现金					
2. 支付其他与筹资活动有关的现金					
筹资活动现金流出小计					
筹资活动产生的现金流量净额					
四、汇率变动对现金及现金等价物的影响					
五、现金及现金等价物净增加额	(303,879,431.97)	(303,879,431.97)	(303,879,431.97)	(323,883,531.97)	(323,883,531.97)
六、期初现金及现金等价物余额	74,600,300.00	74,600,300.00	74,600,300.00	74,600,300.00	74,600,300.00
七、期末现金及现金等价物余额	44,220,868.03	44,220,868.03	44,220,868.03	40,716,768.03	40,716,768.03

会计主管：王明
 主管会计：王明
 财务总监：王明
 总经理：王明

资产负债表附注
 截至2022年12月31日
 (A 币种为人民币)

项目	2022年12月31日	2021年12月31日
流动资产		
货币资金	1,234,567.89	987,654.32
应收账款	567,890.12	432,109.87
预付款项	123,456.78	98,765.43
其他流动资产	345,678.90	210,987.65
非流动资产		
长期股权投资	876,543.21	765,432.10
固定资产	2,345,678.90	1,987,654.32
无形资产	123,456.78	109,876.54
其他非流动资产	456,789.01	321,098.76
负债		
流动负债		
应付账款	654,321.09	543,210.98
预收款项	234,567.89	198,765.43
其他流动负债	123,456.78	109,876.54
非流动负债		
长期借款	765,432.10	654,321.09
其他非流动负债	321,098.76	210,987.65
所有者权益		
实收资本	3,456,789.01	3,210,987.65
资本公积	123,456.78	109,876.54
盈余公积	234,567.89	198,765.43
未分配利润	1,234,567.89	987,654.32

附 表 1 2022 年 度 财 务 报 告 附 录
F 附 表 1 2022
(A 表 单 位: 人 民 币 元)

	初 始 金 额	增 加 金 额	减 少 金 额	结 尾 金 额	备 注
I. 非流动资产合计	74,600,500.00	834,138,174.86	23,311,143.84	36,593,228.71	1,115,307,162.39
长期股权投资				5,430,444.01	5,430,444.01
其他权益工具投资					
其他非流动金融资产					
固定资产					
在建工程					
无形资产					
开发支出					
商誉					
长期待摊费用					
递延所得税资产					
其他非流动资产					
II. 流动资产合计	74,600,500.00	834,138,174.86	23,311,143.84	36,593,228.71	1,120,737,606.60
货币资金					
(一) 库存现金					
(二) 银行存款					
(三) 其他货币资金					
应收账款					
1. 应收票据					
2. 应收账款					
3. 应收款项融资					
其他应收款					
1. 应收股利					
2. 应收利息					
3. 应收其他款项					
4. 其他					
预付款项					
存货					
合同资产					
持有待售资产					
一年内到期的非流动资产					
其他流动资产					
其他非流动资产					
III. 非流动负债合计					
长期应付款					
长期应付职工薪酬					
预计负债					
递延所得税负债					
其他非流动负债					
IV. 流动负债合计					
短期借款					
应付账款					
应付票据					
应付职工薪酬					
应交税费					
其他应付款					
一年内到期的非流动负债					
其他流动负债					
V. 所有者权益合计					
实收资本					
资本公积					
盈余公积					
未分配利润					
其他所有者权益					
VI. 其他综合收益合计					
其他综合收益					
其他					
I. 非流动资产合计	74,600,500.00	834,138,174.86	23,311,143.84	36,593,228.71	1,115,307,162.39
长期股权投资				5,430,444.01	5,430,444.01
其他权益工具投资					
其他非流动金融资产					
固定资产					
在建工程					
无形资产					
开发支出					
商誉					
长期待摊费用					
递延所得税资产					
其他非流动资产					
II. 流动资产合计	74,600,500.00	834,138,174.86	23,311,143.84	36,593,228.71	1,120,737,606.60
货币资金					
(一) 库存现金					
(二) 银行存款					
(三) 其他货币资金					
应收账款					
1. 应收票据					
2. 应收账款					
3. 应收款项融资					
其他应收款					
1. 应收股利					
2. 应收利息					
3. 应收其他款项					
4. 其他					
预付款项					
存货					
合同资产					
持有待售资产					
一年内到期的非流动资产					
其他流动资产					
其他非流动资产					
III. 非流动负债合计					
长期应付款					
长期应付职工薪酬					
预计负债					
递延所得税负债					
其他非流动负债					
IV. 流动负债合计					
短期借款					
应付账款					
应付票据					
应付职工薪酬					
应交税费					
其他应付款					
一年内到期的非流动负债					
其他流动负债					
V. 所有者权益合计					
实收资本					
资本公积					
盈余公积					
未分配利润					
其他所有者权益					
VI. 其他综合收益合计					
其他综合收益					
其他					

制表人: 王 王 王
审核人: 王 王 王
会计: 王 王 王
主管: 王 王 王

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

I. General Information

(I) Company Name

Wenzhou Kangning Hospital Co., Ltd. (Company Name)
温州市康宁精神康复医院 (Wenzhou Kangning Mental Rehabilitation Hospital)
PRC Formed in 1996. The Company is a public company.

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

II. Basis of Preparation

(I) Basis of Preparation

The financial statements are prepared on the basis of the historical cost principle, except for the investment property measured at fair value. The financial statements are prepared on the basis of the accrual basis of accounting. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China.

(II) Going Concern

The Company is a going concern.

III. Significant Accounting Policies

1. The Company's financial statements are prepared on the basis of the historical cost principle, except for the investment property measured at fair value. The financial statements are prepared on the basis of the accrual basis of accounting. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China.
2. The Company's financial statements are prepared on the basis of the historical cost principle, except for the investment property measured at fair value. The financial statements are prepared on the basis of the accrual basis of accounting. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China.
3. The Company's financial statements are prepared on the basis of the historical cost principle, except for the investment property measured at fair value. The financial statements are prepared on the basis of the accrual basis of accounting. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China. The financial statements are prepared on the basis of the Chinese Accounting Standards for Enterprises (CAS) issued by the Ministry of Finance of the People's Republic of China.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(I) **Revenue Recognition**
The Company recognizes revenue when the following conditions are met: (1) the contract is approved and enforceable; (2) the rights and obligations are clearly defined; (3) the payment terms are clear; (4) the probability of receiving the consideration is high; (5) the cost of the transaction can be reliably measured. Revenue is recognized at the time of delivery of goods or services, or when the performance obligation is satisfied.

(II) **Provisions, Contingent Liabilities and Contingent Assets**
Provisions are recognized when the Company has a present obligation as a result of past events, and it is probable that an outflow of resources will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

(III) **Other Accounting Policies**
The Company follows the accounting policies of the PRC.

(I) **Financial Instruments**
Financial instruments are recognized when the Company becomes a party to the financial instrument contract. The classification and measurement of financial instruments depend on the business model and the contractual cash flows characteristics.

() **Other Accounting Policies**
The Company follows the accounting policies of the PRC.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

() A company shall use the historical cost method to measure its assets and liabilities, except for the following cases:

B. Intangible assets: For intangible assets that are identifiable and can be reliably measured, the company shall use the cost method to measure them. For intangible assets that are not identifiable or cannot be reliably measured, the company shall use the amortization method to measure them. For intangible assets that are not identifiable or cannot be reliably measured, the company shall use the amortization method to measure them. For intangible assets that are not identifiable or cannot be reliably measured, the company shall use the amortization method to measure them.

T. For the purpose of this report, the company shall use the historical cost method to measure its assets and liabilities, except for the following cases:

(I) P. For the purpose of this report, the company shall use the historical cost method to measure its assets and liabilities, except for the following cases:

1. S. For the purpose of this report, the company shall use the historical cost method to measure its assets and liabilities, except for the following cases:

T. For the purpose of this report, the company shall use the historical cost method to measure its assets and liabilities, except for the following cases:

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(I) Revenue Recognition

2. Contract Revenue

The Company's revenue is derived from the sale of medical services, including hospitalization, outpatient, and emergency services. Revenue is recognized when the service is provided and the amount is measurable. For hospitalization services, revenue is recognized as the patient is discharged. For outpatient services, revenue is recognized when the patient is seen by the doctor. For emergency services, revenue is recognized when the patient is admitted to the hospital. The Company also provides medical equipment and supplies, which are recognized as revenue when the equipment or supplies are delivered to the customer and the amount is measurable.

(1) Hospitalization Services

For hospitalization services, revenue is recognized when the patient is discharged. The amount of revenue is determined by the hospital's billing system, which is based on the patient's medical history, the services provided, and the hospital's rates.

For outpatient services, revenue is recognized when the patient is seen by the doctor. The amount of revenue is determined by the hospital's billing system, which is based on the patient's medical history, the services provided, and the hospital's rates.

For emergency services, revenue is recognized when the patient is admitted to the hospital. The amount of revenue is determined by the hospital's billing system, which is based on the patient's medical history, the services provided, and the hospital's rates.

For medical equipment and supplies, revenue is recognized when the equipment or supplies are delivered to the customer and the amount is measurable. The amount of revenue is determined by the price of the equipment or supplies and the quantity delivered.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(I) Revenue Recognition

2. Contract Revenue

(1) Income from the Sale of Goods

When the Company sells goods, it recognizes revenue when the following conditions are met: (1) The Company has transferred the ownership of the goods to the buyer; (2) The Company has transferred the risks and rewards of ownership of the goods to the buyer; (3) The amount of revenue can be reliably measured; (4) It is probable that the Company will receive the economic benefits associated with the transaction; (5) The costs incurred by the Company in the transaction can be reliably measured.

(2) Income from the Provision of Services

Governance

When the Company provides services, it recognizes revenue when the following conditions are met: (1) The Company has completed the service; (2) The amount of revenue can be reliably measured; (3) It is probable that the Company will receive the economic benefits associated with the transaction; (4) The costs incurred by the Company in the transaction can be reliably measured.



Wen Zhou Kang Ning Hospital Co., Ltd.
Annual Report
2022
(A RMB Yuan)



Wen Zhou Kang Ning Hospital Co., Ltd.
Annual Report
2022
(A RMB Y)

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Financial Instruments

1. Cash and cash equivalents

1 T 17241 547.5012 T 0 -1.4 TD [(1) 1 T 172 47T (C 2 2 1)

Wen Zhou Kang Ning Hospital Co., Ltd.
Annual Report
2022
(A RMB Yuan)

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Financial instruments

2. Recognition and measurement of financial instruments

(3) Financial liabilities

Financial liabilities are initially measured at fair value. For financial liabilities that are not measured at fair value through profit or loss, transaction costs are included in the initial measurement. For financial liabilities that are measured at fair value through profit or loss, transaction costs are recognized as expenses. Subsequent measurement of financial liabilities is determined by the method of measurement. Financial liabilities are derecognized when the contractual obligations are extinguished or expired, or the transferee has assumed the financial liability.

At the end of the reporting period, the carrying amount of financial liabilities is as follows:

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(1) Financial Instruments

2. Recognition, Measurement and Derecognition

(6) Financial Assets

Financial assets are classified into three categories: financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income, and financial assets measured at fair value through profit or loss.

Derecognition of financial assets occurs when the contractual rights to receive cash flows from the assets expire, or the company has transferred the assets and the transfer qualifies for derecognition.

Assets are derecognized when the company has transferred the risks and rewards of ownership of the assets.

3. Derivatives and Hedging

Wen Zhou Kang Ning Hospital Co., Ltd. uses derivatives to manage its foreign exchange risk:

- To hedge the foreign exchange risk of foreign currency receivables;
- To hedge the foreign exchange risk of foreign currency payables;
- To hedge the foreign exchange risk of foreign currency loans.

All derivatives are measured at fair value through profit or loss.

Interest income and expense on derivatives are recognized in the profit or loss account.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates (continued)

(1) Financial Instruments (continued)

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(1) Financial Instruments

4. Derivatives

Wenzhou Kangning Hospital Co., Ltd. does not use derivatives for trading purposes. The Company's derivatives are primarily used for hedging foreign exchange risk. The Company's derivatives are classified as financial assets or financial liabilities based on the nature of the underlying instrument.

Wenzhou Kangning Hospital Co., Ltd. uses derivatives to hedge foreign exchange risk. The Company's derivatives are classified as financial assets or financial liabilities based on the nature of the underlying instrument. The Company's derivatives are measured at fair value.

Wenzhou Kangning Hospital Co., Ltd. uses derivatives to hedge foreign exchange risk. The Company's derivatives are classified as financial assets or financial liabilities based on the nature of the underlying instrument. The Company's derivatives are measured at fair value. The Company's derivatives are primarily used for hedging foreign exchange risk.

5. Derivatives

The Company's derivatives are primarily used for hedging foreign exchange risk. The Company's derivatives are classified as financial assets or financial liabilities based on the nature of the underlying instrument. The Company's derivatives are measured at fair value. The Company's derivatives are primarily used for hedging foreign exchange risk.

6. Derivatives

The Company's derivatives are primarily used for hedging foreign exchange risk. The Company's derivatives are classified as financial assets or financial liabilities based on the nature of the underlying instrument. The Company's derivatives are measured at fair value. The Company's derivatives are primarily used for hedging foreign exchange risk.

The Company's derivatives are primarily used for hedging foreign exchange risk. The Company's derivatives are classified as financial assets or financial liabilities based on the nature of the underlying instrument. The Company's derivatives are measured at fair value. The Company's derivatives are primarily used for hedging foreign exchange risk.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(一) Financial Instruments

6. Financial Instruments

I. Classification and Measurement of Financial Instruments
C. Measurement of Financial Instruments
The Company measures financial instruments at initial recognition based on their contractual terms and business model. For financial assets, the Company classifies them into three categories: financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income, and financial assets measured at fair value through profit or loss. For financial liabilities, the Company classifies them into two categories: financial liabilities measured at amortized cost and financial liabilities measured at fair value through profit or loss.

I. Classification and Measurement of Financial Instruments
C. Measurement of Financial Instruments
The Company measures financial instruments at initial recognition based on their contractual terms and business model. For financial assets, the Company classifies them into three categories: financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income, and financial assets measured at fair value through profit or loss. For financial liabilities, the Company classifies them into two categories: financial liabilities measured at amortized cost and financial liabilities measured at fair value through profit or loss.

I. Classification and Measurement of Financial Instruments
C. Measurement of Financial Instruments
The Company measures financial instruments at initial recognition based on their contractual terms and business model. For financial assets, the Company classifies them into three categories: financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income, and financial assets measured at fair value through profit or loss. For financial liabilities, the Company classifies them into two categories: financial liabilities measured at amortized cost and financial liabilities measured at fair value through profit or loss.

I. Classification and Measurement of Financial Instruments
C. Measurement of Financial Instruments
The Company measures financial instruments at initial recognition based on their contractual terms and business model. For financial assets, the Company classifies them into three categories: financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income, and financial assets measured at fair value through profit or loss. For financial liabilities, the Company classifies them into two categories: financial liabilities measured at amortized cost and financial liabilities measured at fair value through profit or loss.

F. Impairment of Financial Instruments
B. Expected Credit Loss (ECL) Model
N.14 - R (2017),
C. Measurement of Financial Instruments
The Company measures financial instruments at initial recognition based on their contractual terms and business model. For financial assets, the Company classifies them into three categories: financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income, and financial assets measured at fair value through profit or loss. For financial liabilities, the Company classifies them into two categories: financial liabilities measured at amortized cost and financial liabilities measured at fair value through profit or loss.

Wen Zhou Kang Ning Hospital Co., Ltd.
Annual Report
2022
(A RMB Y)

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(I) Income tax

1. *Company*

Income tax is calculated based on the taxable income for the period, and is recognized as a liability. The company's income tax is calculated based on the taxable income for the period, and is recognized as a liability. The company's income tax is calculated based on the taxable income for the period, and is recognized as a liability.

Income tax is calculated based on the taxable income for the period, and is recognized as a liability. The company's income tax is calculated based on the taxable income for the period, and is recognized as a liability. The company's income tax is calculated based on the taxable income for the period, and is recognized as a liability.
2. *Variable interest entities*

Income tax is calculated based on the taxable income for the period, and is recognized as a liability. The company's income tax is calculated based on the taxable income for the period, and is recognized as a liability. The company's income tax is calculated based on the taxable income for the period, and is recognized as a liability.
3. *Business combinations*

Income tax is calculated based on the taxable income for the period, and is recognized as a liability. The company's income tax is calculated based on the taxable income for the period, and is recognized as a liability. The company's income tax is calculated based on the taxable income for the period, and is recognized as a liability.

Income tax is calculated based on the taxable income for the period, and is recognized as a liability. The company's income tax is calculated based on the taxable income for the period, and is recognized as a liability. The company's income tax is calculated based on the taxable income for the period, and is recognized as a liability.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(I) Income Statement

4. *Investment Income*
 A company's investment income is derived from the dividends and interest received from its investments in equity securities and debt securities.
5. *Other Income*
 This item includes income from the disposal of non-current assets, income from the disposal of intangible assets, income from the disposal of long-term equity investments, and other income.

(II) Cost of Sales

1. *Research and Development Expenses*
 Research and development expenses are the costs incurred by the company in the process of creating new products or technologies. These expenses are recognized as an expense in the period in which they are incurred. If the research and development activities are expected to result in the development of an intangible asset that meets the recognition criteria, the related costs should be capitalized and amortized over its useful life.
2. *Depreciation and Amortization*
 Depreciation and amortization are calculated based on the cost of the asset, its estimated useful life, and its residual value. Depreciation is calculated using the straight-line method, and amortization is calculated using the straight-line method.



Net Profit attributable to the Company
For the year ended December 31, 2022
(All amounts in RMB Yuan)

III. Significant changes in net profit attributable to the Company (in RMB Yuan)

(III) Loss from disposal of long-term investments (in RMB Yuan)

2. Disposal of long-term investments

Notes to Financial Statements

Fiscal year: 2022
(Amount in RMB Yuan)

III. Significant Accounting Policies and Accounting Estimates

(III) Long-Term Equity Investments

3. Significant Accounting Policies and Accounting Estimates

(2) Long-Term Equity Investments

Under the long-term equity investment, the company holds shares in Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital) and Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.). The company holds shares in Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.) and Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.).

The company holds shares in Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.) and Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.). The company holds shares in Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.) and Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.).

() 0.018 GS0)0.. W 0.5 (8 T

Notes to Financial Statements

For the year ended December 31, 2022

(All amounts are in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(III) Long-term equity investments

3. Significant long-term equity investments

(3) Donghai Technology Co., Ltd.

Wenzhou Kangning Hospital Co., Ltd. holds 30% of the equity of Donghai Technology Co., Ltd. (Donghai Technology Co., Ltd. is a company limited by shares). Donghai Technology Co., Ltd. is a company limited by shares established in Zhejiang Province, China, with registered capital of RMB100 million. Donghai Technology Co., Ltd. is engaged in the business of research and development, production and sales of medical equipment. Donghai Technology Co., Ltd. is a company limited by shares established in Zhejiang Province, China, with registered capital of RMB100 million. Donghai Technology Co., Ltd. is engaged in the business of research and development, production and sales of medical equipment.

Donghai Technology Co., Ltd. is a company limited by shares established in Zhejiang Province, China, with registered capital of RMB100 million. Donghai Technology Co., Ltd. is engaged in the business of research and development, production and sales of medical equipment. Donghai Technology Co., Ltd. is a company limited by shares established in Zhejiang Province, China, with registered capital of RMB100 million. Donghai Technology Co., Ltd. is engaged in the business of research and development, production and sales of medical equipment.

Donghai Technology Co., Ltd. is a company limited by shares established in Zhejiang Province, China, with registered capital of RMB100 million. Donghai Technology Co., Ltd. is engaged in the business of research and development, production and sales of medical equipment. Donghai Technology Co., Ltd. is a company limited by shares established in Zhejiang Province, China, with registered capital of RMB100 million. Donghai Technology Co., Ltd. is engaged in the business of research and development, production and sales of medical equipment.

Donghai Technology Co., Ltd. is a company limited by shares established in Zhejiang Province, China, with registered capital of RMB100 million. Donghai Technology Co., Ltd. is engaged in the business of research and development, production and sales of medical equipment. Donghai Technology Co., Ltd. is a company limited by shares established in Zhejiang Province, China, with registered capital of RMB100 million. Donghai Technology Co., Ltd. is engaged in the business of research and development, production and sales of medical equipment.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(I) Financial Instruments

- R**ecognition, measurement and derecognition of financial instruments

Financial instruments are recognized when the company becomes a party to the contractual provisions of the instrument. Financial assets are measured at initial recognition at fair value plus or minus transaction costs that are directly attributable to the acquisition of the financial asset. Financial liabilities are measured at initial recognition at fair value. Subsequent measurement of financial instruments depends on their classification. Financial assets are classified into three categories: financial assets at fair value through profit or loss, financial assets at amortized cost, and financial assets at fair value through other comprehensive income. Financial liabilities are classified into financial liabilities at fair value through profit or loss and financial liabilities at amortized cost. Financial assets at fair value through profit or loss are measured at fair value. Financial assets at amortized cost and financial liabilities at amortized cost are measured at amortized cost using the effective interest rate method. Financial assets at fair value through other comprehensive income are measured at fair value. Changes in the fair value of financial assets at fair value through other comprehensive income are recognized in other comprehensive income. Financial assets at fair value through profit or loss are measured at fair value. Changes in the fair value of financial assets at fair value through profit or loss are recognized in profit or loss. Financial liabilities at fair value through profit or loss are measured at fair value. Changes in the fair value of financial liabilities at fair value through profit or loss are recognized in profit or loss. Financial liabilities at amortized cost are measured at amortized cost using the effective interest rate method. Changes in the fair value of financial liabilities at amortized cost are recognized in profit or loss. Financial assets at fair value through other comprehensive income are measured at fair value. Changes in the fair value of financial assets at fair value through other comprehensive income are recognized in other comprehensive income. Financial assets at fair value through profit or loss are measured at fair value. Changes in the fair value of financial assets at fair value through profit or loss are recognized in profit or loss. Financial liabilities at fair value through profit or loss are measured at fair value. Changes in the fair value of financial liabilities at fair value through profit or loss are recognized in profit or loss. Financial liabilities at amortized cost are measured at amortized cost using the effective interest rate method. Changes in the fair value of financial liabilities at amortized cost are recognized in profit or loss.

 - Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are measured at fair value. Changes in the fair value of financial assets at fair value through profit or loss are recognized in profit or loss.
 - Financial assets at amortized cost

Financial assets at amortized cost are measured at amortized cost using the effective interest rate method. Changes in the fair value of financial assets at amortized cost are recognized in profit or loss.
- D**erecognition of financial instruments

Financial assets are derecognized when the contractual rights to the cash flows from the financial assets expire, or the company transfers the financial assets and the transfer qualifies for derecognition. Financial liabilities are derecognized when the contractual obligations are extinguished, or the company transfers the financial liabilities and the transfer qualifies for derecognition.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(I) Financial Instruments

2. Derivatives

The Company does not use derivatives for trading purposes. The Company uses derivatives to hedge the foreign exchange risk of foreign currency-denominated assets and liabilities.

Instrument	Derivative Instrument	Derivative Instrument (Type)	Notional Amount (%)	Accounting Treatment (%)
Bank	Swap	35	5	2.71
Money	Swap	3-10	0-5	9.50-33.33
Money	Swap	4-10	5	9.50-23.75
Exchange	Swap	3-10	0-5	9.50-33.33

3. Derivatives

The Company uses derivatives to hedge the foreign exchange risk of foreign currency-denominated assets and liabilities. The Company uses derivatives to hedge the foreign exchange risk of foreign currency-denominated assets and liabilities.

(II) Contract Assets and Contract Liabilities

Contract assets are recognized when the Company has performed its obligations under the contract and has the right to receive consideration. Contract liabilities are recognized when the Company has received consideration from the customer but has not yet performed its obligations under the contract.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(I) Basic accounting policies

1. Recognition and measurement basis

The Company uses the accrual basis of accounting. The measurement basis is historical cost, except for financial assets and financial liabilities measured at fair value. The measurement basis of intangible assets is cost, except for intangible assets that are available for sale and measured at fair value.

Assets and liabilities are measured at fair value when they are acquired or disposed of. Fair value is the price that would be received to sell an asset or settle a liability in an orderly transaction between market participants at the measurement date.

2. Depreciation and amortization

The Company uses the straight-line method to depreciate property, plant and equipment and to amortize intangible assets.

The Company uses the straight-line method to depreciate property, plant and equipment and to amortize intangible assets.

(1) Depreciation of property, plant and equipment: The Company uses the straight-line method to depreciate property, plant and equipment. The depreciation period and the estimated residual value are as follows:

(2) Depreciation of property, plant and equipment: The Company uses the straight-line method to depreciate property, plant and equipment.

(3) Depreciation of property, plant and equipment: The Company uses the straight-line method to depreciate property, plant and equipment.

The Company uses the straight-line method to depreciate property, plant and equipment and to amortize intangible assets.

3. Impairment test

The Company tests for impairment of non-financial assets at the end of each reporting period. If the carrying amount of the asset exceeds its recoverable amount, the carrying amount is reduced to its recoverable amount.

The Company tests for impairment of non-financial assets at the end of each reporting period. If the carrying amount of the asset exceeds its recoverable amount, the carrying amount is reduced to its recoverable amount.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(I) Business combination

4. Merger of subsidiaries

Fully controlled subsidiaries are those entities in which the Company holds the majority of the voting rights and has the power to control the financial and operating policies of the entity. Fully controlled subsidiaries are consolidated into the Company's financial statements from the date of acquisition.

Fully controlled subsidiaries are those entities in which the Company holds the majority of the voting rights and has the power to control the financial and operating policies of the entity. Fully controlled subsidiaries are consolidated into the Company's financial statements from the date of acquisition.

Discontinued operations are those operations and cash flows that have been disposed of or are classified as held for sale, and that are measured and presented in the financial statements separately from continuing operations.

(II) Intangible assets

1. Valuation

(1) Intangible assets are those assets without physical form but which can be identified and controlled by the Company, and whose benefits will flow to the Company in the future.

(2) Software

The Company's software is classified as intangible assets. The cost of software is measured at the purchase price plus related taxes and other costs incurred to bring the software to the condition necessary for it to be available for use.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(II) Intangible Assets

2. Expected Useful Life

Intangible Assets	Expected Useful Life		Amortization Method	Residual Value
	Year	Month		
Land Use Rights	40-50	5	Straight-line	None
Software	5	5	Straight-line	None
Patent Rights	20-30	5	Straight-line	None
Medical Licenses	5-20	5	Straight-line	None
Trademarks	10	5	Straight-line	None

- Software: Software is developed internally and its cost is capitalized when the software meets the recognition criteria. The cost of software is amortized over its expected useful life on a straight-line basis.

Patent Rights: Patent rights are recognized as intangible assets when the company obtains the patent rights and the cost is capitalized. The cost of patent rights is amortized over its expected useful life on a straight-line basis.

Medical Licenses: Medical licenses are recognized as intangible assets when the company obtains the licenses and the cost is capitalized. The cost of medical licenses is amortized over its expected useful life on a straight-line basis.

Trademarks: Trademarks are recognized as intangible assets when the company obtains the trademarks and the cost is capitalized. The cost of trademarks is amortized over its expected useful life on a straight-line basis.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(I) Investment in Subsidiaries

4. Cost Method

The Company uses the cost method to account for its investment in subsidiaries. The initial investment cost is determined based on the actual cost of the investment. The carrying amount of the investment is adjusted only when there is a change in the carrying amount of the investment, such as a change in the carrying amount of the investment due to a change in the carrying amount of the investment.

- (1) Investment in subsidiaries: The Company uses the cost method to account for its investment in subsidiaries. The initial investment cost is determined based on the actual cost of the investment. The carrying amount of the investment is adjusted only when there is a change in the carrying amount of the investment, such as a change in the carrying amount of the investment due to a change in the carrying amount of the investment.
- (2) Investment in subsidiaries: The Company uses the cost method to account for its investment in subsidiaries. The initial investment cost is determined based on the actual cost of the investment. The carrying amount of the investment is adjusted only when there is a change in the carrying amount of the investment, such as a change in the carrying amount of the investment due to a change in the carrying amount of the investment.
- (3) Investment in subsidiaries: The Company uses the cost method to account for its investment in subsidiaries. The initial investment cost is determined based on the actual cost of the investment. The carrying amount of the investment is adjusted only when there is a change in the carrying amount of the investment, such as a change in the carrying amount of the investment due to a change in the carrying amount of the investment.
- (4) Investment in subsidiaries: The Company uses the cost method to account for its investment in subsidiaries. The initial investment cost is determined based on the actual cost of the investment. The carrying amount of the investment is adjusted only when there is a change in the carrying amount of the investment, such as a change in the carrying amount of the investment due to a change in the carrying amount of the investment.
- (5) Investment in subsidiaries: The Company uses the cost method to account for its investment in subsidiaries. The initial investment cost is determined based on the actual cost of the investment. The carrying amount of the investment is adjusted only when there is a change in the carrying amount of the investment, such as a change in the carrying amount of the investment due to a change in the carrying amount of the investment.

The Company uses the cost method to account for its investment in subsidiaries. The initial investment cost is determined based on the actual cost of the investment. The carrying amount of the investment is adjusted only when there is a change in the carrying amount of the investment, such as a change in the carrying amount of the investment due to a change in the carrying amount of the investment.

(II) Investment in Associates

The Company uses the equity method to account for its investment in associates. The initial investment cost is determined based on the actual cost of the investment. The carrying amount of the investment is adjusted when there is a change in the carrying amount of the investment, such as a change in the carrying amount of the investment due to a change in the carrying amount of the investment. The Company recognizes its share of the net income or loss of the associate in its profit or loss. The Company also recognizes its share of the other comprehensive income or loss of the associate in its other comprehensive income or loss. The Company recognizes its share of the dividends or distributions received from the associate in its profit or loss.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(III) Intangible assets

Goodwill is recognized as the excess of the cost of an acquisition over the fair value of the identifiable intangible assets acquired. Goodwill is tested for impairment annually, or more frequently if there are indications of impairment. Goodwill impairment loss is recognized in the profit and loss account.

When the carrying amount of an intangible asset exceeds its recoverable amount, the carrying amount is reduced to its recoverable amount. The amount of the reduction is recognized as an impairment loss in the profit and loss account. The impairment loss is reversed in the profit and loss account if the recoverable amount of the intangible asset increases in subsequent periods.

For intangible assets with finite useful lives, the carrying amount is amortized over the useful life. The useful life is determined based on the expected economic benefits that the intangible asset will generate. The amortization expense is recognized in the profit and loss account. For intangible assets with indefinite useful lives, the carrying amount is not amortized, but tested for impairment annually, or more frequently if there are indications of impairment. The impairment loss is recognized in the profit and loss account.

Other intangible assets are tested for impairment annually, or more frequently if there are indications of impairment.

(L) Liabilities

Liabilities are recognized when the company has a present obligation that arises from past events, and the settlement of the obligation is probable and can be measured reliably.

(.) Contingent liabilities

Contingent liabilities are recognized when the company has a present obligation that arises from past events, and the settlement of the obligation is probable and can be measured reliably. Contingent liabilities are recognized in the profit and loss account.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Revenue recognition

1. **Advertising services** - The Company's advertising services are provided to clients through various channels, including television, radio, and print. Revenue is recognized when the advertising spots are aired or published, and the amount is determined based on the agreed-upon rates and the actual number of spots. The Company's advertising services are primarily provided to clients in the pharmaceutical and consumer goods industries.

When the Company provides advertising services to clients, it enters into advertising contracts with them. The Company's advertising services are primarily provided to clients in the pharmaceutical and consumer goods industries. The Company's advertising services are primarily provided to clients in the pharmaceutical and consumer goods industries. The Company's advertising services are primarily provided to clients in the pharmaceutical and consumer goods industries.

When the Company provides advertising services to clients, it enters into advertising contracts with them. The Company's advertising services are primarily provided to clients in the pharmaceutical and consumer goods industries. The Company's advertising services are primarily provided to clients in the pharmaceutical and consumer goods industries.

2. **Advertising services** - The Company's advertising services are provided to clients through various channels, including television, radio, and print. Revenue is recognized when the advertising spots are aired or published, and the amount is determined based on the agreed-upon rates and the actual number of spots.

(1) **Advertising services**

The Company's advertising services are provided to clients through various channels, including television, radio, and print. Revenue is recognized when the advertising spots are aired or published, and the amount is determined based on the agreed-upon rates and the actual number of spots. The Company's advertising services are primarily provided to clients in the pharmaceutical and consumer goods industries. The Company's advertising services are primarily provided to clients in the pharmaceutical and consumer goods industries. The Company's advertising services are primarily provided to clients in the pharmaceutical and consumer goods industries.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(1) Revenue Recognition

2. Advertising services - (continued)

(2) Domestic advertising services

Domestic advertising services refer to advertising services provided within the territory of the People's Republic of China. The revenue is recognized when the advertising spots are aired and the advertiser has accepted the advertising spots. The revenue is measured at the fair value of the advertising spots.

Domestic advertising services are provided by the Company's subsidiaries, Wenzhou Kangning Hospital Co., Ltd. and Wenzhou Kangning Hospital Co., Ltd. The revenue is recognized when the advertising spots are aired and the advertiser has accepted the advertising spots. The revenue is measured at the fair value of the advertising spots.

Domestic advertising services are provided by the Company's subsidiaries, Wenzhou Kangning Hospital Co., Ltd. and Wenzhou Kangning Hospital Co., Ltd. The revenue is recognized when the advertising spots are aired and the advertiser has accepted the advertising spots. The revenue is measured at the fair value of the advertising spots.

Domestic advertising services are provided by the Company's subsidiaries, Wenzhou Kangning Hospital Co., Ltd. and Wenzhou Kangning Hospital Co., Ltd. The revenue is recognized when the advertising spots are aired and the advertiser has accepted the advertising spots. The revenue is measured at the fair value of the advertising spots.

Domestic advertising services are provided by the Company's subsidiaries, Wenzhou Kangning Hospital Co., Ltd. and Wenzhou Kangning Hospital Co., Ltd. The revenue is recognized when the advertising spots are aired and the advertiser has accepted the advertising spots. The revenue is measured at the fair value of the advertising spots.

3. Advertising services

Advertising services refer to advertising services provided by the Company and its subsidiaries. The revenue is recognized when the advertising spots are aired and the advertiser has accepted the advertising spots. The revenue is measured at the fair value of the advertising spots.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Presentation of financial statements

The Company's financial statements are presented in Renminbi Yuan (RMB Yuan), unless otherwise specified.

(1) The Company uses the historical cost method for measuring assets and liabilities.

(2) The Company uses the fair value method for measuring assets and liabilities.

(3) The Company uses the cost of completion method for measuring assets and liabilities.

Assets and liabilities are measured at the lower of cost and net realizable value.

For the purpose of financial reporting, the Company uses the historical cost method for measuring assets and liabilities, except for the following items:

Warrant options are measured at fair value. The fair value of warrant options is determined using the Black-Scholes model.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Revenue recognition

At the end of the reporting period, the Company has not recognized any revenue from the sale of goods, the provision of services, the transfer of assets, or the construction of real estate. The Company has not recognized any revenue from the sale of goods, the provision of services, the transfer of assets, or the construction of real estate.

1. Revenue recognition

The Company recognizes revenue when the following conditions are met: (1) the Company has transferred control of the goods to the customer; (2) the Company has no further obligations to the customer; (3) the revenue amount is measurable; (4) the economic benefits of the transaction will flow to the Company; (5) the transaction has a commercial substance.

The Company recognizes revenue when the following conditions are met: (1) the Company has transferred control of the goods to the customer; (2) the Company has no further obligations to the customer; (3) the revenue amount is measurable; (4) the economic benefits of the transaction will flow to the Company; (5) the transaction has a commercial substance.

The Company recognizes revenue when the following conditions are met: (1) the Company has transferred control of the goods to the customer; (2) the Company has no further obligations to the customer; (3) the revenue amount is measurable; (4) the economic benefits of the transaction will flow to the Company; (5) the transaction has a commercial substance.

The Company recognizes revenue when the following conditions are met: (1) the Company has transferred control of the goods to the customer; (2) the Company has no further obligations to the customer; (3) the revenue amount is measurable; (4) the economic benefits of the transaction will flow to the Company; (5) the transaction has a commercial substance.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Significant accounting policies

2. Government grants

Government grants are recognized when the entity can reasonably be assured that the grant will be received and the entity will comply with the conditions attached to the grant. Government grants are measured at the fair value of the non-monetary asset received, or the fair value of the monetary asset received, less any related taxes. Government grants are recognized in profit or loss on a systematic basis over the period in which the entity recognizes the related costs. Government grants that are used to purchase or construct long-term assets are recognized as deferred income and amortized over the useful life of the related asset. Government grants that are used to compensate for losses or expenses are recognized in profit or loss when the losses or expenses are recognized. Government grants that are used to compensate for depreciation or amortization are recognized in profit or loss when the depreciation or amortization is recognized. Government grants that are used to compensate for research and development expenses are recognized in profit or loss when the research and development expenses are recognized. Government grants that are used to compensate for other expenses are recognized in profit or loss when the other expenses are recognized.

Government grants are classified into two categories: government grants that are used to purchase or construct long-term assets and government grants that are used to compensate for losses or expenses. Government grants that are used to purchase or construct long-term assets are recognized as deferred income and amortized over the useful life of the related asset. Government grants that are used to compensate for losses or expenses are recognized in profit or loss when the losses or expenses are recognized. Government grants that are used to compensate for depreciation or amortization are recognized in profit or loss when the depreciation or amortization is recognized. Government grants that are used to compensate for research and development expenses are recognized in profit or loss when the research and development expenses are recognized. Government grants that are used to compensate for other expenses are recognized in profit or loss when the other expenses are recognized.

(2) Government subsidies

Government subsidies are recognized when the entity can reasonably be assured that the subsidy will be received and the entity will comply with the conditions attached to the subsidy. Government subsidies are measured at the fair value of the non-monetary asset received, or the fair value of the monetary asset received, less any related taxes. Government subsidies are recognized in profit or loss on a systematic basis over the period in which the entity recognizes the related costs. Government subsidies that are used to purchase or construct long-term assets are recognized as deferred income and amortized over the useful life of the related asset. Government subsidies that are used to compensate for losses or expenses are recognized in profit or loss when the losses or expenses are recognized. Government subsidies that are used to compensate for depreciation or amortization are recognized in profit or loss when the depreciation or amortization is recognized. Government subsidies that are used to compensate for research and development expenses are recognized in profit or loss when the research and development expenses are recognized. Government subsidies that are used to compensate for other expenses are recognized in profit or loss when the other expenses are recognized.

Government subsidies are classified into two categories: government subsidies that are used to purchase or construct long-term assets and government subsidies that are used to compensate for losses or expenses. Government subsidies that are used to purchase or construct long-term assets are recognized as deferred income and amortized over the useful life of the related asset. Government subsidies that are used to compensate for losses or expenses are recognized in profit or loss when the losses or expenses are recognized. Government subsidies that are used to compensate for depreciation or amortization are recognized in profit or loss when the depreciation or amortization is recognized. Government subsidies that are used to compensate for research and development expenses are recognized in profit or loss when the research and development expenses are recognized. Government subsidies that are used to compensate for other expenses are recognized in profit or loss when the other expenses are recognized.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates (continued)

(II) Revenue recognition (continued)

1. Accounting policy for revenue recognition (continued)

The Company recognizes revenue when the following conditions are met: (1) The Company has transferred control of the goods to the customer; (2) The Company has no further significant obligations to the customer; (3) The amount of revenue can be reliably measured; (4) It is probable that the economic benefits will flow to the Company; (5) The costs incurred for the transaction can be reliably measured. For the sale of goods, revenue is recognized at the time of delivery. For the provision of services, revenue is recognized over the period of service. For the construction of real estate, revenue is recognized according to the progress of construction. For the provision of medical services, revenue is recognized when the patient is discharged or the service is completed.

When the Company provides medical services, it recognizes revenue based on the actual medical services provided to patients. The revenue is recognized when the patient is discharged or the service is completed.

• For the sale of goods, revenue is recognized at the time of delivery. For the provision of services, revenue is recognized over the period of service. For the construction of real estate, revenue is recognized according to the progress of construction. For the provision of medical services, revenue is recognized when the patient is discharged or the service is completed.

• For the provision of medical services, revenue is recognized when the patient is discharged or the service is completed.

• For the construction of real estate, revenue is recognized according to the progress of construction.

When the Company provides medical services, it recognizes revenue based on the actual medical services provided to patients. The revenue is recognized when the patient is discharged or the service is completed.

For the sale of goods, revenue is recognized at the time of delivery. For the provision of services, revenue is recognized over the period of service. For the construction of real estate, revenue is recognized according to the progress of construction. For the provision of medical services, revenue is recognized when the patient is discharged or the service is completed.

When the Company provides medical services, it recognizes revenue based on the actual medical services provided to patients. The revenue is recognized when the patient is discharged or the service is completed.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Revenue recognition

1. A company shall recognize revenue when it satisfies all the following conditions:

Contract has been approved and signed by the relevant parties; the rights and obligations of the contract are clearly defined; the contract has commercial substance; the company has transferred the control of the goods to the customer, and the customer has accepted the goods. The company shall recognize revenue on the basis of the expected consideration to be received from the contract.

- For contracts with a fixed or determinable price, the company shall recognize revenue at the point in time when the customer obtains control of the goods.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(1) Classification of Assets and Liabilities

I. Classification of Assets and Liabilities: Assets and liabilities are classified as current or non-current based on the expected realization of assets and the settlement of liabilities within one year (or within one operating cycle).

A. Classification of Assets: Assets are classified as current assets if they are expected to be realized within one year (or within one operating cycle). Assets that are not expected to be realized within one year (or within one operating cycle) are classified as non-current assets.

F. Classification of Liabilities: Liabilities are classified as current liabilities if they are expected to be settled within one year (or within one operating cycle). Liabilities that are not expected to be settled within one year (or within one operating cycle) are classified as non-current liabilities.

1. Classification of Current Assets: Current assets include cash, accounts receivable, prepaid expenses, other receivables, inventory, and other current assets.

2. Classification of Current Liabilities: Current liabilities include accounts payable, short-term borrowings, contract liabilities, and other current liabilities.

I. Classification of Non-current Assets: Non-current assets include long-term investments, property, plant, and equipment, intangible assets, and other non-current assets.

(2) Classification of Income and Expenses

1. Types of Income

G. Classification of Income: Income is classified as operating income or non-operating income based on whether it is derived from the company's main business activities.

G. Classification of Expenses: Expenses are classified as operating expenses or non-operating expenses based on whether they are incurred in the company's main business activities.

2. Types of Expenses

G. Classification of Expenses: Expenses are classified as operating expenses or non-operating expenses based on whether they are incurred in the company's main business activities.

Notes to Financial Statements

For the period ending December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(1) Government Grants

3. A government grant is recognized when the entity can reasonably be assured that it will receive the grant and that it will comply with the conditions attached to the grant.

A government grant related to the purchase of fixed assets is recognized as a deferred income and amortized over the useful life of the related fixed assets. The amortization is recorded as other income in the profit and loss account.

A government grant related to the purchase of intangible assets is recognized as a deferred income and amortized over the useful life of the related intangible assets. The amortization is recorded as other income in the profit and loss account.

A government grant related to the purchase of financial assets is recognized as a deferred income and amortized over the useful life of the related financial assets. The amortization is recorded as other income in the profit and loss account.

A government grant related to the purchase of other assets is recognized as a deferred income and amortized over the useful life of the related other assets. The amortization is recorded as other income in the profit and loss account.

A government grant related to the purchase of other assets is recognized as a deferred income and amortized over the useful life of the related other assets. The amortization is recorded as other income in the profit and loss account.

(2) Depreciation and Amortization

I. Depreciation is calculated using the straight-line method over the estimated useful life of the asset. The estimated useful life and depreciation rates are as follows:

Asset Category	Estimated Useful Life (Years)	Depreciation Rate (%)
Buildings	20-30	3.33-5.00
Equipment	5-10	10.00-20.00
Intangible Assets	5-10	10.00-20.00
Other Assets	5-10	10.00-20.00

D. Depreciation is recorded as depreciation expense in the profit and loss account. Amortization is recorded as amortization expense in the profit and loss account.

浙 江 康 宁 医 院 有 限 公 司
2022 年 度 报 告
(A 股 上 市 公 司 年 度 报 告)

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(1) Depreciation and Amortization

All fixed assets are depreciated on a straight-line basis over their estimated useful lives. The depreciation rates are as follows:

- **W**: Buildings, 20 years; Leasehold improvements, 5-10 years; Office equipment, 5 years; Furniture, 5 years; Transportation vehicles, 5 years; Information technology equipment, 3-5 years; Intangible assets, 5-10 years; Right-of-use assets, 5 years.
- **W**: Land use rights, 50 years; Patents, 10 years; Trademarks, 10 years; Software, 5 years; Other intangible assets, 5-10 years.

(2) Leases

All leases are classified as operating leases. The lessee recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is measured at cost, which includes the lease liability, lease payments, and other costs incurred by the lessee. The lease liability is measured at the present value of the lease payments. The right-of-use asset is depreciated over the lease term. The lease liability is recognized as an expense over the lease term.

For the year ended December 31, 2022, the company has no significant lease transactions.

The company has no significant lease transactions for COVID-19 related assets.

- **T**: The company has no significant lease transactions for COVID-19 related assets.

- **A**: The company has no significant lease transactions for COVID-19 related assets.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(1) Revenue Recognition

1. Total Revenue

(1) Revenue

Revenue is recognized when the following conditions are met: (1) the company has transferred control of the goods to the customer; (2) the company has no further significant obligations to the customer; (3) the amount of revenue can be reliably measured; (4) it is probable that the company will receive the economic benefits associated with the revenue; (5) the costs incurred or to be incurred in the process of providing the service can be reliably measured.

Revenue from the sale of goods is recognized when the goods have been delivered to the customer and the customer has accepted them.

Revenue from the provision of services is recognized over the period of time that the service is provided.

Revenue from the provision of services is recognized when the service has been completed.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Revenue from the provision of services is recognized when the service has been completed and the customer has accepted it.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Revenue

1. Total revenue

(2) License fee

As of the end of the reporting period, the Company has entered into license agreements with C... (the following table shows the details of the license fees). License fees are recognized as revenue when the license agreement is signed and the license fee is received.

• License fees (including license fees for...), license fees for...;

• License fees for...;

• License fees for... C...;

• License fees for... C...;

• License fees for... C...;

T... C... I...;

T... C...;

V...;

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Revenue recognition

1. Total revenue ()

(2) Less: ()

A. () , () , C ()

A () ()

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Revenue recognition

1. Total revenue recognition

(4) Licenses

Total revenue recognition is based on the following principles:

- Licenses are recognized as revenue when the license fee is received and the license is issued.
- Licenses are recognized as revenue when the license fee is received and the license is issued.

For licenses, the revenue is recognized when the license fee is received and the license is issued.

For licenses, the revenue is recognized when the license fee is received and the license is issued.

(5) Revenue from COVID-19

For COVID-19, the revenue is recognized when the license fee is received and the license is issued.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Revenue recognition

1. Total revenue recognition

(5) Revenue from COVID-19 testing

For the year ended December 31, 2022, the Company's revenue from COVID-19 testing is primarily derived from the provision of COVID-19 testing services to patients. The Company recognizes revenue from COVID-19 testing services when the testing results are confirmed and the related costs have been incurred. The revenue is recognized on a net basis, after deducting the related costs of the testing services. The revenue is recognized in the period in which the testing services are provided.

2. Total revenue recognition

For the year ended December 31, 2022, the Company's revenue from COVID-19 testing is primarily derived from the provision of COVID-19 testing services to patients. The Company recognizes revenue from COVID-19 testing services when the testing results are confirmed and the related costs have been incurred. The revenue is recognized on a net basis, after deducting the related costs of the testing services. The revenue is recognized in the period in which the testing services are provided. ()0.5 ()0.366.5 (▼)0.5 ()0.5 ()0.5

Notes to Financial Statements

Fiscal Year 2022
(All amounts in RMB Yuan)

III. Significant accounting policies and accounting estimates

(1) III

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(1) Revenue Recognition

2. Total Revenue Recognition

(3) Revenue Recognition of COVID-19

- For COVID-19, the Company recognizes revenue based on the progress of the service. The Company provides COVID-19 testing services to patients. The Company recognizes revenue when the patient has completed the testing process and the Company has provided the test results to the patient. The Company recognizes revenue for COVID-19 testing services based on the number of tests performed. The Company recognizes revenue for COVID-19 testing services based on the number of tests performed. The Company recognizes revenue for COVID-19 testing services based on the number of tests performed.
- For COVID-19, the Company recognizes revenue based on the progress of the service. The Company provides COVID-19 testing services to patients. The Company recognizes revenue when the patient has completed the testing process and the Company has provided the test results to the patient. The Company recognizes revenue for COVID-19 testing services based on the number of tests performed. The Company recognizes revenue for COVID-19 testing services based on the number of tests performed. The Company recognizes revenue for COVID-19 testing services based on the number of tests performed.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Revenue

3. Significant accounting policies and accounting estimates

(2) Tangible Intangible Assets

Intangible assets are those assets that are identifiable and can be separated from the company, and their benefits can be brought to the company in the future. Intangible assets are measured at cost. The company's intangible assets are mainly software, patents, and trademarks. The company's intangible assets are measured at cost less accumulated amortization and impairment loss. The company's intangible assets are amortized on a straight-line basis over their useful lives. The company's intangible assets are tested for impairment when there are indications of impairment or when the carrying amount exceeds the recoverable amount. The company's intangible assets are measured at the higher of carrying amount and recoverable amount. The company's intangible assets are measured at cost less accumulated amortization and impairment loss. The company's intangible assets are amortized on a straight-line basis over their useful lives. The company's intangible assets are tested for impairment when there are indications of impairment or when the carrying amount exceeds the recoverable amount. The company's intangible assets are measured at the higher of carrying amount and recoverable amount.

(2) Tangible Intangible Assets

Tangible Intangible Assets are those assets that are identifiable and can be separated from the company, and their benefits can be brought to the company in the future. Tangible Intangible Assets are measured at cost. The company's tangible Intangible Assets are mainly land use rights, buildings, and equipment. The company's tangible Intangible Assets are measured at cost less accumulated depreciation and impairment loss. The company's tangible Intangible Assets are depreciated on a straight-line basis over their useful lives. The company's tangible Intangible Assets are tested for impairment when there are indications of impairment or when the carrying amount exceeds the recoverable amount. The company's tangible Intangible Assets are measured at the higher of carrying amount and recoverable amount.

Assets are measured at cost less accumulated depreciation and impairment loss. The company's assets are depreciated on a straight-line basis over their useful lives. The company's assets are tested for impairment when there are indications of impairment or when the carrying amount exceeds the recoverable amount. The company's assets are measured at the higher of carrying amount and recoverable amount.

Assets are measured at cost less accumulated depreciation and impairment loss. The company's assets are depreciated on a straight-line basis over their useful lives. The company's assets are tested for impairment when there are indications of impairment or when the carrying amount exceeds the recoverable amount. The company's assets are measured at the higher of carrying amount and recoverable amount.

(3) Revenue

Tangible Intangible Assets are those assets that are identifiable and can be separated from the company, and their benefits can be brought to the company in the future. Tangible Intangible Assets are measured at cost. The company's tangible Intangible Assets are mainly land use rights, buildings, and equipment. The company's tangible Intangible Assets are measured at cost less accumulated depreciation and impairment loss. The company's tangible Intangible Assets are depreciated on a straight-line basis over their useful lives. The company's tangible Intangible Assets are tested for impairment when there are indications of impairment or when the carrying amount exceeds the recoverable amount. The company's tangible Intangible Assets are measured at the higher of carrying amount and recoverable amount.

1. Revenue

Revenue is recognized when the company has transferred control of the goods or services to the customer, and the amount of revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized when the company has transferred control of the goods or services to the customer, and the amount of revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized when the company has transferred control of the goods or services to the customer, and the amount of revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized when the company has transferred control of the goods or services to the customer, and the amount of revenue is measured at the fair value of the consideration received or receivable.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(1) Significant Accounting Policies

2. Earnings Per Share

As of the end of the reporting period, the Company has issued 100,000,000 shares of ordinary shares. Pursuant to the Company's Articles of Association, the Company's financial statements are prepared on a consolidated basis. The Company's financial statements are prepared on a consolidated basis. Pursuant to the Company's Articles of Association, the Company's financial statements are prepared on a consolidated basis.

The Company's earnings per share is calculated based on the following formula: $\text{EPS} = \frac{\text{EBIT} - \text{Interest Expense}}{\text{Weighted Average Number of Shares Outstanding}}$. The Company's earnings per share is calculated based on the following formula: $\text{EPS} = \frac{\text{EBIT} - \text{Interest Expense}}{\text{Weighted Average Number of Shares Outstanding}}$.

3. Earnings Per Share

The Company's earnings per share is calculated based on the following formula: $\text{EPS} = \frac{\text{EBIT} - \text{Interest Expense}}{\text{Weighted Average Number of Shares Outstanding}}$. The Company's earnings per share is calculated based on the following formula: $\text{EPS} = \frac{\text{EBIT} - \text{Interest Expense}}{\text{Weighted Average Number of Shares Outstanding}}$.

4. Management Discussion and Analysis

In 2022, the Company's management has discussed and analyzed the Company's financial performance and prospects. The Company's management has discussed and analyzed the Company's financial performance and prospects.

Item	End of Reporting Period
Assets	180
Liabilities	570
Net Income	10.79%
Gross Profit	60
Debt	14.00%
Profit	2.50%

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant Accounting Policies and Accounting Estimates

(1) Recognition and Measurement of Intangible Assets

In 2021, the Company recognized intangible assets with an initial cost of RMB 15 million. In 2022 and 2023, the Company recognized intangible assets with an initial cost of RMB 16 million. The Company's intangible assets are primarily software licenses. The Company amortizes intangible assets on a straight-line basis over their estimated useful lives. The estimated useful lives of the Company's intangible assets are 3 to 5 years.

IV. Taxation

(1) Major Taxation

Tax Type	Tax Rate
Value Added Tax (VAT) on Sales of Goods	3%, 6%, 13%
Corporate Income Tax	25%
Urban Maintenance and Construction Tax	7%
Education Surcharge	5%
Local Education Surcharge	15%, 20%, 25%
Stamp Duty	
Income Tax on Dividends	
Withholding Tax on Interest Income	15%
Withholding Tax on Dividend Income	15%
Withholding Tax on Management Fee Income	20%

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

IV. Taxation (continued)

(II) Provisions for income tax

1. Provisions for income tax
- L. VAT Payable: Business Tax (China's VAT [2016] N. 36), Consumption Tax, and Stamp Duty (Ordinance of the State Council N. 149)
 S. C. Income Tax: M. I. A. M. H. (Ordinance of the State Council N. 35)

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(I) Intangible Assets

	Balance at the beginning of the year	Balance at the end of the year
I		
Goodwill	454,907.26	971,773.72

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(III) Available-for-sale Financial Assets

1. Available-for-sale Financial Assets

Available-for-sale Financial Assets	Balance at the beginning of the year	Balance at the end of the year
Warrant		
Warrant 1	388,961,193.05	303,910,574.15
Warrant 1-2	4,755,919.87	9,812,859.20
Warrant 2-3	3,941,367.25	4,259,870.27
Warrant 3	5,180,894.08	3,140,407.07
Warrant -	402,839,374.25	321,123,710.69
Warrant :P	20,002,683.36	9,365,835.23
Total	382,836,690.89	311,757,875.46

The Company's available-for-sale financial assets are primarily composed of warrants issued by various companies, which are classified as available-for-sale financial assets in accordance with the Company's accounting policy.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(III) Intangible Assets

2. Amortization of Intangible Assets

Item	Beginning of the year		End of the year		Beginning of the year		End of the year		Book value at the end of the year	
	Amount	Percentage (%)	Amount	Percentage (%)	Amount	Percentage (%)	Amount	Percentage (%)		
Patent										
Software	18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22	7,247,978.61	2.26	4,590,286.39	63.33	2,657,692.22
Intangible Assets	18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22	7,247,978.61	50.00	4,590,286.39	63.33	2,657,692.22
Patent										
Software	384,617,398.37	95.48	7,488,540.70							

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(III) Available-for-sale financial assets

2. Available-for-sale financial assets (continued)

Item	Balance at the end of the reporting period		
	Original value	Impairment allowance	Carrying amount
Monetary assets	18,221,975.88	12,514,142.66	68.68
			Impairment allowance for expected credit losses (ECL)
Total	18,221,975.88	12,514,142.66	/

Details of the impairment allowance: See Note III. (X)

3. Available-for-sale equity instruments

Item	Balance at the end of the reporting period		
	Original value	Impairment allowance	Carrying amount
Other equity instruments	384,617,398.37	7,488,540.70	1.95
Total	384,617,398.37	7,488,540.70	

Details of the impairment allowance: See Note III. (X)

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(III) Available-for-sale Financial Assets

3. Available-for-sale Financial Assets

Based on the Company's business model and the contractual cash flow characteristics, the Company classifies available-for-sale financial assets as follows:

Category	Initial Investment	Carrying Amount	Impairment Allowance	Net Carrying Amount	Change in Fair Value	Net Carrying Amount
Available-for-sale Financial Assets						
Available-for-sale Financial Assets		4,590,286.39	8,289,230.88		365,374.61	12,514,142.66
Available-for-sale Financial Assets		4,775,548.84	3,379,914.39		666,922.53	7,488,540.70
Total		9,365,835.23	11,669,145.27		1,032,297.14	20,002,683.36

4. Available-for-sale Financial Assets

Category	Change in Fair Value	Net Carrying Amount
Available-for-sale Financial Assets		365,374.61

五、非经常性损益及其他收益

非经常性损益及其他收益 2022
(A 元, RMB Yuan)

五、非经常性损益及其他收益 (元)

(一) 其他收益

1. 其他收益

A 类	2022 年		2021 年	
	金额	占比 (%)	金额	占比 (%)
W 1 年	29,973,748.69	93.08	11,751,451.87	99.11
1-2 年	2,127,484.58	6.61	58,511.20	0.49
2-3 年	56,690.70	0.18	24,163.99	0.20
0-3 年	43,300.00	0.13	24,300.00	0.20
T 元	32,201,223.97	100.00	11,858,427.06	100.00

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(1) Other Intangible Assets

Item	Balance at the beginning of the year	Balance at the end of the year
Intangible assets		
Initial cost		
Depreciation		
Other		
Total	37,195,219.68	29,925,487.99

(1) Other Intangible Assets

Item	Balance at the beginning of the year	Balance at the end of the year
Amortization		
Year 1	31,752,956.09	20,470,501.76
1-2	12,384,779.19	4,096,700.18
2-3	4,035,447.86	838,693.49
3-4	1,755,508.40	2,814,221.11
4-5	101,363.87	1,452,266.68
Over 5	3,877,306.68	2,930,000.00
Sum	53,907,362.09	32,602,383.22
Less: Provision for impairment		
Total	16,712,142.41	2,676,895.23
Total	37,195,219.68	29,925,487.99

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Notes to Financial Statements (Continued)

(1) Other Intangible Assets (Continued)

(2) Other Intangible Assets (Continued)

Item	Beginning of the year		End of the year		Increase/decrease		Percentage		Percentage of total
	Amount	(%)	Amount	(%)	Amount	(%)	Amount	(%)	
Patent									
Software	25,337,819.20	47.00	15,852,030.91	62.56	9,485,788.29	1,435,560.00	4.40	1,435,560.00	100.00
Intangible assets									
Healthcare									
University									
Copyright									
Trademark, Patent									
Copyright						1,435,560.00	100.00	1,435,560.00	100.00
Healthcare									
Copyright	25,337,819.20	47.00	15,852,030.91	62.56	9,485,788.29				
Patent									
Software	28,569,542.89	53.00	860,111.50	3.01	27,709,431.39	31,166,823.22	95.60	1,241,335.23	3.98
Intangible assets									
Patent	28,569,542.89	53.00	860,111.50	3.01	27,709,431.39	31,166,823.22	95.60	1,241,335.23	3.98
Total	53,907,362.09	100.00	16,712,142.41		37,195,219.68	32,602,383.22	100.00	2,676,895.23	29,925,487.99

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(1) Other Intangible Assets

(2) Other Intangible Assets

Particulars

Item	Balance at the beginning of the year	Additions	Disposals	Balance at the end of the year	Impairment loss
Healthcare software					
Healthcare software	25,337,819.20			15,852,030.91	62.56
Total	25,337,819.20			15,852,030.91	

Particulars

Particulars

Item	Balance at the beginning of the year	Additions	Disposals	Balance at the end of the year	Impairment loss
Patent					
Patent	28,569,542.89			860,111.50	3.01
Total	28,569,542.89			860,111.50	

Particulars

Notes to Financial Statements

For the year ended 2022

(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(1) Other Intangible Assets

(3) Development Intangible Assets

Project Name	12-month ECL	12-month ECL (at the end of the reporting period)	12-month ECL	
			2022	2021
Balance at the beginning of the year	1,241,335.23		1,435,560.00	2,676,895.23
Balance at the end of the year				
Change during the year				
- Transfer in				
- Transfer out				
- Rollover				
- Rollover				
Provision	141,793.04		15,852,030.91	15,993,823.95
Reversal	485,492.80		1,435,560.00	1,921,052.80
Write-off	37,523.97			37,523.97
Write-down				
Other				
Balance at the end of the year	860,111.50		15,852,030.91	16,712,142.41

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(3) Other Intangible Assets

(3) Details of Other Intangible Assets

Cost of Other Intangible Assets

Balance at the beginning of the year	2022	2021	2020
	12-31	12-31	12-31
Balance at the beginning of the year	31,166,823.22	1,435,560.00	32,602,383.22
Balance at the end of the year			
Change during the year			
- Transfer in			
- Transfer out			
- Rollover			
- Rollover			
A	2,428,909.82	25,337,819.20	27,766,729.02
D	4,306,570.80	1,435,560.00	5,742,130.80
O	-719,619.35		-719,619.35
Balance at the end of the year	28,569,542.89	25,337,819.20	53,907,362.09

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current Assets

(1) Other Intangible Assets

(4) Patents

Item	Balance at the beginning of the year	Change during the year	Balance at the end of the year	Book value at the end of the year
Patents	1,435,560.00	15,852,030.91	1,435,560.00	15,852,030.91
Patents	1,241,335.23	141,793.04	485,492.80	37,523.97
Total	2,676,895.23	15,993,823.95	1,921,052.80	37,523.97

Other Intangible Assets: 16,712,142.41

Item	Balance at the beginning of the year	Change during the year	Balance at the end of the year
Patents	1,435,560.00	15,852,030.91	1,435,560.00
Patents	1,241,335.23	141,793.04	485,492.80
Total	2,676,895.23	15,993,823.95	1,921,052.80

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(1) Other Intangible Assets

(5) Other Intangible Assets

Item	Amount
Other Intangible Assets	37,523.97

(6) Other Intangible Assets

Item	Balance at the beginning of the year	Balance at the end of the year
Debt	20,677,631.31	23,577,997.61
Patent	816,666.30	4,228,330.66

Notes to Financial Statements

For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(I) Intangible Assets

Item	Balance at the beginning of the year		Balance at the end of the year	
	Original value	Accumulated amortization	Original value	Accumulated amortization
Trademark	3,697,607.74		3,697,607.74	2,242,027.51
Copyright	54,633,789.63		54,633,789.63	54,277,273.72
Total	58,331,397.37		58,331,397.37	56,519,301.23

(II) Other Intangible Assets

Item	Balance at the beginning of the year		Balance at the end of the year	
	Original value	Accumulated amortization	Original value	Accumulated amortization
Investment			196,008.48	137,228.50
Patent			269,072.88	321,191.35
Patent			287,243.41	348,266.00
Total			752,324.77	806,685.85

Non-current Assets

As of December 31, 2022

(All amounts in RMB Yuan)

V. Non-current Assets (Continued)

(III) Long-term Equity Investment

Item	Beginning Balance	Changes during the Period	Ending Balance
Balance at the beginning of the year	14,000,000.00		14,000,000.00
Balance at the end of the year	14,000,000.00		14,000,000.00

(L) Long-term Debt

Item	Beginning Balance	Changes during the Period	Ending Balance					
Accounts Payable								
Wenzhou Kangning Hospital Co., Ltd.	13,156,356.09	-4,287,457.64	5,310,451.69					
Wenzhou Kangning Hospital Co., Ltd.	58,100,000.00	500,000.00	57,600,000.00					
Zhejiang Kangning Hospital Co., Ltd.	22,193,790.14	-1,090,147.47	21,103,642.67					
Shanghai Kangning Hospital Co., Ltd.	23,198,356.89	-1,102,416.10	22,095,940.79					
Chongqing Kangning Hospital Co., Ltd.	18,687,211.65	74,969.38	400,000.00					
Chongqing Kangning Hospital Co., Ltd.	11,514,784.92	-1,309,653.45	18,362,181.03					
Jiangsu Kangning Hospital Co., Ltd.	5,191,069.69		5,191,069.69					
Wenzhou Kangning Hospital Co., Ltd.								
(N/A)								
Total	129,847,779.24	22,193,790.14	500,000.00	-7,714,705.28	5,310,451.69	400,000.00	5,191,069.69	143,546,246.10

Notes: On December 31, 2022, Zhejiang Kangning Hospital Co., Ltd. (Zhejiang Kangning Hospital Co., Ltd.) held 28% of the shares of Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.), and the total amount of long-term debt is RMB14,000,000.00. Shanghai Kangning Hospital Co., Ltd. (Shanghai Kangning Hospital Co., Ltd.) held 20% of the shares of Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.), and the total amount of long-term debt is RMB13,922,929.38. Chongqing Kangning Hospital Co., Ltd. (Chongqing Kangning Hospital Co., Ltd.) held 10% of the shares of Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.), and the total amount of long-term debt is RMB8,212,142.17. Jiangsu Kangning Hospital Co., Ltd. (Jiangsu Kangning Hospital Co., Ltd.) held 4% of the shares of Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.), and the total amount of long-term debt is RMB5,191,069.69.

Notes to Financial Statements
For the Year 2022
(All amounts in RMB Yuan)

V. Non-current assets (continued)

(1) Other non-current assets

	Balance at the beginning of the year	Balance at the end of the year
Financial assets		
Investment in subsidiaries	63,116,852.05	65,812,274.58
Investment in associates	63,116,852.05	65,812,274.58
Total	63,116,852.05	65,812,274.58

W. N
N t t t E a a a t t t
F 2022
(A RMB Y)

	B	M	E	F
1. O				
(1) B	745,833,959.90	142,218,120.78	6,548,724.87	962,639,426.17
(2) I	811,977.80	25,247,491.51	6,016,909.41	181,611,758.16
-P	811,977.80	14,854,645.52	2,906,555.91	24,321,413.69
-T				
-I		10,392,845.99	3,110,353.50	17,263,110.62
-O				140,027,233.85
(3) D	70,270,990.67	65,654,865.68	3,162,440.49	164,474,456.39
-D		12,438,192.49	658,984.47	16,407,902.14
-D		5,259,711.00	565,764.12	
-O	70,270,990.67	47,956,962.19	1,937,691.90	140,027,233.85
(4) B	676,374,947.03	101,810,746.61	9,403,193.79	979,776,727.94

V. N

()

2. D ()

()

N t t E a a t t
 F 2022
 (A RMB Y)

	B	M	M	E	F
2. A					
(1) B	97,583,529.57	93,448,930.55	2,620,876.20	47,139,318.33	240,792,654.65
(2) I	21,780,272.36	23,765,333.80	3,918,211.31	9,282,744.01	125,367,546.38
-P	21,780,272.36	21,259,481.17	1,035,359.81	8,378,127.80	53,029,785.07
-I		2,505,852.63	2,882,851.50	904,616.21	6,293,320.34
-O					66,044,440.97
(3) D	12,029,010.56	48,647,077.77	1,557,788.21	19,170,037.34	81,403,913.88
-D		6,650,418.76	620,766.50	1,300,387.75	8,571,573.01
-D	1,654,288.20	3,475,806.87	214,904.65	1,442,900.18	
-O	10,374,722.36	38,520,852.14	722,117.06	16,426,749.41	66,044,440.97
(4) B	107,334,791.37	68,567,186.58	4,981,299.30	37,252,025.00	284,756,287.15
3. I					
(1) B					
(2) I					
(3) D					
(4) B					
4. C					
(1) C	569,040,155.66	33,243,560.03	4,421,894.49	14,908,581.66	695,020,440.79
(2) C	648,250,430.33	48,769,190.23	3,927,848.67	20,899,302.29	721,846,771.52

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(II) Intangible Assets

1. Goodwill

Item	Balance at the beginning of the year	Balance at the end of the year
Goodwill	152,497,399.68	43,795,718.15
Total	152,497,399.68	43,795,718.15

2. Other Intangible Assets

Item	Balance at the beginning of the year	Balance at the end of the year	Balance at the beginning of the year	Balance at the end of the year
Wenke Technology Co., Ltd.	311,600.00	311,600.00	782,356.00	782,356.00
Netanyahu			1,027,373.54	1,027,373.54
Li Yuhang	72,377,326.40	72,377,326.40	6,213,670.10	6,213,670.10
Peace Channel			7,504,860.00	7,504,860.00
Orly Hospital			27,288,058.64	27,288,058.64
Lincaihang	27,536,449.81	27,536,449.81	150,609.00	150,609.00
Qiyuhang	16,073,697.42	16,073,697.42		
Jiusheng Hospital	35,508,167.99	35,508,167.99		
Others	690,158.06	690,158.06	828,790.87	828,790.87
Total	152,497,399.68	152,497,399.68	43,795,718.15	43,795,718.15

V. N
(二) 子公司 ()
3. 主要子公司 ()

P (A)	T (B)	Y (C)	H (D)	MB'0,000	B (E)		A (F)		I (G)		T (H)	B (I)
					100%	(%)	100%	(%)	100%	(%)		
18,003.00	6,213,670.10	66,247,515.67	72,461,185.77	40.25	40.00	1,883,479.17	1,608,608.70	4.90	B			
1,897.75	7,504,860.00	17,107,073.00	24,611,933.00	100.00	100.00	0	0	0	O			
4,047.80	27,288,038.64	11,021,933.76	38,310,012.40	100.00	100.00	0	0	0	O			
16,020.00	150,609.00	27,385,840.81	27,536,449.81	17.19	20.00	0	0	0	O			
9,848.00	16,073,697.42	16,073,697.42	16,073,697.42	16.32	15.00	0	0	0	O			
6,666.00	35,508,167.99	35,508,167.99	35,508,167.99	54.15	55.00	0	0	0	O			
	41,157,197.74	173,344,248.65	62,921,945.40	151,579,500.99	1,883,479.17	1,608,608.70						

附注三、资产减值准备

五、其他非流动资产

(三) 其他非流动资产

项目	本报告期末余额	上年期末余额
1. 其他非流动资产		
(1) 预付账款	363,270,419.51	363,270,419.51
(2) 其他应收款	37,254,480.17	37,254,480.17
- 应收利息	21,847,297.56	21,847,297.56
- 应收股利	15,407,182.61	15,407,182.61
(3) 其他流动资产	81,876,743.78	81,876,743.78
- 待摊费用	16,772,968.78	16,772,968.78
- 其他流动资产	65,103,775.00	65,103,775.00
(4) 其他非流动资产	318,648,155.90	318,648,155.90
2. 长期股权投资		
(1) 长期股权投资	105,858,149.38	105,858,149.38
(2) 其他权益工具投资	38,189,335.84	38,189,335.84
- 可供出售金融资产	38,189,335.84	38,189,335.84
(3) 其他非流动资产	15,803,080.90	15,803,080.90
- 长期股权投资	4,949,246.94	4,949,246.94
- 其他非流动资产	10,853,833.96	10,853,833.96
(4) 其他非流动资产	128,244,404.32	128,244,404.32
3. 其他权益工具投资		
(1) 其他权益工具投资		
(2) 其他非流动资产		
(3) 其他非流动资产		
(4) 其他非流动资产		
4. 其他非流动资产		
(1) 其他非流动资产	190,403,751.58	190,403,751.58
(2) 其他非流动资产	257,412,270.13	257,412,270.13

附 表 10: 2022 年 12 月 31 日 的 非 流 动 资 产 负 债 表
(A 股 公 司 人 民 币 百 万 元)

V. N 非 流 动 资 产 负 债 表 (续)

(. I) I 非 流 动 资 产 负 债 表

项 目	2022 年 12 月 31 日		2021 年 12 月 31 日		2020 年 12 月 31 日		备 注
	账 面 价 值	减: 备 抵 金 额	账 面 价 值	减: 备 抵 金 额	账 面 价 值	减: 备 抵 金 额	
1.0 非 流 动 资 产							
(1) 非 流 动 资 产	102,977,820.17	3,061,637.13	14,252,889.08	129,837,000.00	32,400,000.00	282,529,346.38	
(2) I 非 流 动 资 产	25,616,355.88		-3,433,306.28	29,000,000.00		51,183,049.60	
- P 非 流 动 资 产	19,841,690.88		-4,460,006.28			15,381,684.60	
- I 非 流 动 资 产	5,774,665.00		1,026,700.00	29,000,000.00		35,801,365.00	
(3) D 非 流 动 资 产			1,141,970.00			1,141,970.00	
- D 非 流 动 资 产			508,000.00			508,000.00	
- D 非 流 动 资 产			633,970.00			633,970.00	
(4) 非 流 动 资 产	128,594,176.05	3,061,637.13	9,677,612.80	158,837,000.00	32,400,000.00	332,570,425.98	
2.A 非 流 动 资 产							
(1) 非 流 动 资 产	9,610,253.66	360,120.18	9,441,245.79	27,772,369.86	7,353,571.43	54,537,560.92	
(2) I 非 流 动 资 产	2,889,207.41	330,465.48	1,799,113.48	17,315,075.42	1,500,000.00	23,833,861.79	
- P 非 流 动 资 产	2,889,207.41	330,465.48	1,072,248.57	17,315,075.42	1,500,000.00	23,106,996.88	
- I 非 流 动 资 产			726,864.91			726,864.91	
(3) D 非 流 动 资 产			485,345.23			485,345.23	
- D 非 流 动 资 产			39,066.67			39,066.67	
- D 非 流 动 资 产			446,278.56			446,278.56	
(4) 非 流 动 资 产	12,499,461.07	690,585.66	10,755,014.04	45,087,445.28	8,853,571.43	77,886,077.48	
3. I 非 流 动 资 产							
(1) 非 流 动 资 产							
(2) I 非 流 动 资 产							
(3) D 非 流 动 资 产							
(4) 非 流 动 资 产							
4. C 非 流 动 资 产							
(1) C 非 流 动 资 产	116,094,714.98	2,371,051.47	-1,077,401.24	113,749,554.72	23,546,428.57	254,684,348.50	
(2) C 非 流 动 资 产	93,367,566.51	2,701,516.95	4,811,643.29	102,064,630.14	25,046,428.57	227,991,785.46	

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(1) Goodwill

2. Intangible Assets

As of December 31, 2022, the Company has the following intangible assets:

Unit: RMB'0,000

As of December 31, 2022	31 December 2022
Wenzhou Kangning Hospital Co., Ltd.	927.18
Hangzhou Puhua Hospital Co., Ltd.	69.03
Guangdong Yuhua Hospital Co., Ltd.	154.90
Wenzhou Nanyang Puhua Sanyuan Hospital Co., Ltd.	778.49
Benzhou Yuhua Hospital Co., Ltd.	2,298.73
Wenzhou Yuhua Tiantian Hospital Co., Ltd.	15.11
Hangzhou Kangning Hospital Co., Ltd.	506.9
Chengde Kangning Puhua Hospital Co., Ltd.	684.33
Wenzhou Chuanhua Hospital Co., Ltd.	1,941.63
Puhua Chengde Yuhua Hospital Co., Ltd.	5,177.02
Hangzhou Yuhua Nanyang Hospital Co., Ltd.	127.26
Zhejiang Fuzhou Nanyang Hospital Co., Ltd.	32.60
Jiangsu Sanyuan Hospital Co., Ltd.	506.03
Total	13,219.21

Intangible assets are measured at cost less accumulated amortization and impairment losses. The Company uses the straight-line method to amortize intangible assets with finite useful lives over their expected useful lives. The useful lives of intangible assets are determined on the basis of the expected period over which the Company will derive economic benefits from the assets.

Net Profit attributable to the ordinary shareholders of the Company

For the year ended December 31, 2022
(All figures in RMB Yuan, unless otherwise specified)

V. Net Profit attributable to the ordinary shareholders of the Company (in million RMB Yuan)

(1) Government grants

3. Pursuant to the relevant provisions of the Accounting Standards for Business Enterprises, the Company's government grants are classified into the following categories:

Accounting classification of government grants	Amount of government grants recognized in the current period (in million RMB Yuan)	Amount of government grants recognized in the previous period (in million RMB Yuan)	Percentage of government grants recognized in the current period to net profit attributable to the ordinary shareholders of the Company	Percentage of government grants recognized in the previous period to net profit attributable to the ordinary shareholders of the Company	Percentage of government grants recognized in the current period to net profit attributable to the ordinary shareholders of the Company
Ningbo Yuhong Hospital Co., Ltd.	219	337	2.50%	21.33%	14.00%
Hangzhou Puyuan Hospital Co., Ltd.	267	289	2.50%	20.60%	14.00%
Guangdong Yuhong Hospital Co., Ltd.					
Wenzhou Nanpu Hospital Sanyuan Hospital Co., Ltd.	323	291	2.50%	22.06%	14.00%
Beijing Yuhong Hospital Co., Ltd.	32	1,810	2.50%	-2.40%	14.00%
Wenzhou Yuhong Hospital Taizhou Hospital Co., Ltd.					
Hangzhou Kehu Hospital Co., Ltd.	211	196	2.50%	16.94%	14.00%
Chengde Kehu Puyuan Hospital Co., Ltd.	315	205	2.50%	17.48%	14.00%
Wenzhou Chuhong Hospital Co., Ltd.	325	546	2.50%	9.59%	14.00%
Chengde Kehu Hospital Hangzhou Hospital Co., Ltd.	213	400	2.50%	19.01%	14.00%
Puyuan Chengde Yuhong Hospital Co., Ltd.	425	594	2.50%	6.71%	14.00%
Puyuan Yuhong Hospital Hangzhou Hospital Co., Ltd.	270	273	2.50%	15.82%	14.00%
Hangzhou Yuhong Hospital Ningbo Hospital Co., Ltd.	72	117	2.50%	21.92%	14.00%
Jiangsu Sanyuan Hospital Co., Ltd.	382	284	2.50%	22.65%	14.00%

Other government grants:

All government grants are recognized in the current period. The amount of government grants recognized in the current period is 1,810 million RMB Yuan, and the amount of government grants recognized in the previous period is 1,810 million RMB Yuan.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(1) Goodwill

4. Intangible Assets

In 2022, the Company's intangible assets decreased significantly due to the impact of COVID-19, with the decrease in the value of the intangible assets of the subsidiary Wenzhou Kangning Hospital Co., Ltd. being the main reason. The decrease in the value of the intangible assets was RMB10,345,460.56.

(1) Intangible Assets

Item	Balance at the beginning of the year	Increase	Decrease	Other changes	Balance at the end of the year
Right of use assets	150,328,412.40	100,049,601.67	46,186,845.31	14,777,100.83	189,414,067.93
Lease assets	172,625.00	94,613.90	94,967.96		172,270.94
Total	150,501,037.40	100,144,215.57	46,281,813.27	14,777,100.83	189,586,338.87

(2) Deferred Intangible Assets

1. Deferred Intangible Assets

Item	Balance at the beginning of the year	Decrease	Other changes	Balance at the end of the year
Patent	16,979,155.87	3,164,380.59	8,026,079.93	1,687,621.09
Unpatented technology				
Domain name	50,169,236.15	8,217,114.53	18,012,806.84	4,503,201.71
Other intangible assets	4,390,510.38	1,097,627.60	4,653,187.96	1,163,296.99
Software	54,688,502.33	8,203,275.35	46,552,302.33	6,982,845.35
Total	126,227,404.73	20,682,398.07	77,244,377.06	14,336,965.14

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(II) Intangible Assets

2. Intangible Assets

Item	Beginning of the year		End of the year	
	Balance	Change	Balance	Change
Patent rights				
Software	148,564,631.76	37,141,157.94	144,340,394.12	36,085,098.53
Other	13,116,852.07	1,967,527.81	15,812,274.60	2,371,841.19
Others	6,620,111.12	1,439,193.06	6,958,909.45	1,418,850.23
Total	168,301,594.95	40,547,878.81	167,111,578.17	39,875,789.95

(III) Other Intangible Assets

Item	Beginning of the year		End of the year	
	Balance	Change	Balance	Change
Patent rights	6,936,000.00	6,936,000.00	6,936,000.00	6,936,000.00
Patent rights	6,605,047.21	6,605,047.21	130,386.60	130,386.60
Others			14,000,000.00	14,000,000.00
Total	13,541,047.21	13,541,047.21	21,066,386.60	21,066,386.60

(L) Other Non-current Assets

Item	Beginning of the year		End of the year	
	Balance	Change	Balance	Change
Share investments	195,000,000.00		200,000,000.00	
Others	8,000,000.00		54,050,000.00	
Total	203,000,000.00		254,050,000.00	

五、非流动资产减值准备
 2022 年 12 月 31 日
 (单位:人民币元)

五. 非流动资产减值准备 (元)

(一) 固定资产减值准备

项目	年初余额	本年增加	本年减少	年末余额
房屋				
专用设备				
其他设备				
合计		13,922,929.38		13,922,929.38
合计		13,922,929.38		13,922,929.38

(二) 无形资产减值准备

项目	年初余额	本年增加	本年减少	年末余额
土地使用权	997,944.00			997,944.00
合计	997,944.00			997,944.00

(三) 长期股权投资减值准备

长期股权投资减值准备按被投资单位分类如下:

被投资单位	年初余额	本年增加	本年减少	年末余额
温州康宁医院	84,193,738.77			84,193,738.77
温州康宁医院 1-2	1,161,389.02			1,161,389.02
温州康宁医院 2-3	71,968.47			71,968.47
温州康宁医院 3	345,965.27			345,965.27
合计	86,373,061.53			86,373,061.53

Non-current Assets

截至2022年12月31日
(A 截至 2022 年 12 月 31 日)

V. Non-current Assets

(III) Assets

	2022 12/31	2021 12/31
Intangible Assets		
Available-for-sale Financial Assets	29,436,207.46	16,275,602.70
Receivables	458,629.04	
Total	29,894,836.50	16,275,602.70

(I) Current Assets

	2022 12/31	2021 12/31
Intangible Assets		
Available-for-sale Financial Assets		3,240.59
Total		3,240.59

(II) Equity

1. Limited Equity

	2022 12/31	2021 12/31	2021 12/31	2022 12/31
Shareholders' Equity				
Share Capital	57,969,287.42	498,871,976.49	488,702,553.33	68,138,710.58
Reserves	2,518,896.85	30,311,176.43	30,410,434.15	2,419,639.13
Total	60,488,184.27	529,183,152.92	519,112,987.48	70,558,349.71

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets (Continued)

(Continued)

2. Long-term Equity Investments

Item	Balance at the beginning of the year	Increase	Decrease	Balance at the end of the year
				Yuan
(1) Wuzhou Kangning Hospital Co., Ltd.	56,230,979.61	447,906,594.96	437,976,426.00	66,161,148.57
(2) Sanyuan Hospital	87,835.30	10,184,665.65	9,965,118.81	307,382.14
(3) Sanyuan Hospital Investment Management Co., Ltd.	1,334,394.89	19,527,025.66	19,397,236.12	1,464,184.43
Wenzhou Kangning Hospital Management Co., Ltd.	1,290,685.28	18,813,797.48	18,678,735.17	1,425,747.59
Wenzhou Kangning Hospital Management Co., Ltd.	38,841.61	641,567.33	643,107.24	37,301.70
Wenzhou Kangning Hospital Management Co., Ltd.	4,868.00	55,652.85	60,096.21	424.64
O		16,008.00	15,297.50	710.50
(4) H				

附注七、应交税费

截至2022年12月31日，应交税费为人民币16,848.52元。

截至2021年12月31日，应交税费为人民币22,060,348.34元。

(续上表)

项目	2022年12月31日	2021年12月31日
VAT	2,399,813.52	2,194,179.27
企业所得税	26,859,279.46	22,060,348.34
个人所得税	1,260,918.02	1,102,372.67
城市维护建设税	163,205.29	39,305.94
房产税	2,292,516.47	4,544,055.56
教育费附加	116,587.33	28,135.83
印花税	387,329.69	250,083.20
其他	25,663.04	16,848.52
合计	1,696.00	

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(1) Other Intangible Assets (continued)

2. Development Costs

	Balance at the beginning of the year	Balance at the end of the year
Intangible assets	735,000.00	86,550.00
Other intangible assets		86,550.00
Development costs	735,000.00	
Total	735,000.00	86,550.00

3. Other Assets

	Balance at the beginning of the year	Balance at the end of the year
Intangible assets		
Patent	25,932,146.03	8,703,936.40
Patent	7,000,000.00	15,000,000.00
Work in progress	3,682,272.62	7,166,038.37
Debt	1,900,552.80	1,094,722.20
Contract	17,695,375.57	7,496,808.30
Prepaid	4,374,261.21	4,312,000.00
Advance	3,673,024.53	6,981,466.40
Other	6,624,054.06	4,025,654.97
Total	70,881,686.82	54,780,626.64

五、非流动资产减值准备

单位: 人民币元
2022年12月31日

五.1 非流动资产减值准备

(五.1.1) 非流动资产减值准备

项目	2022年12月31日	2021年12月31日
合计		
长期股权投资	22,470,000.00	18,200,000.00
固定资产	99,580,000.00	
无形资产	25,548,324.39	30,040,752.22
合计	147,598,324.39	48,240,752.22

(五.1.2) 长期股权投资减值准备

项目	2022年12月31日	2021年12月31日
合计		

五、非流动资产减值准备

五. 非流动资产减值准备 (人民币元)

(一) 长期股权投资

	本期期末余额	上期期末余额
减值准备		
合计	42,404,938.54	
长期股权投资减值准备		
合计	42,404,938.54	

(二) 固定资产

	本期期末余额	上期期末余额
减值准备		
合计	141,984,938.54	
无形资产减值准备	9,382,772.07	
长期股权投资减值准备	99,580,000.00	
合计	42,404,938.54	

(三) 递延所得税资产

	本期期末余额	上期期末余额
递延所得税资产		
合计	9,341,683.00	303,792.00
递延所得税负债		
合计		9,037,891.00

附注七、公允价值计量

财务报表附注
(A股上市公司适用)

五、金融资产

(一) 金融资产分类

单位：人民币元

项目	2022年12月31日		2021年12月31日	
	账面余额	减值准备	账面余额	减值准备
流动资产				
应收账款	9,341,683.00	303,792.00	9,037,891.00	
合计	9,341,683.00	303,792.00	9,037,891.00	

(二) 金融资产减值

项目	2022年12月31日		2021年12月31日	
	账面余额	减值准备	账面余额	减值准备
流动资产				
应收账款	74,600,300.00		74,600,300.00	
合计	74,600,300.00		74,600,300.00	

(三) 金融资产转移

项目	2022年12月31日		2021年12月31日	
	账面余额	减值准备	账面余额	减值准备
流动资产				
应收账款	783,420,735.87		783,420,735.87	
其他流动资产				
- 应收票据	32,642,955.35	12,214,418.85	44,857,374.20	
- 其他	22,101,704.37	4,698,718.86	26,800,423.23	
合计	838,165,395.59	16,913,137.71	855,078,533.30	

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets Held for Sale

(1) Classification and Measurement

On December 31, 2022, the Company has the following non-current assets held for sale:

- (1) Financial assets - on December 31, 2022, the Company held 100% of the equity of Ningbo Kangning Hospital Co., Ltd. (NIX).
- (2) In 2022, the Company transferred the ownership of Ningbo Kangning Hospital Co., Ltd. (NIX) to Ningbo Kangning Hospital Co., Ltd. (NIX) for RMB4,698,718.86. The Company has transferred the ownership of Ningbo Kangning Hospital Co., Ltd. (NIX) to Ningbo Kangning Hospital Co., Ltd. (NIX) on December 31, 2022.

(2) Measurement

Item	Balance at the beginning of the year	Balance at the end of the year	Increase	Decrease	Balance at the end of the year
Financial assets					
Subtotal					
Salvage value					
Total					

On December 31, 2022:

The Company holds 100% of the equity of Ningbo Kangning Hospital Co., Ltd. (NIX). The Company has transferred the ownership of Ningbo Kangning Hospital Co., Ltd. (NIX) to Ningbo Kangning Hospital Co., Ltd. (NIX) on December 31, 2022. The Company has transferred the ownership of Ningbo Kangning Hospital Co., Ltd. (NIX) to Ningbo Kangning Hospital Co., Ltd. (NIX) on December 31, 2022. The Company has transferred the ownership of Ningbo Kangning Hospital Co., Ltd. (NIX) to Ningbo Kangning Hospital Co., Ltd. (NIX) on December 31, 2022.

Wen Zhou Kang Ning Hospital Co., Ltd.
Annual Report
2022
(A RMB Yuan)

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(1) Intangible Assets

1. Amortizable Intangible Assets

Item	At the beginning of the year	Cost	Accumulated amortization	Net book value
Medical equipment	1,366,816,938.51	1,040,114,649.97	1,202,774,377.74	897,111,635.75
Others	118,086,103.74	91,857,292.80	94,655,992.09	71,320,820.01
Total	1,484,903,042.25	1,131,971,942.77	1,297,430,369.83	968,432,455.76

Book value at the end of the year:

Item	At the beginning of the year	Accumulated amortization
Medical equipment	1,366,816,938.51	1,202,774,377.74
Intangible assets		
: Patents	305,118,303.27	267,588,282.25
: Trademarks	1,061,698,635.24	935,186,095.49
Others	118,086,103.74	94,655,992.09
Intangible assets		
: Workforce	85,464,736.39	51,613,429.22
: Medical equipment	3,000,000.00	2,970,297.00
: Real estate	8,067,969.32	7,515,329.40
: Real estate		16,043,547.63
: Others	21,553,398.03	16,513,388.84
Total	1,484,903,042.25	1,297,430,369.83

2. Depreciable Intangible Assets

Item	At the beginning of the year	Cost	Accumulated depreciation	Net book value
Medical equipment	1,366,816,938.51	1,040,114,649.97	1,202,774,377.74	897,111,635.75
Others	118,086,103.74	91,857,292.80	94,655,992.09	71,320,820.01
Total	1,484,903,042.25	1,131,971,942.77	1,297,430,369.83	968,432,455.76

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(continued)

Intangible Assets

As at December 31, 2022



Notes to Financial Statements

For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(1) Long-term Equity Investments

Item	Amount at the end of the reporting period	Amount at the beginning of the reporting period
Equity investments in subsidiaries	106,839,736.87	92,095,322.35
Equity investments in associates	22,821,067.41	11,791,502.03
Equity investments in joint ventures	12,364,390.29	10,327,372.91
Equity investments in other entities	7,928,268.21	7,688,976.40
Available-for-sale financial assets	7,169,511.48	7,803,052.34
Other financial assets	6,366,300.00	1,222,900.00
Other long-term assets	5,452,608.66	5,171,123.31
Other long-term assets	5,226,706.30	3,986,627.45
Other long-term assets	4,539,506.45	2,946,383.00
Other long-term assets	4,412,652.14	8,414,462.03
Other long-term assets	4,358,637.42	2,835,174.29
Other long-term assets	2,798,524.34	3,204,882.36
Other long-term assets	2,653,266.15	4,644,062.36
Other long-term assets	2,527,587.52	3,580,020.08
Other long-term assets	2,521,353.37	1,319,556.59
Other long-term assets	2,099,610.09	3,313,286.64
Other long-term assets	1,889,937.19	1,974,023.35
Other long-term assets		96,657.59
Other long-term assets	3,917,508.51	3,956,503.74
Total	205,887,172.40	176,371,888.82

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(. LI) Intangible Assets

Item	Amount at the end of the reporting period	Amount at the beginning of the reporting period
Patent rights	29,575,455.47	24,627,424.22
Software	1,164,368.95	1,346,035.33
Other intangible assets	550,065.23	594,882.24
Goodwill	400,114.92	311,882.70
Other	76,467.92	-
Total	68,877.00	134,907.60
Cost	58,690.00	-
Accumulated amortization	30,200.00	-
Accumulated impairment loss	19,682.96	76,999.34
Residual value	11,090.48	-
Other	3,000.00	-
Total	1,069,974.86	870,041.96
Total	33,027,987.79	27,962,173.39

(. LII) Financial Assets

Item	Amount at the end of the reporting period	Amount at the beginning of the reporting period
Long-term equity investments	45,149,998.30	36,267,756.91
Debt investments	11,935,506.62	14,290,203.16
Other financial assets	2,761,765.05	1,691,366.88
Financial assets at fair value through profit or loss	-78,462.87	38,704.15
Total	1,999,946.76	3,043,331.77
Total	44,309,717.14	37,658,425.95

Notes to Financial Statements

For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(, LIII) Other Intangible Assets

Item	Amount at the end of the reporting period	Amount at the beginning of the reporting period
Goodwill	14,602,195.91	13,486,446.80
Amortization of intangible assets (including VAT)	37,171.75	
Impairment loss	162,213.15	133,188.26
Others	106,130.00	
Total	14,907,710.81	13,619,635.06

Item	Amount at the end of the reporting period	Amount at the beginning of the reporting period	Change
Trademark	859,807.09	1,231,900.37	Decrease
Software	3,408,933.78	3,325,154.99	Increase
Software	1,018,900.00	2,270,000.00	Increase
Patent			
Software	973,813.11	244,079.31	Increase
Intangible assets under development			
Development of R&D	638,519.98		Increase
Software	600,000.00	50,000.00	Increase
Software	600,000.00		Increase
Value-added tax	440,197.00	814,795.52	Increase
Software	311,520.00	744,608.99	Increase
Right of use assets			
Lease	303,792.00	303,792.00	Change
Software	300,000.00		Increase
Software	284,000.00	284,000.00	Increase
Software	249,000.00		Increase
Software			
Software	238,400.00		Increase

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(.LIII) Other Intangible Assets

Goodwill (continued)

Item	At the end of the reporting period	At the beginning of the reporting period	Change / Decrease
Healthcare services (COVID-19)			
Healthcare services (COVID-19) - Patent	197,750.00		I - -
Healthcare services (COVID-19) - Copyright	174,653.70		I - -
University Science and Technology Innovation Project - Health Research	138,796.96		I - -
Other Software	120,835.00		I - -
Software	117,625.00		I - -
Workshop - Data Hardware			
Software	64,000.00		I - -
Healthcare services (COVID-19) - Health Information	63,971.59		I - -
Intangible Assets			
Development of Research and Innovation	55,332.00	50,000.00	I - -
Software - Innovation	50,000.00		I - -
Software	90,000.00	168,696.99	I - -
Software - Development	40,000.00	40,000.00	I - -
Trademark - Innovation			
Trademark	38,201.19		I - -
Equipment	36,218.55		I - -
Trademark 2022			
Equipment - Innovation	22,045.69		I - -
Software - Innovation	20,000.00		I - -
Trademark - Innovation			
Workshop - Innovation	20,000.00		I - -
Trademark - Innovation			
Healthcare services (COVID-19) - Innovation	20,000.00		I - -
Trademark - Innovation			
Workshop - Innovation	20,000.00		I - -

Net Profit Available for Distribution
 2022
 (A RMB Yuan)

V. Net Profit Available for Distribution ()

(, LIII) Other ()

GV ()

Item	Amount	Amount	Amount /
Reserve for Contingencies	17,000.00		I -
Reserve for Employee Compensation	13,610.61		I -
Reserve for Employee Welfare	12,000.00		I -
Reserve for Employee Housing	10,200.00	13,500.00	I -
Reserve for Employee Medical	7,000.00		I -
Reserve for Employee Retirement	6,700.00		I -
Reserve for Employee Pension	4,433.33		I -
Reserve for Employee Pension	3,000.00	1,904,299.94	I -
Reserve for Employee Pension	3,000.00		I -
Reserve for Employee Pension	1,833.33		I -
Reserve for Employee Pension	1,600.00		I -
Reserve for Employee Pension	1,500.00	74,237.34	I -
Reserve for Employee Pension	1,380.00		I -
Reserve for Employee Pension	1,000.00		I -
Reserve for Employee Pension	476.00		I -
Reserve for Employee Pension	450.00		I -
Reserve for Employee Pension	360.00		I -

浙 江 康 宁 医 院 有 限 公 司
2022 年 度 报 告
(A 股 上 市 公 司 年 度 报 告)

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets ()

(, I) **Goodwill**

	At the end of the reporting period	At the beginning of the reporting period
Final balance	-2,054,396.53	8,407,356.31
Initial balance	-13,922,929.38	
IV		1,010,034.42
Total	-15,977,325.91	9,417,390.73

(, L I) **Intangible Assets**

	At the end of the reporting period	At the beginning of the reporting period
Initial balance		
L	11,260,563.08	3,005,695.74
L	13,930,978.11	-865,499.29
Total	25,191,541.19	2,140,196.45

(, L II) **Assets Held for Sale**

	At the end of the reporting period	At the beginning of the reporting period
Initial balance		
G	10,345,460.56	6,179,290.37
Total	10,345,460.56	6,179,290.37

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(L III) Goodwill

Item	Amount in RMB Yuan		A
	2022/12/31	2021/12/31	
Goodwill	-	-	-
(Decrease)	406,184.95	-101,512.90	406,184.95
Initial Goodwill	406,184.95	-101,512.90	406,184.95
Other		22,109.35	
Total	406,184.95	-79,403.55	406,184.95

(L II) Non-current Intangible Assets

Item	Amount in RMB Yuan		A
	2022/12/31	2021/12/31	
Goodwill	12,737.42	154,603.42	12,737.42
Intangible Assets	12,737.42	154,603.42	12,737.42
Development Costs	7,435,774.26	9,470,530.18	7,435,774.26
Goodwill	55,075.00	265,600.00	55,075.00
Goodwill	60.10	60.10	60.10
Patent	35,711.51		35,711.51
Other		1,800,000.00	
Value	12,000.00		12,000.00
Unamortized	15,000.00		15,000.00
Other	987,619.57	145,198.20	987,619.57
Total	8,553,977.86	11,835,931.80	8,553,977.86

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current Assets

(L) Non-current Assets (Continued)

Goodwill (Continued)

Item	Amount at the end of the reporting period	Amount at the beginning of the reporting period	Change
Subsidiary goodwill			
Wenzhou Kangning Hospital		100,000.00	100,000.00
Wenzhou Kangning Hospital (2021)			
Wenzhou Kangning Hospital (2021)		150,000.00	150,000.00
Wenzhou Kangning Hospital (2021)	5,000.00		5,000.00
Wenzhou Kangning Hospital (2021)		75.00	75.00
Wenzhou Kangning Hospital (2021)	5,000.00		5,000.00
Wenzhou Kangning Hospital (2021)	40,000.00		40,000.00
Wenzhou Kangning Hospital (2021)	5,000.00		5,000.00
Wenzhou Kangning Hospital (2021)		15,600.00	15,600.00
Total	55,075.00	265,600.00	

(L) Non-current Assets (Continued)

Assets

Item	Amount at the end of the reporting period	Amount at the beginning of the reporting period	Change
Long-term equity investments			
Wenzhou Kangning Hospital	1,587,610.46	165,976.73	1,587,610.46
Wenzhou Kangning Hospital	1,587,610.46	165,976.73	1,587,610.46
Wenzhou Kangning Hospital	3,927,631.03	3,333,396.94	3,927,631.03
Wenzhou Kangning Hospital	521,375.57		521,375.57
Wenzhou Kangning Hospital	99,809.90		99,809.90
Wenzhou Kangning Hospital	267,628.43		267,628.43
Wenzhou Kangning Hospital	1,754,450.54	3,398,511.21	1,754,450.54
Wenzhou Kangning Hospital	1,182,532.80	1,738,698.54	1,182,532.80
Total	9,341,038.73	8,636,583.42	9,341,038.73

附注七、公允价值计量 (续)

2022年12月31日

(人民币元)

五、非金融资产公允价值 (续)

(一) 无形资产

1. 土地使用权

项目	公允价值	公允价值
名称	2022年12月31日	2021年12月31日
C 土地使用权	40,192,565.61	26,919,820.08
D 土地使用权	-13,618,853.12	

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(LIII) Intangible Assets

The following table shows the carrying amounts of the Company's intangible assets at the end of the reporting period:

Item	At the end of the reporting period	At the beginning of the reporting period
Patent rights	538,910,495.15	435,967,572.12
Software	417,971,255.04	353,105,992.03
Copyrights		15,204,373.00
Other intangible assets	53,029,785.07	45,173,131.23
Goodwill	38,189,335.84	45,435,380.70
Other intangible assets	22,991,163.56	15,010,629.62
Other intangible assets	46,397,646.59	38,371,918.45
Other intangible assets	17,904,619.09	15,472,884.97
Other intangible assets	66,553,544.09	57,050,465.71
Other intangible assets	29,928,936.30	24,096,157.46
Other intangible assets	23,086,080.63	21,047,712.17
Other intangible assets	27,657,239.14	25,603,836.37
Other intangible assets	28,302,685.02	13,820,361.56
Other intangible assets	6,366,300.00	1,222,900.00
Other intangible assets	3,526,992.98	2,990,339.08
Other intangible assets	5,332,487.78	4,416,545.06
Other intangible assets	8,492,200.89	9,312,807.52
Other intangible assets	12,214,418.85	15,932,752.35
Other intangible assets	39,035,944.67	43,866,151.22
Total	1,385,891,130.69	1,183,101,910.62

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan)

V. Non-current Assets

(LI) Intangible Assets

1. Goodwill

Item	Amount at the end of the reporting period	Amount at the beginning of the reporting period
Initial recognition	40,253,328.59	45,945,728.57
Goodwill impairment loss	14,633,117.41	13,579,087.19
Transfer	8,067,969.32	7,012,773.24
Disposal	10,116,855.54	12,851,693.57
Other	12,751,158.99	14,960,534.77
Net change	1,035,391.18	1,870,927.58
Reversal	14,000,000.00	
Total	100,857,821.03	96,220,744.92

2. Intangible Assets

Item	Amount at the end of the reporting period	Amount at the beginning of the reporting period
Initial recognition	30,632,892.49	23,313,110.97
Goodwill impairment loss	82,155,141.49	54,235,967.08
Disposal	6,608,712.31	6,714,560.33
Net change	2,927,440.32	4,469,403.02
Final recognition	1,082,364.51	1,442,594.04
Reversal	12,498,972.00	
Total	135,905,523.12	90,175,635.44

3. Other Intangible Assets

Item	Amount at the end of the reporting period	Amount at the beginning of the reporting period
Initial recognition	8,770,704.43	
Total	8,770,704.43	

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(LI) Intangible Assets (Continued)

4. Goodwill

	At the end of the reporting period	At the beginning of the reporting period
Intangible Assets		↓
Goodwill	150,684,059.10	
Goodwill	736,190.90	
Total	151,420,250.00	

5. Goodwill

	At the end of the reporting period	At the beginning of the reporting period
Intangible Assets		↓
Goodwill	8,096,992.56	
Goodwill	43,524,302.81	44,807,765.61
Fair value adjustment	4,500,000.00	750,000.00
Goodwill	-	-
		15,118,800.00
Total	56,121,295.37	60,676,565.61

附 表 10 2022 年 12 月 31 日
资产负债表

单位：人民币元

截至 2022 年 12 月 31 日止

1. 流动资产

项 目	2022 年 12 月 31 日	2021 年 12 月 31 日
1. 货币资金		
库存现金	-10,968,838.36	40,860,230.05
银行存款	25,191,541.19	2,140,196.45
其他货币资金	10,345,460.56	6,179,290.37
应收票据	53,029,785.07	48,274,868.81
应收账款		
应收款项融资		
预付款项	38,189,335.84	41,779,572.06
其他应收款	22,991,163.56	14,530,192.10
存货	46,397,646.59	38,836,785.71
合同资产		
持有待售资产		
一年内到期的非流动资产		
其他流动资产	-406,184.95	79,403.55
流动资产合计	1,574,873.04	11,373.31
2. 非流动资产		
长期股权投资	15,977,325.91	-9,417,390.73
债权投资	45,071,535.43	36,306,461.06
其他债权投资	-2,850,458.27	-6,937,845.27
其他权益工具投资	-6,345,432.93	27,745,384.58
其他非流动金融资产	672,088.86	14,843,351.28
固定资产	-1,812,096.14	-19,010,829.84
在建工程	-137,055,559.27	-37,743,452.80
无形资产	127,218,378.32	-4,581,092.21
开发支出		
其他非流动资产	227,220,564.45	193,896,498.48
非流动资产合计		
2. 所有者权益		
实收资本		
资本公积		
其他综合收益		
盈余公积		
未分配利润		
所有者权益合计		
3. 负债		
短期借款	258,595,990.97	188,734,845.77
应付账款	188,734,845.77	200,092,665.42
应付票据		
应付职工薪酬		
应交税费		
其他应付款		
合同负债		
其他流动负债		
长期借款	69,861,145.20	-11,357,819.65
应付债券		
其他非流动负债		
负债合计		

五、非经常性损益及其他收益

2022年度非经常性损益及其他收益合计为人民币 54,309,855.16 元。

五、净资产收益率

(L) 加权平均净资产收益率

2. 净资产收益率

单位：元

归属于母公司股东的非经常性损益	54,309,855.16
归属于母公司股东的经常性损益	21,684,900.00
归属于母公司股东的非经常性损益扣除经常性损益后的净额	32,624,955.16
归属于少数股东的非经常性损益	624,153.88
归属于少数股东的经常性损益	624,153.88
归属于少数股东的非经常性损益扣除经常性损益后的净额	
归属于少数股东的非经常性损益	53,685,701.28

3. 净资产收益率

项目	加权平均净资产收益率	净资产收益率
I. 归属于母公司股东的非经常性损益	258,595,990.97	188,734,845.77
I. 归属于母公司股东的经常性损益	454,907.26	971,773.72
D. 归属于母公司股东的非经常性损益扣除经常性损益后的净额	257,534,338.59	187,484,938.31
O. 归属于少数股东的非经常性损益	606,745.12	278,133.74
D. 归属于少数股东的非经常性损益扣除经常性损益后的净额		
D. 归属于少数股东的非经常性损益		
L. 归属于少数股东的非经常性损益		
II. 归属于少数股东的非经常性损益		
I. 归属于少数股东的经常性损益		
III. 归属于少数股东的非经常性损益	258,595,990.97	188,734,845.77
I. 归属于少数股东的非经常性损益		

G

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(L I) Available-for-sale financial assets

Item	2022	2021
Monetary funds	498,972.00	Bank deposits
Equity investments	12,000,000.00	Prepaid expenses
Intangible assets	35,612,151.67	Contract assets
	73,406,248.95	Other receivables
	6,107,838.02	Contract liabilities
Total	133,942,408.61	

(L II) Government grants

Part of the government grants are classified as non-current assets (see Note V (XLIII) and Note V (XLIX)).

VI. Current Assets

(I) Bank deposits

1. Bank deposits

Item	2022	2021
Current deposits	1,000,000.00	1,000,000.00
Time deposits	1,000,000.00	1,000,000.00
Total	2,000,000.00	2,000,000.00

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

VI. Contingent Liabilities

(I) Bank Guarantees

2. Contingent Liabilities

Y Y J Y S Z F

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

VI. Capital and Reserve

(I) Balance Sheet

2. Capital and Reserve (Continued)

(2) In January 2022, Zhenjiang Kangning Hospital Management (Group) Co., Ltd. (Zhenjiang Kangning Hospital) issued 10,000,000 shares of ordinary shares to Xiangyang, Zhenjiang Fuzhen, Nantong Yichang, and Lishui (Zhenjiang Fuzhen), with a total amount of RMB3,000,000.00. The amount of RMB2,673,987.56 was used to pay the subscription fee, and the amount of RMB326,012.44 was used to pay the subscription fee.

3. Income Statement

	Year		January to September		Year-to-date	
	Balance	Change	Balance	Change	Balance	Change
A : Total	59,544,389.38	46,544,389.38	37,912,065.31	21,595,600.11	3,596,967.56	3,596,967.56
Capital Reserve			624,153.88	624,153.88	3,003,084.38	3,003,084.38
Reserve	3,060,406.64	3,060,406.64	7,552,399.46	7,552,399.46		
Other			505,619.01	504,706.60	590,783.18	590,783.18
Other			22,965.97	22,965.97		
Financial	4,043,853.80	4,043,853.80	847,808.30	394,720.51	3,100.00	3,100.00
Capital			6,651,653.69	6,651,653.69		
Income	13,299,835.09	299,835.09	15,862,465.00			
Loss	24,864,697.08	24,864,697.08				
Other	14,275,596.77	14,275,596.77	5,845,000.00	5,845,000.00		
Loss	17,960,741.79	17,960,741.79	8,244,110.73	4,164,994.43	422,980.00	422,980.00
Other						
Other	14,710,741.79	14,710,741.79	4,099,565.00	4,099,565.00	261,041.74	261,041.74
Other			618,827.28	618,827.28	159,133.43	159,133.43
Other			-553,397.85	-553,397.85	2,804.83	2,804.83
Other	3,250,000.00	3,250,000.00	4,079,116.30			
Net	41,583,647.59	28,583,647.59	29,667,954.58	17,430,605.68	3,173,987.56	3,173,987.56
Loss			15,130,745.84	8,889,661.19	500,000.00	500,000.00
Net	41,583,647.59	28,583,647.59	14,537,208.74	8,540,944.49	2,673,987.56	2,673,987.56

M : Total : T C : V

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

VI. C ()

(II) D

1. L

Item	2022	2021	2020
Capital Reserve	14,000,000.00	42,078,792.16	16,500,000.00
Surplus Reserve	28.00	33.00	16,500,000.00
Other Reserves			
Total	14,028,000.00	42,111,792.16	16,516,500.00

Notes: The capital reserve is derived from the share premium of the company. The surplus reserve is derived from the undistributed profits of the company. The other reserves are derived from the other comprehensive income of the company.

On October 10, 2022, Zhe Kang Hospital Management (Group) Company Limited (Zhe Kang Hospital Management (Group) Company Limited) held a shareholders' meeting and decided to increase the capital reserve by RMB14,000,000.00. The total amount of the capital reserve after the increase is RMB14,000,000.00. The total amount of the surplus reserve after the increase is RMB13,922,929.38. The total amount of the other reserves after the increase is RMB10,000,000.00.

Net Profit attributable to the Company
For the Year Ended December 31, 2022
(All figures in RMB Yuan)

VI. Capital Reserve

(III) Capital Reserve

The Company's capital reserve for the year ended December 31, 2022 was RMB7.23 million, an increase of 47.48% over the year ended December 31, 2021.

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

VII.1

(I) Intangible Assets

1. Software

Item	Original Value	Accumulated Depreciation	Impairment Provision	Net Book Value	Percentage of Total Intangible Assets (%)
Software	1,000,000	200,000	0	800,000	100%
Total	1,000,000	200,000	0	800,000	100%

Non-current Assets
February 28, 2022
(Amount in RMB Yuan)

VII.1 Intangible Assets

(I) Intangible Assets (Total)

1. Software

Name of Software	Original Value	Accumulated Depreciation	Net Book Value	Original Value	Accumulated Depreciation	Net Book Value	Percentage (%)		
							Original Value	Net Book Value	Percentage
Zhejiang Hantong Technology Co., Ltd.	2,040.82		2,040.82	100.00		100.00			
Wendy Design Co., Ltd.	50		50	100.00		100.00			
Yimeng Health E-Health (Wenzhou) Co., Ltd.	500		500	100.00		100.00			
Zhejiang Dapeng Technology Co., Ltd.	1,000		1,000	80.00		100.00			
Chengkai Pinyuan Healthcare Co., Ltd.	2,700		2,700	64.55		100.00			
Chengde Qianlan Healthcare Co., Ltd.	1,000		1,000	100.00		100.00			
Hengyuan Medical Research & Development Co., Ltd.	500		500	100.00		100.00			
Hengyuan Nanyang Technology Co., Ltd.	100		100	100.00		100.00			
Linchuan Healthcare Co., Ltd.	5,000		5,000	100.00		100.00			
Siyuan Healthcare Co., Ltd.	6,000		6,000	55.00		100.00			
Pingyang Healthcare Co., Ltd. (Puzhou Yiqing Huangling Hospital Co., Ltd.)	1,660		1,660	100.00		100.00			
Chengkai Healthcare Co., Ltd.	1,000		1,000	100.00		100.00			
Chengkai Healthcare Co., Ltd.	5,000		5,000	100.00		100.00			
Chengkai Healthcare Co., Ltd.	1,000		1,000	100.00		100.00			
Yingkai Healthcare Co., Ltd.	100		100	100.00		100.00			
Linchuan Healthcare Co., Ltd.	200		200	80.00		100.00			
Ouyang E-health Co., Ltd.	1,000		1,000	100.00		100.00			
Qingkai Healthcare Co., Ltd.	3,200		3,200	100.00		100.00			
Siyuan Medical Information Co., Ltd.	1,000		1,000	100.00		100.00			

附 录 A
F
(A 表 人民币元)

名称	统一社会信用代码	注册地	注册资本	币种	持股比例 (%)	表决权比例 (%)	持股比例 (%)	表决权比例 (%)
温州康宁医院有限公司	91330300MA28322281	浙江温州	2,585.98	人民币	100.00	100.00	100.00	100.00

VII.I
(II) 合并现金流量表 (续)

项目	2022		2021	
	人民币元	人民币元	人民币元	人民币元
一、经营活动产生的现金流量	19,028,799.19	98,436,498.17	117,465,297.36	20,546,971.67
二、投资活动产生的现金流量	10,169,929.61	8,893,422.97	19,063,352.58	14,393,845.02
三、筹资活动产生的现金流量	14,888,059.45	19,086,594.25	33,574,653.70	34,702,233.46
四、汇率变动对现金及现金等价物的影响				
五、现金及现金等价物净增加额	44,175,848.25	126,426,515.09	170,103,283.64	70,043,050.15
六、期初现金及现金等价物余额	1,012,150,000.00	1,012,150,000.00	1,012,150,000.00	1,012,150,000.00
七、期末现金及现金等价物余额	1,453,928,848.25	1,138,576,515.09	1,182,253,283.64	1,082,193,050.15

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

VIII. Revenue

Details of revenue recognition and measurement are provided in Note 5. Revenue is recognized when the company has transferred control of the goods to the customer, and the amount of revenue is determined based on the contract price less discounts and other adjustments.

The company's revenue is primarily derived from the sale of medical products. The revenue is recognized when the goods are delivered to the customer and the customer has accepted them. The company's revenue is measured at the fair value of the consideration received or receivable, less discounts and other adjustments. The company's revenue is reported net of sales tax and other taxes.

The company's revenue is reported net of sales tax and other taxes. The company's revenue is reported net of sales tax and other taxes.

(I) Contract revenue

Contract revenue is recognized when the company has transferred control of the goods to the customer, and the amount of revenue is determined based on the contract price less discounts and other adjustments.

Contract revenue is recognized when the company has transferred control of the goods to the customer, and the amount of revenue is determined based on the contract price less discounts and other adjustments.

Contract revenue is recognized when the company has transferred control of the goods to the customer, and the amount of revenue is determined based on the contract price less discounts and other adjustments.

Notes to Financial Statements

For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

VIII. Revenue (Continued)

(I) Contract revenue (Continued)

The Company's revenue is primarily derived from the sale of medical services, including hospitalization fees, outpatient fees, and medical examination fees. The revenue is recognized when the service is provided and the amount is due. The revenue is recorded in the following categories: Hospitalization fees, Outpatient fees, Medical examination fees, and Other medical services. The revenue is recorded in the following categories: Hospitalization fees, Outpatient fees, Medical examination fees, and Other medical services. The revenue is recorded in the following categories: Hospitalization fees, Outpatient fees, Medical examination fees, and Other medical services.

(II) Lease revenue

The Company's lease revenue is primarily derived from the lease of medical equipment and facilities. The revenue is recognized when the lease term begins and the amount is due. The revenue is recorded in the following categories: Lease of medical equipment, Lease of medical facilities, and Other lease revenue. The revenue is recorded in the following categories: Lease of medical equipment, Lease of medical facilities, and Other lease revenue.

The Company's revenue is primarily derived from the sale of medical services, including hospitalization fees, outpatient fees, and medical examination fees. The revenue is recognized when the service is provided and the amount is due. The revenue is recorded in the following categories: Hospitalization fees, Outpatient fees, Medical examination fees, and Other medical services.

Contract Balances

Item	Initial recognition	1-2 months	2-5 months	Over 5 months	Total
Net amount	997,944.00				997,944.00
Balance B	211,396,818.18	223,154,176.00	153,052,040.00	69,285,680.00	656,888,714.18
Loss - amount	99,580,000.00	28,954,752.75	26,076,534.51		154,611,287.26
Total	311,974,762.18	252,108,928.75	179,128,574.51	69,285,680.00	812,497,945.44

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

VIII. Revenue ()
(III) Medical Revenue ()

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

VIII. Revenue

(III) Medical services revenue

3) Other

Other revenue includes revenue from the sale of medical supplies, etc. The amount of other revenue for the year ended December 31, 2022 is RMB1,893,506, which is 3% of the total revenue.

The amount of other revenue for the year ended December 31, 2022 is RMB1,893,506, which is 3% of the total revenue.

On December 31, 2022, the amount of other revenue is RMB1,893,506, which is 3% of the total revenue.

IX. Expenses

The amount of expenses for the year ended December 31, 2022 is RMB1,893,506, which is 3% of the total expenses.

Level 1 expenses include expenses for medical supplies, etc. The amount of level 1 expenses for the year ended December 31, 2022 is RMB1,893,506, which is 3% of the total expenses.

Level 2 expenses include expenses for medical supplies, etc. The amount of level 2 expenses for the year ended December 31, 2022 is RMB1,893,506, which is 3% of the total expenses.

Level 3 expenses include expenses for medical supplies, etc. The amount of level 3 expenses for the year ended December 31, 2022 is RMB1,893,506, which is 3% of the total expenses.

The amount of expenses for the year ended December 31, 2022 is RMB1,893,506, which is 3% of the total expenses.

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

IX. D. Other Intangible Assets

(I) Other Intangible Assets

Item	Original Value			Accumulated Amortization	Net Book Value
	At the Beginning of the Year	During the Year	At the End of the Year		
I. Other Intangible Assets					
Fair Value			10,641,026.00		10,641,026.00
1. Fair Value			10,641,026.00		10,641,026.00
(1) Land Use Rights			10,641,026.00		10,641,026.00
(2) Intangible Assets					
(3) Other Intangible Assets					
2. Fair Value					
Totals			10,641,026.00		10,641,026.00
Accumulated Amortization			13,922,929.38		13,922,929.38
1. Accumulated Amortization			13,922,929.38		13,922,929.38
(1) Land Use Rights					
(2) Intangible Assets					
(3) Other Intangible Assets			13,922,929.38		13,922,929.38
2. Accumulated Amortization					
Totals			13,922,929.38		13,922,929.38

(II) Other Intangible Assets

1. Land Use Rights
 2. Intangible Assets
- C. Other Intangible Assets
- Other Intangible Assets are those intangible assets that do not have an identifiable future economic benefit, such as patents, trademarks, and other intangible assets. They are measured at cost and amortized over their useful lives. The amortization method is straight-line. The useful life is determined based on the expected economic benefit period. The amortization period is generally 10 years.
- Other Intangible Assets are measured at cost and amortized over their useful lives. The amortization method is straight-line. The useful life is determined based on the expected economic benefit period. The amortization period is generally 10 years.
- Other Intangible Assets are measured at cost and amortized over their useful lives. The amortization method is straight-line. The useful life is determined based on the expected economic benefit period. The amortization period is generally 10 years.

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

X. Related Party Relationships

(i) Immediate Family Members

Mr. Gao Wenzhi, Chairman of the Board, Director, and General Manager

(ii) Immediate Family Members of Directors

Mr. Chen Yuxin, Director, Chairman of the Supervisory Board, and Chairman of the Board

(iii) Immediate Family Members of Senior Management Personnel

Mr. Chen Yuxin, Chairman of the Supervisory Board, Chairman of the Board, and Chairman of the Board

Mr. Chen Yuxin, Chairman of the Supervisory Board, Chairman of the Board, and Chairman of the Board

Mr. Chen Yuxin, Chairman of the Supervisory Board, Chairman of the Board, and Chairman of the Board

Chen Hongkang, Chairman of the Board	Chen Yuxin, Chairman of the Supervisory Board
Wang Aiping, Chairman of the Board	Chen Yuxin, Chairman of the Supervisory Board
Chen Yuhong, Chairman of the Board	Chen Yuxin, Chairman of the Supervisory Board
Hu Yuhong, Chairman of the Board	Chen Yuxin, Chairman of the Supervisory Board

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

X. Receivables (Continued)

(I) Impairment Allowance

Account Name	Impairment Allowance	Percentage	Method
Yongming Hospital	Nil	0%	Individual
Ningbo Bepark Park Management Co., Ltd. (Luzhou Park)	1,000,000.00	100%	Individual
Ningbo Fuzhou Sifeng Hospital Management Co., Ltd.	Nil	0%	Individual
Wenzhou Qianjiang Hospital	Nil	0%	Individual
Wenzhou Hengsheng Hospital	1,000,000.00	100%	Individual
Zhejiang Taizhou Evic Management Co., Ltd.	Nil	0%	Individual

(II) Impairment Allowance

Account Name	Impairment Allowance	Percentage	Method	Balance at the beginning of the year	Balance at the end of the year
Yongming Hospital	3,000,000.00	100%	Individual	3,000,000.00	3,000,000.00
Chengde Hospital Management Co., Ltd.	71,199.48		Individual		71,199.48
Wenzhou Apac Management Co., Ltd.	54,281.47		Individual		456,272.70
Jiangsu Hengsheng Management Co., Ltd.			Individual		2,372,524.98
Others			Individual		682,184.79

附注三、应收账款

截至2022年12月31日

(单位：人民币元)

续前表

按账龄组合计提坏账准备的应收账款

2. 账龄组合

计提坏账准备的应收账款

应收账款	期末余额	计提坏账准备	账面价值
浙江泰顺医药有限公司	24,380.95		24,380.95

计提坏账准备的应收账款

应收账款	期末余额	计提坏账准备	账面价值
浙江泰顺医药有限公司	1,089,194.31	260,402.86	828,791.45

浙江泰顺医药有限公司

期末余额

1,089,194.31

计提坏账准备

260,402.86

账面价值

828,791.45

浙江泰顺医药有限公司

期末余额

24,380.95

计提坏账准备

账面价值

24,380.95

Notes to Financial Statements

For the year ended 2022

(All amounts in RMB Yuan unless otherwise specified)

X. Restricted Assets ()

() Includes: ()

3. Restricted Assets

TC ():

Asset Name	Original Value	Contract Date	Expiration Date	Notes
Yan Kehua H & C, L.	50,200,000.00	2019/8/26	2029/8/20	N
Qian Kehua H & C, L.	45,000,000.00	2019/12/31	2024/12/31	N

TC ():

Asset Name	Original Value	Contract Date	Expiration Date	Notes
Gao Wenhua W & L	30,000,000.00	2020/6/30	2027/6/30	N
Gao Wenhua, Wang Hui W & L	75,000,000.00	2021/11/29	2028/11/29	N
Gao Wenhua, Wang Hui, Wang Lixia X	150,000,000.00	2020/10/26	2026/10/25	N
Gao Wenhua, Wang Lixia W & H	200,000,000.00	2020/9/17	2023/9/17	N

4. Assets Held for Sale

Contract Date: 9/17

Notes to Financial Statements

For the year ended 2022

(All amounts in RMB Yuan unless otherwise specified)

X. Receivables ()

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

X. Receivables (continued)

(II) Expected credit loss

In 2022, the Company's expected credit loss for receivables is as follows:

Item	Expected credit loss		Credit loss		Other	
	Balance at the beginning of the year	Change during the year	Balance at the end of the year	Change during the year	Balance at the beginning of the year	Change during the year
Expected credit loss						
Government receivables	413,976.00	70,950.72	79,754.00	2,000.00	566,680.72	
Wholesale receivables	516,000.00		96,000.00	71,000.00	683,000.00	
Wholesale receivables	231,450.00	50,888.16		600.00	282,938.16	
Notes receivable						
Quality receivables						
Loan receivables						
Intangible assets						
Zhang X	70,000.00					70,000.00
Zhang W	70,000.00					70,000.00
Liu N	70,000.00					70,000.00
Other receivables						
Quality receivables						
Xiang Y						
Sun F						
Xu N	313,320.00	56,939.80	36,000.00	32,200.00	438,459.80	
Xu T	98,760.00	40,146.72	67,954.00	3,485.45	210,346.17	
Total	210,000.00	1,573,506.00	218,925.40	279,708.00	109,285.45	2,391,424.85

Other:

On September 1, 2022, Wholesale receivables, Government receivables, Quality receivables, and Loan receivables were transferred to Zhang X, Zhang W, Liu N, Xu N, and Xu T. The carrying amount of these receivables at the end of 2021 was RMB 210,000.00. The carrying amount of these receivables at the end of 2022 was RMB 218,925.40. The carrying amount of these receivables at the beginning of 2022 was RMB 210,000.00. The carrying amount of these receivables at the end of 2021 was RMB 210,000.00. The carrying amount of these receivables at the end of 2022 was RMB 218,925.40. The carrying amount of these receivables at the beginning of 2022 was RMB 210,000.00.

附注七、营业收入

单位：人民币元

续上表

(二) 营业收入按业务类型分类

2022年，公司营业收入按业务类型分类如下：

项目	2022年 营业收入	2022年 营业成本	2021年 营业收入	2021年 营业成本
营业收入				
药品				
批发	398,742.00	15,795.90	78,916.40	4,300.00
零售	375,592.00	-	46,714.60	44,680.00
其他	208,108.00	-	42,396.60	1,200.00
医疗服务				
门诊	-	-	-	-
住院	28,200.00	4,986.80	32,385.97	8,932.90
其他				
租赁	70,000.00	-	-	-
其他	70,000.00	-	-	-
其他	70,000.00	-	-	-
其他				
其他	-	-	-	-
其他	-	-	-	-
其他	-	-	-	-
其他	-	-	-	-
其他	82,613.40	8,885.40	54,030.60	18,936.60
合计	210,000.00	1,093,255.40	29,668.10	254,444.17
				78,049.50
				1,665,417.17

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan)

X. Receivables ()

(III) Financial Instruments

In 2022, the company's receivables are classified into two categories: (2021: 3),

Item	Amount at the end of the reporting period	Amount at the beginning of the reporting period
Without impairment, and other receivables	3,764,039.10	3,424,382.50
Specific impairment	4,109,519.26	4,411,564.18
Total	7,873,558.36	7,835,946.68

Category	Number of receivables	Number
500,000-1,000,000.00	1	1
Over 1,000,000.00	4	4
Total	5	5

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

XI. Significant Accounting Policies

(II) Employee Benefits

1. Retirement benefits: The Company participates in the State Pension Insurance Plan and the State Pension Insurance Plan.

2. Short-term employee benefits: Short-term employee benefits include wages, salaries, bonuses, short-term employee accruals, short-term employee benefits, and short-term employee benefits. Short-term employee benefits are measured at the undiscounted amount of the benefits expected to be paid in full. Short-term employee benefits are recognized as an expense when the employee provides services to the Company. Short-term employee benefits are recognized as an expense when the employee provides services to the Company.

3. Long-term employee benefits: Long-term employee benefits include long-term employee accruals, long-term employee benefits, and long-term employee benefits. Long-term employee benefits are measured at the present value of the benefits expected to be paid in full. Long-term employee benefits are recognized as an expense when the employee provides services to the Company.

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

XII. C

(I)

1. C

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

XIV. Contingent Liabilities

The following table shows the Company's contingent liabilities:

- The Company has provided a guarantee for the bank loans of other companies. The total amount of the guarantee is RMB 100 million. The Company has not received any compensation for the guarantee.

- The Company has provided a guarantee for the bank loans of other companies. The total amount of the guarantee is RMB 100 million. The Company has not received any compensation for the guarantee.

The Company has provided a guarantee for the bank loans of other companies. The total amount of the guarantee is RMB 100 million. The Company has not received any compensation for the guarantee. The Company has provided a guarantee for the bank loans of other companies. The total amount of the guarantee is RMB 100 million. The Company has not received any compensation for the guarantee.

The Company has provided a guarantee for the bank loans of other companies. The total amount of the guarantee is RMB 100 million. The Company has not received any compensation for the guarantee.

All amounts are in RMB Yuan, unless otherwise specified.

	Balance at the beginning of the year	Balance at the end of the year
Contingent liabilities		
Guarantees		
D / RMB Yuan	49.73%	46.16%

Notes to Financial Statements
2022
(All amounts in RMB Yuan)

XV. Other

(I) Current

Reserves

As at March 31, 2022, the Company has established the following reserves: 38 million RMB Yuan. The Company has established the following reserves as at March 31, 2021:

Current Reserves	Reserves	Amount	Change
Reserves	Bar	0	-9,203,741.45
	Div		12,877.91
	U		9,190,863.54

(II) Other

The Company has established the following other reserves: 38 million RMB Yuan. The Company has established the following other reserves as at March 31, 2021:

As at March 31, 2022, the Company has established the following other reserves: 38 million RMB Yuan. The Company has established the following other reserves as at March 31, 2021:

(III) Other

1. Other

On April 14, 2023, the Company established the following other reserves: 38 million RMB Yuan. The Company has established the following other reserves as at March 31, 2021:

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

XV. Other Intangible Assets

(III) Other Intangible Assets

1. Other Intangible Assets

(1) Other Intangible Assets

Balance at the beginning of the year 2022, I
 Intangible Assets, A, 2019 2020 RMB14.43, RMB5.25
 RMB9.18, T
 Ka H, I
 I C B D, 2021, N XV
 (I)

(2) Research and Development Costs

A, RMB2,190,700, C
 C, C
 T C
 C, C
 C

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

XV. Other Intangible Assets

(III) Other Intangible Assets

1. Other Intangible Assets

(3) Research and Development Intangible Assets

Based on the Company's accounting policy, the research and development intangible assets are measured at cost less accumulated amortization and impairment losses. The amortization period is determined based on the expected useful life of the intangible asset.

For the year ended December 31, 2022, the Company's research and development intangible assets are as follows:

Item	Original Value (RMB Yuan)	Accumulated Amortization (RMB Yuan)	Impairment Loss (RMB Yuan)	Net Book Value (RMB Yuan)
Research and Development Intangible Assets	10,000,000	2,000,000	0	8,000,000

As of December 31, 2022, the Company's research and development intangible assets are as follows:

Item	Original Value (RMB Yuan)	Accumulated Amortization (RMB Yuan)	Impairment Loss (RMB Yuan)	Net Book Value (RMB Yuan)
Research and Development Intangible Assets	10,000,000	2,000,000	0	8,000,000

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

XV. Other Intangible Assets

(III) Other Intangible Assets

2. Amortization

(2) Intangible assets with finite lives are amortized over their estimated useful lives. The amortization period and method for each intangible asset with finite lives are determined on the basis of the expected pattern of consumption of the economic benefits. The amortization expense is recorded as an expense in the profit and loss statement. The carrying amount of intangible assets with finite lives is reduced by the accumulated amortization. The carrying amount of intangible assets with finite lives is RMB428,900 at the end of 2020 and RMB335,100 at the end of 2021. The carrying amount of intangible assets with finite lives is RMB428,900 at the end of 2020 and RMB335,100 at the end of 2021. The carrying amount of intangible assets with finite lives is RMB428,900 at the end of 2020 and RMB335,100 at the end of 2021.

(3) Other intangible assets, which are not amortized, are recorded at cost less impairment. Other intangible assets are tested for impairment annually, and whenever there is an indication that other intangible assets may be impaired. The carrying amount of other intangible assets is reduced to its recoverable amount. The impairment loss is recorded as an expense in the profit and loss statement.

XVI. Non-current Assets Held for Sale

(I) Assets Held for Sale

1. Assets Held for Sale

	Balance at the beginning of the year	Balance at the end of the year
A. Assets Held for Sale		
Ward	49,024,983.98	40,904,137.67
1-2	709,878.26	1,282,268.26
2-3	1,158,221.95	2,748,299.92
Over 3 years	2,748,299.92	1,204,242.08
S	Over 3 years 1,158,221.95	

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

XVI. Non-current Assets

(I) Available-for-sale financial assets

2. Available-for-sale financial assets

Item	Balance at the end of the reporting period		
	Amount	Percentage	Percentage
			(%)
Original value	48,767,668.85	487,676.69	1.00
Total	48,767,668.85	487,676.69	

3. Available-for-sale financial assets

0.00

Wen Zhou Kang Ning Hospital Co., Ltd.
Financial Statement
for the Year ended December 31, 2022
(All figures in RMB Yuan)

XVI. Non-current Assets (RMB Yuan)

(II) Other Long-term Assets

	Balance at the beginning of the year	Balance at the end of the year
Intangible Assets		
Investments in Subsidiaries		
Investments in Associates		
Long-term Equity Investments	53,000,000.00	
Other Long-term Assets	547,014,558.58	492,034,884.26
Total	600,014,558.58	492,034,884.26
1. Dividends Receivable		
Guangdong Kangning Hospital Co., Ltd.	33,000,000.00	
Yunnan Kangning Hospital Co., Ltd.	10,000,000.00	
Qinghai Kangning Hospital Co., Ltd.	10,000,000.00	
Sichuan Kangning Hospital Co., Ltd.	53,000,000.00	
Long-term Prepaid Expenses		

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

)

()

•

•

•

•

•

XVI. N

(II) Other ()

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

XVI. Non-current Assets

(II) Other Intangible Assets

(3) Patents

Patent Name	12-month ECL	12-month ECL (Net)	12-month ECL (Cost)	Balance
Balance at beginning of year	123,061.04			123,061.04
Balance at end of year				
Change during the year				
- Transfer in				
- Transfer out				
- Rollover				
- Rollover				
Patent acquisition	103,420.62			103,420.62
Rollover				
Write-off				
Write-off				
Other				
Balance at end of year	226,481.66			226,481.66

Change in the carrying amount of intangible assets:

Balance at beginning of year	12-month ECL	12-month ECL (Net)	12-month ECL (Cost)	Balance
Balance at beginning of year	492,157,945.30			492,157,945.30
Balance at end of year				
Change during the year				
- Transfer in				
- Transfer out				
- Rollover				
- Rollover				
Acquisition	55,083,094.94			55,083,094.94
Disposal				
Other				
Balance at end of year	547,241,040.24			547,241,040.24

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

XVI. Non-current Assets (continued)

(II) Other Intangible Assets (continued)

(4) Patent Rights, Copyrights, Trademarks, etc.

	Balance at the beginning of the year	Change during the year	Balance at the end of the year
Original value			
Patent Rights	123,061.04	103,420.62	226,481.66
Trademarks	123,061.04	103,420.62	226,481.66

(5) Other Intangible Assets

	Balance at the beginning of the year	Change during the year	Balance at the end of the year
Accounts receivable	507,207,052.64		481,560,443.31
Prepaid expenses	33,132,118.55		8,954,970.91
Due to related parties	5,933,350.00		854,300.00
Others	968,519.05		788,231.08
Total	547,241,040.24		492,157,945.30

附 录 A

2022
(A 股上市首年)

XVI. 非流动资产

(III) 长期股权投资

项 目	2022 年 12 月 31 日		2021 年 12 月 31 日	
	账面余额	减值准备	账面余额	减值准备
可供出售金融资产	649,079,592.72		649,079,592.72	613,070,215.90
长期股权投资	92,882,992.81		92,882,992.81	71,256,356.09
合 计	741,962,585.53		741,962,585.53	684,326,571.99

1. 可供出售金融资产

项 目	2022 年 12 月 31 日		2021 年 12 月 31 日	
	账面余额	减值准备	账面余额	减值准备
SYMIVC, L.	10,354,979.06			10,354,979.06
ZHMHMC, L.	34,627,432.36		34,627,432.36	
WKEJFC	500,000.00			500,000.00
ZKHMHMC, L.	203,344,031.86	1,322,222.01		204,666,253.87
CKHMC, L.	51,982,515.15	715,222.35		52,697,737.50
YKHMC, L.	1,832,112.13	301,146.25		2,133,258.38
YKHMC, L.	27,447,511.21	239,581.90		27,687,093.11
QKHMC, L.	32,626,079.15	230,565.10		32,856,644.25
LKHMC, L.	2,110,854.98	188,216.41		2,299,071.39
WCHMC, L.	53,500,000.00			53,500,000.00
WLYHMC, L.	30,000,000.00			30,000,000.00
WORYRHC, L.	10,000,000.00			10,000,000.00
PCYHMC, L.	154,744,700.00			154,744,700.00
JSHMC, L.		26,684,900.00		26,684,900.00
YYTH				
WMHMC, L.		40,954,955.16		40,954,955.16
合 计	613,070,215.90	70,636,809.18	34,627,432.36	649,079,592.72

Notes to Financial Statements
 2022
 (All amounts in RMB Yuan)

	2022	2021
(III) Long-term equity investments		
2. Investment in subsidiaries		
C. Investment in subsidiaries		
I. Investment in subsidiaries		
A. Investment in subsidiaries		
B. Investment in subsidiaries		
N D		
I		
O		
X		

Notes to Financial Statements

附注

XVI. Non-current Assets (continued)

(I) Intangible Assets

1. Right of Use Assets

Item	Amount at the beginning of the year	Change	Amount at the end of the year	Change
Medical equipment	337,586,514.02	264,978,847.50	365,462,139.23	270,930,179.07
Office	5,554,936.61	45,300.00	4,336,166.89	559,209.63
Total	343,141,450.63	265,024,147.50	369,798,306.12	271,489,388.70

Accounting policy:

Item	Amount at the beginning of the year	Amount at the end of the year
Prepaid expenses	90,612,303.06	93,506,118.66
Trade receivables	246,974,210.96	271,956,020.57
Total	337,586,514.02	365,462,139.23

2. Depletion of Right of Use Assets

Total amount of right of use assets at the beginning of the year: 343,141,450.63 RMB Yuan. At the end of the year, the total amount of right of use assets is 369,798,306.12 RMB Yuan. The amount of right of use assets that has been depleted is 265,024,147.50 RMB Yuan.

(II) Intangible Assets

Item	Amount at the beginning of the year	Amount at the end of the year
Intangible assets	54,584,000.00	1,980,000.00
Intangible assets	-5,377,605.11	-3,485,811.81
Intangible assets	-18,462.42	
Intangible assets	714,348.18	6,429,189.35
Total	49,902,280.65	4,923,377.54

Definitions

AGM	Annual General Meeting	Annual General Meeting of the Company	2022
A	Company	Wenzhou Kangning Hospital Co., Ltd.	
A C	Company	Company	
B Y H	Beiyi Hospital	Beiyi Hospital Co., Ltd. (北京怡寧醫院有限公司), PRC	17, 2015, C
B D	Beidong Hospital	Beidong Hospital Co., Ltd.	C
C K H	Cangnan Kangning Hospital	Cangnan Kangning Hospital Co., Ltd. (蒼南康寧醫院有限公司), PRC	J 15, 2012, C
CGC	China General Corporation	China General Corporation	A 14 H K L R
C K P H	Changchun Kanglin Psychological Hospital	Changchun Kanglin Psychological Hospital Co., Ltd. (長春康林心理醫院有限公司), PRC	F 16, 2016, C
C K H	Chun'an Kangning Huangfeng Hospital	Chun'an Kangning Huangfeng Hospital Co., Ltd. (淳安康寧黃鋒醫院有限公司), PRC	A 16, 2020, C
C W K H	Wenzhou Kangning Hospital	Wenzhou Kangning Hospital Co., Ltd. (溫州康寧醫院有限公司), PRC, HS	M
C S	Company Secretary	M. Guan W	M. Wang L

Definitions

CSRC	中國證券監督管理委員會
D ()	() 中國
D S ()	人民幣 () 中國 人民幣 1.00 , RMB 人民幣 S
G H	溫州怡寧老年醫院有限公司 (Wenzhou Yining Old People's Hospital Co., Ltd.), PRC 寧 2, 2015, C
G	C
G Y H	冠縣怡寧醫院有限公司 (Guanxian Yining Hospital Co., Ltd.), PRC 寧 1, 2017, C
HS ()	香港證券及期貨委員會 () RMB1.00 , M B H K S E
H C H	杭州慈寧醫院有限公司 (Hangzhou Cining Hospital Co., Ltd.), PRC 寧 18, 2017, C
H Y H	杭州怡寧醫院有限公司 (Hangzhou Yining Hospital Co., Ltd.), PRC 寧 A 25, 2016, C . O J 30, 2022, C 28% H Y H T W L L H M C , L . (桐鄉烏鎮蓮芯蓮意健康管理有限公司). U 33% H Y H
H Y H	荷澤怡寧精神病醫院有限公司 (Heze Yining Psychiatric Hospital Co., Ltd.), PRC 寧 A 6, 2017, C
HK\$ HKD	香港

Definitions

H K

H K S A R

PRC

H K L R

Definitions

Nanjing Yihuan Hospital	Nanjing Yihuan Hospital Co., Ltd. (南京怡寧醫院有限公司), a PRC company established on July 22, 2018, and is a wholly-owned subsidiary of the Company.
Ningbo C	Ningbo C
Ningbo A	Ningbo A, established on May 11, 2015, is a wholly-owned subsidiary of the Company.
Pudong Yihuan Hospital	Pudong Yihuan Hospital Co., Ltd. (浦江怡寧黃鋒醫院有限公司), a PRC company established on September 3, 2018, and is a wholly-owned subsidiary of the Company.
PRC Company	PRC Company, established in Hangzhou, Zhejiang Province, PRC, on May 28, 2013, and is a wholly-owned subsidiary of the Company.
PRC Company	PRC Company, established in Hangzhou, Zhejiang Province, PRC, on May 1, 2014, and is a wholly-owned subsidiary of the Company.
P	P, established on November 10, 2015, is a wholly-owned subsidiary of the Company.
Qiantian Kangning Hospital	Qiantian Kangning Hospital Co., Ltd. (青田康寧醫院有限公司), a PRC company established on August 1, 2011, and is a wholly-owned subsidiary of the Company.
Qiyuan Hospital	Qiyuan Hospital Co., Ltd. (衢州怡寧醫院有限公司), a PRC company established on November 20, 2015, and is a wholly-owned subsidiary of the Company.

Definitions

T R P R P	截至 2022 年 12 月 31 日
R C	人民币
RMB	人民币 (PRC)
SFO	深圳证券交易所 (深交所) (股票代码: 002190)
S ()	S () 人民币 1.00 元, D S () HS ()
S ()	() S ()
S Y H	S Y H (深圳怡宁医院, S Y H C., L. (深圳市怡宁医院有限公司)), S 22, 2014, C -
S R M C	S R M C B C O (C 622 H K)
()	H K L R
S ()	S C
S C	C S C PRC C
T K H	T K H C., L. (台州康宁医院有限公司), PRC J 30, 2016, C -

Definitions

W N H W N P S H C ., L . (溫嶺南方精神疾病專科醫院
 有限公司), PRC J 20, 2018,
 C T1 T -05.4175 -30538T (°)T 0.556 -0.

